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Inappropriate activation of the Ras-mitogen activated protein kinase (MAPK) signalling 
pathway has long been implicated in many types of human cancers, implying that strict 
regulation of Ras-MAPK signalling is important for regulating the growth and survival of 
cells. Sprouty (Spry) proteins are endogeneous inhibitors of Ras/MAP kinase pathway that 
play an important role in the remodeling of branching tissues such as in development of the 
lung, kidney tubules and vascular system. This study evaluates the potential role of Sprouty 
proteins in cancer. The expression of Sprys in various types of cancer has been analyzed and 
Spry 1 and 2 were found to be significantly down-regulated in more than 90% of breast 
cancers. Spry 2 was also found to be down-regulated in liver cancers. Analysis of the possible 
genetic and epigenetic mechanisms causing the down-regulation of Spry genes indicates that 
methylation is not responsible for the down-regulation observed in breast and liver cancer. In 
liver cancers, no loss of heterozygosity was observed in the microstatellite markers flanking 
the hSpry2 gene locus.  
 
In this study, the suppressed expression and therefore function of Spry was found to 
potentiate aberrant signalling in tumourigenesis. Overexpression of the putative dominant 
negative hSpry2Y55F mutant that quenches the function of endogenous wild-type Spry in 
MCF-7 cells caused cells to proliferate faster, exhibit anchorage-independent growth and loss 
of contact inhibition. As a result, hSpry2Y55F over-expression in MCF-7 cells also caused the 
formation of larger tumours in nude mice assay compared to control MCF-7 cells. The knock 
down of Spry2 expression in NIH3T3 cells was also found to cause NIH3T3 cells to be more 
susceptible to growth factor induced transformation. The study subsequently demonstrates 
that Sprys were able to inhibit colony formation induced by Polyoma Middle T antigen 
(PyMT) oncogene via the inhibition of the activation of the Ras/ERK signalling pathway. 
NIH3T3-hSpry2 stable cells were more resistant to transformation by PyMT as compared 





indicating that the over-expression of Spry2 in NIH3T3 cells inhibited colony formation. In 
contrast, NIH3T3-hSpry2Y55F stable cells were not as resistant to transformation, indicating 
that the Tyr55 residue in Spry2 was important for Spry2's ability to inhibit transformation 
downstream of PyMT.  
 
Overall, this thesis shows that Spry proteins are down-regulated in cancers and that they may 
play a crucial role in preventing cell transformation. Down-regulation of these genes may 





















1.1 Mammalian cell signalling 
Various cell types existing in multicellular organisms dynamically coordinate their activities 
with cues from environmental and/or neighbouring cells to maintain tissue homeostasis and 
organ function. This ability depends on an elaborate intercellular communication network that 
coordinates the growth, differentiation, metabolism and apoptosis of the multitude of cells in 
diverse tissues and organs. Cells communicate by means of signalling ligands (such as 
secreted hormones and growth and differentiation factors) that activate a number of 
intracellular signalling molecules via specific receptors. Signal transduction refers to any 
process by which a cell converts one kind of signal or stimulus into another, most often 
involving ordered sequences of biochemical reactions inside the cell, that are carried out by 
enzymes and often linked through second messengers. Such processes are usually rapid, 
lasting on the order of milliseconds, in the case of ion fluxes, to minutes, for the activation of 
protein and lipid mediated kinase cascades (Hancock, 1998; Krauss, 1999).  
 
Communication by extracellular signals usually involves six steps: (1) synthesis and (2) 
release of the signalling molecule by the manufacturing cell; (3) transport of the signal to the 
target cell; (4) detection of the signal by a specific receptor protein; (5) signal transmission 
within the cell by various biochemical mechanisms of signal transduction, ranging from direct 
transcriptional regulation by the nuclear receptor proteins to the extended protein 
phosphorylation cascades characteristic of RTK pathways; (6) a change in cellular 
metabolism, function, or development triggered by the receptor-signal complex; (7) removal 






The binding of extracellular signalling molecules to cell surface receptors triggers a series of 
events inside the cell, particularly targeting intracellular pathways that ultimately modulate 
cellular metabolism, function or development. Different types of receptors stimulate different 
intracellular responses. In eukaryotic cells, various proteins within the cell are activated upon 
ligand/receptor binding and they serve to transmit the signal within a cell. Most of these 
proteins possess enzymatic activity. These proteins include heterotrimeric G proteins, small 
GTPases, various protein kinases and phosphatases, and lipid kinases, phosphatases and 
hydrolases. Some receptor stimulated enzymes create specific second messengers including 
cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), 
phosphatidylinositol derivatives, such as phosphatidylinositol-triphosphate (PIP3), 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate [Ins (1,4,5)P3], which cause the release 
of calcium ions. Thus, activation of receptors on the cell surface stimulates the activities of a 
combination of enzymes and second messengers within the cytoplasm and alters the 
chemistry of the cell to elicit specific responses by the cell (Hancock, 1998; Krauss, 1999). 
 
Signal transduction, which underlies the ability of cells to perceive and correctly respond to 
their microenvironment, is the basis of development, tissue repair, and immunity as well as 
normal tissue homeostasis. Abnormalities in signal transduction are responsible for diseases 
such as cancer, autoimmunity, and diabetes. As such, a detailed knowledge of the signalling 
pathways involved in these diseases will provide important cues for the design of specific 
therapies (Hancock, 1998; Krauss, 1999). 
 
1.2 Receptor tyrosine (RTK) signalling pathways 
Receptor tyrosine kinases (RTKs) are transmembrane glycoproteins that are activated by the 
binding to their cognate receptors, and they transduce the extracellullar signal to the cytoplasm 
by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on 





cell, leading to cell proliferation, differentiation, migration, metabolic changes, apoptosis or 
survival (Schlessinger, 2000; Manning et al., 2002).  
 
Ligand binding to the RTK's extracellular domain leads to conformation changes that induce 
and stabilize receptor dimerization, therefore juxtaposing the kinase domains of the RTKs on 
the cytosolic face of the membrane. These kinase domains cross-activate each other by 
phosphorylating critical residues within the catalytic domain, and then further 
phosphorylating the tyrosines outside the catalytic domain (Greenfield et al., 1989; Ulrich and 
Schlessinger, 1990; Heldin, 1995), which in turn function as docking sites for cytoplasmic 
signalling proteins containing Src homology 2 (SH2)- and phosphotyrosine-binding (PTB) 
domain containing proteins such as Shc, Grb2, Src, Cbl or phospholipase Cγ (PLCγ). These 
proteins then recruit additional effector molecules containing SH2, SH3, PTB and pleckstrin-
homology (PH) domains to the activated receptor, which results in the assembly of signalling 
complexes at the membrane and the activation of a cascade of intracellular biochemical 
signals (Pawson, 1995). The most important downstream signalling cascades activated by 
RTKs include the Ras–extracellular signal-regulated kinase (ERK)–mitogen activated protein 
(MAP) kinase pathway (Dhanasekaran and Premkumar Reddy, 1998), the phosphoinositide-
3-kinase (PI3K)–Akt and the JAK/STAT pathway. Ultimately, the complex signalling 
network triggered by RTKs leads either to activation or repression of various subsets of genes 
and thus defines the biological response to a given signal (Krolewski, 2005). 
 
1.3 Ras /ERK pathway 
1.3.1 Introduction 
Extracellular signals transduced via receptor tyrosine kinases, G-protein coupled receptors or 
integrins activate Ras, a key switch in cellular signalling (Widmann et al., 1999).   Although 
Ras can activate multiple downstream effectors (such PI3K and RalGDS), one of the major 
pathways activated is the conserved sequential protein kinase cascade referred to as the 





in the control of many fundamental cellular processes that include cell proliferation, survival, 
differentiation, apoptosis, motility and metabolism (Chong et al., 2003; O'Neill and Kolch, 
2004; Wellbrock et al., 2004).  
 
Signals induced upon ligand binding are carried via Grb2 and SOS to small G-protein Ras, 
leading to its activation (Fig 1.3.1). Ras is a small GTPase that binds to the N-terminal 
domain of Raf, a serine/threonine kinase, and recruits it to the cell membrane for subsequent 
activation (Dhillon and Kolch, 2002; Chong et al., 2003; Wellbrock et al, 2004). In a complex 
with scaffolding proteins such as CNK (connector enhancer of kinase suppressor of Ras 1) 
and KSR (kinase suppressor of Ras 1), activated Raf phosphorylates dual-specificity 
MAPK/ERK (MEK) kinases, which then phosphorylate and activate the ERK1 (extracellular-
signal-regulated kinase 1) and ERK2 mitogen-activated protein kinases (MAPKs). ERK 
phosphorylates a wide variety of substrates that mediate cell growth and cell-cycle entry. In 
addition to transcription factors (for example Myc, Elk1 and c-Fos), ERK phosphorylates and 
activates the RSK (ribosomal protein S6 kinase) and MNK (MAPK-interacting 
serine/threonine kinase) families of kinases. The substrates of these kinases that contribute to 





































The Ras/ERK pathway.   The binding of growth factors to their cell-surface receptor 
tyrosine kinases (RTKs) signals through adaptors such as growth-factor-receptor bound-2 
(GRB2) and exchange factors such as son-of-sevenless (SOS) to activate Ras. Similarly, 
hormone binding to G-Protein coupled receptors  (GPCRs) activates Ras through 
heterotrimeric G-proteins. This initiates membrane recruitment and activation of Raf, which 
leads to the activation of the dual-specificity mitogen-activated protein kinase (MAPK) and 
extracellular signal-regulated kinase (ERK) kinases, MEK1 and/or MEK2 and, subsequently, 
ERK1 and/or ERK2. The ERKs have many cytosolic and nuclear substrates.  
 
















1.3.2 Adapter and scaffold proteins 
Adaptor and scaffolding proteins are important components of Ras/ERK signalling in 
eukaryotic cells. These proteins play a role in intracellular signalling by both recruiting 
various proteins to specific locations and by assembling networks of proteins particular to a 
cascade. Adaptor proteins, through protein-protein interactions via specific motifs, provide a 
link between molecules of a signalling cascade and proteins such as RTKs. These adapter 
proteins often contain a variety of motifs that mediate protein-protein interactions. An 
example of an adapter protein is Grb2. It contains both SH2 and SH3 sequences and its 
function is to recruit cytoplasmic proteins via its SH3 domain to an activated RTK via SH2 
domains-binding to phosphorylated residues of the receptors. In the Ras/ERK pathway, Grb2 
plays an important role in the recruitment of the Ras signalling complex, which in turn 
activates MAP kinase (MAPK) cascade (Pawson et al., 2001). The role of scaffold proteins 
differs slightly from that of adapter proteins. Scaffold proteins increase the frequency of 
signalling by locally concentrating proteins and positioning kinases in close proximity to their 
substrates via their ability to simultaneously interact with two or more components of the 
Ras/ERK cascade (Dard and Peter, 2006). In the ERK pathway, upon Ras activation, Kinase 
Suppressor of Raf (KSR) Ser 392 site is dephosphorylated by Ser/Thr phosphatase PP2A. 
KSR is liberated from 14-3-3 binding and translocates to the plasma membrane where it 
brings MEK and ERK to the active Raf signalling complex (Ory et al., 2003). Scaffolds can 
also target signalling complexes to a specific organelle. The scaffold MEK partner-1 (MP-1) 
has been reported to promote the formation of ERK complexes at endosomes. MP-1 interacts 
with p14, a protein enriched at the surface of late endosomal/lysosomal compartments, and 
mediates the formation of p14-MP1-MEK1 and p14-MP1-ERK1 complexes (Wunderlich et 
al., 2001). 
 
1.3.3 Ras  
Grb2 adaptor proteins recruit further effectors, including Ras guanine-nucleotide-exchange 





genes encode 4 highly related proteins: H-Ras, N-Ras, K-Ras4A and K-Ras4B; founding 
members of a large superfamily of Ras-related proteins. Ras proteins are associated with the 
inner face of the plasma membrane where they facilitate signalling initiated by diverse 
extracellular stimuli (Shields et al., 2000). SOS activates Ras by stimulating the exchange of 
GDP for GTP on Ras. On binding GTP, Ras undergoes a conformational change that allows 
downstream effectors, such as Raf-1, to bind to its 'switch I' region (Quilliam et al., 2002). 
GTPase-activating proteins (GAPs) such as p120GAP and neurofibromin 1 (NF1) also bind to 
activated Ras and catalyse GTP hydrolysis, thereby returning Ras to the inactive, GDP-bound 
state (Shaw and Cantley, 2006). Thus, Ras activity is regulated by cycling between inactive 
GDP-bound and active GTP-bound forms (Fig 1.3.3). Through the switching of the Ras-
family GTPases from the inactive and active forms, external signals are transmitted from 
receptors on the cytoplasmic membrane to the interior of the cell (Bourne et al., 1991).  
 
1.3.4 Raf 
Raf proteins act downstream of Ras in the Ras/ERK pathway. There are three Raf paralogs in 
humans: A-Raf, B-Raf, and C-Raf (also called Raf-1) (Marais and Marshall, 1996). The 
binding of Raf to Ras recruits Raf to the plasma membrane and although this is insufficient to 
stimulate kinase activity, by itself, it is an initiating event in Raf activation (Hancock, 2003). 
Once activated by a complex set of phosphorylations, Raf serine phosphorylates MEK1 and 
MEK2, which in turn phosphorylate ERK. Although all three Raf isoforms can activate both 
MEK1 and MEK2 in vitro (Marais et al., 1997), they do so to differing degrees. In cell 
extracts, B-Raf binds to and phosphorylates MEK1 and MEK2 more efficiently than either A-
Raf or C-Raf (Papin et al., 1996; Marais et al., 1997). B-Raf was proposed to be the main 
activator of MEK in cells and its primary function is to activate MEK, either directly or 
indirectly through the recruitment of C-Raf. In contrast, C-Raf and A-Raf only signal to fine 
tune the levels and/or duration of ERK activity and therefore to determine cell fate 















Ras proteins function as regulated GDP–GTP binary switches. Extracellular signals are 
received by membrane-bound receptors such as G-protein-coupled receptors (GPCRs) and 
receptor tyrosine kinases (RTKs). These receptors activate guanine-nucleotide-exchange 
factors (GEFs), which then cause transient activation of Ras. Activated Ras GTP adopts a 
conformation that facilitates binding to, and activation of, downstream effectors. Ras 
signalling is terminated by Ras GAP-mediated stimulation of hydrolysis of bound GTP to 
GDP, and release of the bound effector. Tumour-associated Ras mutant proteins with 
missense mutations (at residues G12, G13 or Q61) are GAP insensitive and are chronically 
GTP bound and active.  
 







which does not require its kinase activity or its ability to activate MEK (Huser et al., 2001; 
Mikula et al., 2001). 
 
1.3.5 MEK 
Raf proteins cause the activation of MEK1/2 via the phosphorylation of 2 serine residues at 
positions 217 and 221 of MEK. MEK1 and MEK2, also known as ERK kinases, are dual-
specificity protein kinases that function in the Ras/ERK cascade, controlling cell growth and 
differentiation. MEK1/2 is activated by a wide variety of growth factors and cytokines and 
also by membrane depolarisation and calcium influx (Crews et al., 1992).  
 
1.3.6 ERK 
The Ser/Thr kinases ERK1/2 were discovered in a screen for protein kinases that are activated 
upon growth factor stimulation (Boulton et al., 1990; 1991). ERK1/2 belongs to the MAPK 
superfamily (Pearson et al., 2001) and can be activated in response to a wide variety of 
extracellular stimuli by upstream kinases MEK1/2 via the co-phosphorylation of a Tyr-Glu-
Thr motif in ERK1/2. On activation, ERK enzymes phosphorylate several cytoplasmic targets 
or migrate to the nucleus, where they phosphorylate and activate various transcriptional 
factors, including c-Fos and Elk1 (Treisman, 1994). ERK1/2 and other MAPKs target not 
only transcriptional factors but also membrane proteins. Activation of ERK1/2 culminates in 
the phosphorylation of transcriptional factors that regulate genes which cause a number of 
biological effects including cell proliferation, differentiation and survival (Lewis et al., 1998). 
 
1.3.7 Modulators of the strength and duration of ERK signalling  
Clearly, the ERK pathway must be tightly controlled in its duration of activation and sub-
cellular localization to ensure proper outcome of integrated biological responses such as cell 
proliferation, differentiation and survival. Endogeneous inhibitors of the Ras/ERK signalling 
exist to regulate the strength and duration of ERK activation. Both constitutive and ERK 





Constitutive inhibitory mechanisms, which do not depend on ERK activation, act to limit 
ERK signalling in cells. These regulatory molecules include Raf kinase inhibitor protein 
(RKIP), which interferes with MEK phosphorylation (Yeung et al., 2000); Ras and Rab 
interactor 1 (RIN1), which competes with Raf for binding to activated Ras (Wang et al., 
2002); Impedes mitogenic signal propagation (IMP), which interacts with kinase suppressor 
of Ras (KSR) to prevent recruitment of MEK to activated Raf (Matheny et al., 2004) and the 
MAP kinase phosphatase (MKP) (MKP1,3) family of MAPK phosphatases, which reduce the 
activation state of the RAF–MEK–ERK module (Shapiro and Ahn, 1998; Farooq and Zhou, 
2004). Other negative regulators include both Akt and serum/glucocorticoid inducible kinase 
(SGK), which can phosphorylate B-Raf (Guan et al., 2000; Zhang BH et al., 2001). 
 
Another regulatory mechanism is provided by transcriptional induction of negative feedback 
loops. The activation of downstream signalling cascades by activated receptors triggers the 
synthesis of inhibitory proteins, which in turn act to attenuate receptor-mediated signalling 
events. Transcription-mediated loops of negative regulation are best characterized in insects, 
and they include the membrane-spanning Kekkon protein and the antagonistic ligand of insect 
EGFR, Argos (Shilo, 2003). Similarly, mammalian RTK inhibitors such as the pan-ErbB 
inhibitor, RALT/Mig-6 (Fiorini et al., 2002) and the FGFR inhibitors, Sef (Furthauer et al., 
2002) and Sprouty (Hacohen et al., 1998), are also transcriptionally induced following 
receptor activation. 
 
1.4 Sprouty family of proteins  
1.4.1 Discovery of Sprouty 
The recently identified Sprouty (Spry) proteins are one such family of common regulatory 
proteins that modulate the Ras/ERK MAPK signalling pathway (Guy et al., 2003; Christofori 






dSpry was initially discovered as an inhibitor of fibroblast growth factor (FGF) signalling 
during tracheal development. It was involved in modulating branching in Drosophila tracheal 
formation and its absence led to random ‘sprouting’ of tracheal tubules. dSpry has also been 
found to inhibit epidermal growth factor (EGF)-mediated development of the eye, wing, and 
ovary, among other organs (Hacohen et al., 1998; Casci et al., 1999; Kramer et al., 1999; 
Reich et al., 1999). Genetic evidence and biochemical analysis in cultured Drosophila cells 
showed that dSpry negatively regulates RTK signalling pathways by inhibiting the Ras/ERK 
pathway (Casci et al., 1999). 
 
To date, four mammalian Sprys (Spry1-4) have been identified with sequence similarity to the 
Drosophila protein (Hacohen et al., 1998; Tefft et al., 1999; de Maximy et al., 1999; 
Minowada et al., 1999) (Fig 1.4.1). These are expressed in the brain, heart, lung, kidney, 
limbs and skeletal muscle (Minowada et al., 1999; Chambers et al., 2000; Zhang S et al., 
2001). The Spry proteins have a highly conserved cysteine-rich carboxyl (C)-termini and that 
contains a highly conserved motif that mediates binding to Raf1 (Raf1-binding domain, RBD) 
(Sasaki et al., 2003). The N-terminal half of the Spry proteins is more divergent, however, 
except for the presence of an invariant tyrosine residue (Y) located in a short, conserved 
NxYxxxP motif. Many of the inhibitory functions of the Spry proteins are dependent on this 
residue. Of note, Spry1, 2 and 4 are tyrosine phosphorylated in response to receptor tyrosine 
kinase (RTK) stimulation while the ability of growth factors to induce tyrosine 
phosphorylation of Spry3 is unknown (Hanafusa et al., 2002; Fong et al., 2003; Hall et al., 
2003; Rubin et al., 2003; Mason et al., 2004; Lao et al., 2006). As in Drosophila, mammalian 
Spry proteins work as feedback inhibitors of FGF signalling during organogenesis (Tefft et 












Various isoforms of Sprouty proteins and their respective domains. 
(A) Drosophila Spry is a 591-amino-acid (63-kDa) protein with a unique 124-residue 
cysteine-rich C-terminal domain, which is flanked by cysteine-free regions that contain many 
stretches of repeated or alternating amino acids. The vertebrate Spry proteins are considerably 
smaller than the Drosophila homolog, with predicted molecular masses in the 32–35 kDa 
range. Similarity to the fly protein is primarily restricted to the cysteine-rich region (44–52% 
identity) termed the Spry domain, shown in blue. The Spry domain also contains a highly 
conserved motif, represented in red, that mediates binding to Raf1 (Raf1-binding domain, 
RBD). The N-terminal half of the Spry proteins is more divergent, however, except for the 
presence of an invariant tyrosine residue (Y) located in a short, conserved motif, indicated in 
yellow. Many of the inhibitory functions of the Spry proteins are dependent on this residue. 
(B) Amino acid sequence alignment of regions containing the invariant N-terminal tyrosine 
residues of mouse Sprouty proteins. Conserved residues are indicated in red and boxed.  
 









1.4.2 Structure of Sproutys 
Drosophila Spry is a 591-amino-acid (63-kDa) protein with a unique 124-residue cysteine-
rich C-terminal domain, flanked by cysteine-free regions that contain many stretches of 
repeated or alternating amino acids (Hacohen et al., 1998). Additionally, Drosophila Spry 
contains eight potential N-linked glycosylation sites but no other recognizable protein 
domain. Based on sequence homology to Drosophila Spry, orthologs were identified in the 
mouse, human, chicken, zebrafish and frog (Xenopus laevis and Xenopus tropicalis (Hacohen 
et al., 1998; Minowada et al., 1999; de Maximy et al., 1999; Tefft et al., 1999; Chambers et 
al., 2000; Furthauer et al., 2001; Nutt et al., 2001). The vertebrate Spry proteins are 
considerably smaller than the Drosophila homolog, with predicted molecular masses in the 
32–35 kDa range. Similarity to the fly protein is restricted primarily to the cysteine-rich 
region (44–52% identity) termed the Spry domain as well as the conserved N-terminal 
tyrosine motif (Fig 1.4.1). Of the 22 cysteine residues found in Drosophila Spry, 18 or more 
are present in each vertebrate protein. The Spry2 gene product exhibits the highest sequence 
conservation across species (Minowada et al., 1999); human Spry2 is 97% homologous to 
mouse Spry2, 85% to chick Spry2 and 51% to Drosophila Spry, in the cysteine-rich region.  
 
1.4.3 Sproutys and their mechanisms of inhibition of RTK signalling 
The experimental evidence that has been gathered so far indicates that Spry proteins 
negatively regulate RTK signalling. Various studies on mammalian cells confirm Spry 
proteins as negative regulators of the Ras/ERK pathways (Gross et al., 2001; Impagnatiello et 
al., 2001; Yusoff et al., 2002).  
 
Two different groups showed that Spry proteins mainly affect the FGF-activated Ras/ERK 
pathway. Spry proteins were shown not to affect the other MAPK and PI3 kinase pathways. 
While these studies agreed on the specific MAPK pathway that Spry inhibits, they differed in 
their conclusions as to the specific point at which Spry acts in the Ras/ERK pathway (Gross et 





not prevent the formation of FRS2-Grb2-SOS complex upon FGF stimulation, but block Ras 
activation, indicating that Spry1 and 2 act at the level of Ras. Yusoff et al. (2002) compared 
the inhibitory activity of Spry isoforms 1, 2 and 4 and determined that Spry2 was the most 
potent inhibitor of the Ras/ ERK kinase pathway. Spry2 was found to have no inhibitory 
effect on the activation of Ras. Constitutively active mutants of Ras, Raf and MEK were 
employed to locate the exact point of inhibition of Spry2 downstream of activated Ras. 
Results from the study indicated that Spry2 exerted its inhibitory effect at the level of Raf.  
 
In 293T cells, Spry4 was also found to inhibit at the level of Raf in vascular endothelial 
growth factor (VEGF) signalling (Sasaki et al., 2003). VEGF-induced ERK/MAPK activation 
is reportedly mediated by the PLCγ-PKC pathway and is independent of Ras. Therefore, Spry 
is able to inhibit ERK activity through a Ras-independent pathway. Spry4 binds to the 
catalytic domain of Raf1 through its carboxyl-terminal cysteine-rich domain (Raf-binding 
domain) and this binding is necessary for inhibitory activity of Spry4. Lee et al. (2001) also 
discovered that Spry4 inhibited FGF and VEGF-induced MAPK phosphorylation in HUVEC 
(endothelial) cells. However, Spry4 was found to act at a different position in the Ras/MAPK 
pathway. Lee et al. (2001) found that this inhibition could be rescued by over-expresssion of 
constitutively activated mutant Ras(L61) indicating that Spry4 inhibits receptor tyrosine 
kinase signalling upstream of Ras. 
 
Hanafusa et al. (2002) discovered another molecular mechanism underlying Sprouty's 
inhibition of RTK signalling. They showed that, in C2C12 (mouse fibroblast) cells, upon FGF 
stimulation, Xenopus Spry1 (xSpry1) and mouse Spry2 (mSpry2) become phosphorylated on 
the conserved tyrosine (Tyr53 for Spry1 and Tyr55 for Spry2) and that the phosphorylation is 
required for Sprys' inhibitory activity. xSpry and mSpry2 bound to the SH2 domain of Grb2 
and prevented the recruitment of Grb2-SOS complex to the membrane, leading to inhibition 
of ERK activation. Subsequent studies by Mason et al. (2004) agreed with these findings that 





showed that Spry2 interacted with Grb2 constitutively and this interaction did not depend on 
phosphorylation on the Tyr55 on Spry2. In contrast, the conserved tyrosine (Y55) in Spry2 
was found to be essential for its interaction with c-Cbl. To determine whether c-Cbl was 
required for Spry2-dependent cellular events, Sprouty2 was introduced into c-Cbl-null 
fibroblasts. Spry2 efficiently inhibited FGF-induced ERK activation, indicating that FGF-
dependent interaction between Spry2 and c-Cbl is dispensable for its inhibitory activity. This 
result, however, does not take into account the presence of other Cbl isoforms in the cells. 
The interaction of Spry and c-Cbl was found to be important for c-Cbl-mediated 
polyubiquitin/proteosomal degradation of Spry2 in response to FGF (Mason et al., 2004). 
 
Data from our laboratory agreed with that of Hanafusa et al. (2002), showing that Spry2's 
inhibitory activity stems from its ability to bind to Grb2, thus preventing the recruitment of 
Grb2-SOS complex to the membrane, only upon FGF stimulation. However, the domain of 
Grb2 that interacted with Spry2 was found to be the N-SH3 domain, and not the SH2 domain 
of Grb2 (Lao et al., 2006). PP2A was found to mediate the change in the Spry2 tertiary 
protein structure by binding to Spry2 at amino acids (aa) 50-60 upon FGF stimulation and 
causing the dephosphorylation of at least 2 conserved Ser/Thr residues (S112 and S115) in the 
Spry2 protein. The resulting change in tertiary structure enables the proline-rich PxxPxR 
motif to be revealed, and thus enables the subsequent binding of the SH3 domain of Grb2. 
(Lao et al., 2007). In line with these observations, Rubin et al. (2005b) showed that a SH2-
defective Grb2 mutant, that cannot bind phosphorylated substrates (R86K), was able to bind 
to Spry2. In addition, pull down experiments using bacterially-produced proteins indicated 
that Spry2 associates with wild-type as well as R86K Grb2 but the isolated SH2 domain of 
Grb2 is not necessary for binding of Spry2. The SH2 domain of Grb2 is known to recognize a 








1.4.4 Regulation of the activity of Sproutys 
As a negative regulator, Spry is subjected to tight control at multiple levels. Specifically, this 
occurs through post-translational modifications (section 1.4.4.1) and regulation of protein 
levels (section 1.4.4.2). 
 
1.4.4.1 Post translational modifications of Sproutys 
The activity of Spry proteins are regulated by post-translational modifications such as serine 
and tyrosine phosphorylation. 
 
1.4.4.1.1 Tyrosine phosphorylation of Sproutys 
In their N-terminal domain, Spry proteins contain a conserved tyrosine residue (Tyr55 in 
Spry2) that undergoes phosphorylation in response to growth factor (FGF and EGF) 
stimulation (Sasaki et al., 2001; Hanafusa et al., 2002; Hall et al., 2003; Rubin et al., 2003; 
Fong et al., 2003; Mason et al., 2004). This tyrosine residue is necessary for Spry proteins to 
function as inhibitors of FGF signalling (Sasaki et al., 2001; Hanafusa et al., 2002; Fong et 
al., 2003; Mason et al., 2004). Mutation of the N-terminal tyrosine causes Spry proteins to 
lose their ability to inhibit growth-factor dependent ERK phosphorylation. While the N-
terminal tyrosine residue of Spry2 is important for its ability to inhibit FGF signalling, the 
function of Spry2 is also modulated to some degree by phosphorylation of its C-terminal 
tyrosines (Rubin et al., 2005b). While the conserved tyrosine residue in Spry is required for 
repression of FGF-signalling, it is not required for inhibition of VEGF signalling, as the N-
terminal Tyr53 mutant of Spry4 retains its ability to inhibit VEGF signalling. It is likely that 
in VEGF signalling, Spry's activity may be regulated only by transcription of Spry genes upon 
growth factor stimulation (Sasaki et al., 2003). 
 
While phosphorylation on the conserved tyrosine on Spry2 is important for the functional 
activity of Spry, it also mediates degradation and termination of the activity of Spry2 protein. 





leading to polyubiquitination and proteosomal degradation of Spry2 (Fong et al., 2003; Hall 
et al., 2003; Rubin et al., 2003). This pathway has been postulated to serve as a mechanism to 
control the duration of Spry activity (Rubin et al., 2005a). 
 
1.4.4.1.2 Serine  phosphorylation and palmitoylation of Sproutys 
In HUVECs endothelial cells, Spry1 and 2 were discovered to be palmitoylated which was 
suggested to be a mechanism by which Spry proteins anchor themselves to the membrane. In 
addition, Spry1 and 2 were found to be post-translationally modified by serine 
phosphorylation (Impagnatiello et al., 2001). Upon EGF and FGF stimulation, MAPK-
interacting kinase 1 (MNK1) was found to be the kinase that phosphorylated human Spry2 on 
serines 112 and 121, causing an up-shift and accumulation of the slower migrating-form of 
Spry2 in SDS-PAGE. A mutant of Spry2 that was deficient in serine phosphorylation displays 
enhanced tyrosine phosphorylation and c-Cbl binding as well as an accelerated rate of ligand-
induced degradation of Spry2. Hence, serine phosphorylation was found to stabilize Spry2 by 
exerting an effect on tyrosine phosphorylation (DaSilva et al., 2006). 
 
Other evidence did not completely agree with that of DaSilva et al. (2006). Lao et al. (2007) 
found that upon FGFR1 stimulation, Spry was selectively dephosphorylated on some residues 
by a phosphatase, most likely PP2A, that binds to Spry2 around residues 50-60 and an 
accumulation of the faster migrating (downshifting) Spry band was observed. Serine 
dephosphorylation of at least 2 conserved Ser residues (S112 and S115) in the Spry2 protein 
was found to occur in FGFR1-stimulated cells. Dephosphorylation of these residues 
constitutes a necessary step in the activation of Spry2 leading to likely changes in protein 
tertiary structure to unveil the cryptic proline-rich PxxPxR motif. This would permit the 
binding of Grb2, a necessary step for Spry2 to act as a Ras/ERK pathway inhibitor in FGF 
signalling (Lao et al., 2007). Lao et al. (2007) also found that FGFR1-stimulated Spry2 is 





and Y191) residues. However, these do not appear to contribute to the bandshifting of the 
Spry2. 
 
1.4.4.2 Regulation of Sprouty levels 
Spry activity can also be regulated by controlling its expression in the cell. Spry proteins are 
induced by the same signalling pathways they negatively regulate. In mouse embryonic 
development, a close spatial and temporal interdependence between FGF signalling activity 
and Spry gene expression has been seen in various other mammalian embryonic tissues, 
including brain, heart, gut and muscle (Hacohen et al., 1998; Chambers and Mason, 2000). 
During vertebrate development, Spry genes are often expressed at sites of FGF activity 
associated with the mesenchymal-to-epithelial transition (Minowada et al., 1999; de Maximy 
et al., 1999; Chambers and Mason, 2000; Chambers et al., 2000; Zhang S et al., 2001). 
Specific FGF and Spry expression can be overlapping but not completely identical (de 
Maximy et al., 1999). This might allow for the creation of complex signalling gradients 
during development or could indicate that Spry gene expression is governed by several 
growth factors. EGF signalling was also found to induce dSpry expression during embryonic 
development, most notably in the eye disc, the wing imaginal disc and the follicle cells of the 
ovary (Kramer et al., 1999; Casci et al., 1999; Reich et al., 1999). Spry expression is 
augmented by a constitutively active EGFR and blocked by a dominant-negative EGFR allele 
(Kramer et al., 1999; Casci et al., 1999; Reich et al., 1999). However, in vertebrates, Spry 
genes do not frequently overlap with sites of EGF activity, perhaps indicating an evolutionary 
divergence from Drosophila (Chambers and Mason, 2000).   
 
Spry was also observed to be up-regulated upon stimulation of RTK signalling in cells in vitro 
culture. In mammalian fibroblasts, EGF and FGF stimulation induces the expression of Spry2 
and Spry4 through the activation of ERK/MAPK cascade, and in mammalian endothelial 
cells, the expression of Spry1 and Spry2 is induced by FGF stimulation (Impagnatiello et al., 





and over-expressed Spry2 negatively regulates HGF signalling (Lee et al., 2004). Mice 
engineered to harbor a K-RasG12D mutation in lung tissues demonstrate a striking up-
regulation Spry2 within the lung epithelium. As a result, mutant embryos exhibited defective 
branching in their lungs, with significantly fewer branches compared to that of the lungs of 
control embryos (Shaw et al., 2007). 
 
RTK–dependent regulation of Spry gene expression by alternative signalling pathways might 
be important in tissues that express Spry proteins but are not engaged in active ERK/MAPK 
signalling (Corson et al., 2003; Kawakami et al., 2003). For example, in a mouse 
chrondrogenic cell line, FGF induced Spry1 and Spry2 expression through Ca2+ dependent 
pathways that require PLCγ (Abe and Naski., 2004).  
 
The regulation of Spry expression in adult tissue has not been extensively characterized. 
Tissue-specific transcription factors also regulate the spatiotemporal expression profile of the 
Spry genes. During mouse kidney development, Spry1 is expressed in both the metanephric 
mesenchyme, destined to become the nephron, as well as the ureteric tree, which forms the 
collecting system (Gross et al., 2003). By contrast, Spry2 expression is restricted to the 
ureteric tree (Gross et al., 2003). Spry1, but not Spry2, is expressed in an overlapping pattern 
with kidney-specific Wilms tumour-suppressor gene (WT1) transcriptional factor, which 
induces expression of Spry1 by directly binding to the Spry1 promoter (Gross et al., 2003). 
The Spry1, Spry2 and Spry4 promoters contain GC-rich regions that include putative binding 
sites for numerous transcription factors (Gross et al., 2003; Ding et al., 2003; Ding et al., 
2004). However, the factors that control the tissue-specific expression of these Spry genes 
remains to be identified. Also, growth factor-dependent activation of the Spry promoters is 
not well understood. A 69-bp Ras–responsive element has been mapped only in the Spry4 







1.4.5 Physiological functions of Sproutys 
The physiological role of vertebrate Sproutys as an antagonist of growth factor signals have 
been investigated using ectopic over-expression, gene-targeting studies and knockout (KO) 
mouse models. 
 
1.4.5.1 Vertebrate development 
The mammalian Sprys are expressed in highly restricted patterns during early development in 
the embryo and their expression shows close correlation with known sites of FGF signalling, 
suggesting that they function as negative regulators of FGF signalling during vertebrate 
embryonic development (Minowada et al., 1999; Chambers et al., 2000).  
 
FGF signalling is regulated by Sprys in lung branching morphogenesis. Similar to 
observations in the Drosophila, using antisense oligonucleotides, knock down of mouse 
Sprouty2 (Spry2) expression in lung organ cultures leads to the significant enhancement of 
lung branching morphogenesis (Tefft et al., 1999). Conversely, targeted over-expression of 
Spry2 or 4 in the peripheral lung epithelium impedes branching (Mailleux et al, 2001; Perl et 
al., 2003), indicating that Spry 2 and 4 inhibit branching morphogenesis of the respiratory 
system. Besides its role in regulating lung morphogenesis, Sprys have a role in regulating the 
development of other organs such as limb, ear and testis development (Minowada et al., 1999; 
Shim et al., 2005; Chi et al., 2006). Sproutys have been implicated in the limb bud formation 
by modulation of FGF signals. Over-expression of Spry2 or Spry4 in the developing chick 
forelimb causes reduced outgrowth, consistent with a decrease in FGF signalling (Minowada 
et al., 1999). In another study, Spry2 was found to also negatively regulate FGF8 signalling in 
the morphogenesis of the organ of Corti in the ear. Spry2-/- mice exhibit severe hearing 
impairment with an abnormal organ of Corti and abnormal cochlear hair cell morphology; this 
defect can be partially reduced by FGF8 dosage (Shim et al., 2005). Recently, Spry genes 
have been shown to regulate odontogenesis via the inhibition of FGF signalling. Sprys are 





and Spry4 in mesenchyme. Loss of function of either gene results in the same phenotype i.e. 
formation of teeth in a region, the diastema, that is normally toothless (Klein et al., 2006). In 
the testis, Sprouty2 was found to be involved in male sex organogenesis by controlling FGF9-
induced mesonephric cell migration to the developing testis (Chi et al., 2006). 
 
Similar to the process of lung branching, the formation of new blood vessels (angiogenesis) 
during the development of the cardiovascular system involves the sequential rounds of 
branching of endothelial cells (Flamme et al., 1997). Signalling through VEGF and FGF 
RTKs is a well established component of angiogenic regulation (Hanahan, 1997). Over-
expression of Spry4 in the vasculature of mouse embryos inhibited blood vessel branching 
during in vivo angiogenesis, suggesting a role for Spry in the regulation of angiogenesis. In 
vitro, Spry4 inhibited bFGF- and VEGF-mediated cell proliferation and migration and 
prevented bFGF- and VEGF-induced MAPK phosphorylation in endothelial cells. These 
findings indicate that Spry4 may repress these tyrosine kinase pathways in the regulation of 
angiogenesis (Lee et al., 2001). 
 
Glial cell line-derived neurotrophic factor (GDNF) signalling is also regulated by Sprys in 
mediating ureteric bud branching. Ureteric branching is induced by GDNF through activation 
of its cognate receptor RET/GFRα1, on cells in the Wolffian duct. Over-expression of human 
Spry2 transgene in mouse kidneys interferes with GDNF-induced ureteric branching 
morphogenesis (Chi et al., 2004). Conversely, Spry1-/- mice display multiple ureteric buds 
due to hypersensitivity of the Wolffian duct to GDNF/RET signalling (Basson et al., 2005). 
GDNF signalling is also important for the development of the peripheral nervous system 
(Edery et al., 1997). Spry2-/- mice suffered from enteric nerve hyperplasia and 
hypergangliosis resulting in esophageal and intestinal contractions. This indicates that the 
abrogation of Spry2 expression results in the hypersensitivity of the enteric neurons to GDNF 






Others studied mice with the combined effects of deletion of Spry2 and Spry4 genes. Half of 
Spry2-/- KOs died after birth (postnatal day 21-28) due to abnormalities in the gastrointestinal 
tract. Similarly, 4 out of 7 Spry4-/- KOs died shortly after birth as they could not breathe 
and/or suckle properly due to mandible defects. The remaining mice were viable and fertile. 
However, Spry2-/- and Spry4-/- double KO mice were embryonically lethal and showed severe 
defects in craniofacial, limb and lung morphogenesis. These findings indicate that Spry2 and 4 
have both redundant and non-redundant functions in embryonic development (Taniguchi et al., 
2007). 
 
1.4.5.2 Proliferation and differentiation 
Over-expressed Spry1 and 2 inhibited FGF- and VEGF-induced endothelial cell proliferation 
and differentiation by repressing FGF- and VEGF-induced MAPK phosphorylation activation 
in endothelial cells (Impagnatiello et al., 2001). Gross et al. (2001) also discovered that Spry1 
and 2 antagonized FGF- and VEGF-induced MAPK phosphorylation in fibroblast cells. Spry 
1 and Spry2 were also found to inhibit serum-induced proliferation of fibroblast cells by 
limiting DNA synthesis in these cells (Gross et al., 2001).  
 
1.4.5.3 Cell motility 
Spry2 has been shown to be involved in regulating the migratory behaviour of cells. In HeLa 
cells, Spry2 inhibits EGF, FGF and platelet-derived growth factor (PDGF) -dependent cell 
migration. The C-terminus region (residues 123-194) was found to be important for mediating 
cell migration (Yigzaw et al., 2001). Further studies by Yigzaw et al. (2003) indicated the 
anti-migratory effect of Spry was mediated by the up-regulation of the activity of protein-
tyrosine phosphatase-1B (PTP-1B). This was responsible for the decrease in phosphorylation 
of p130Cas, an important component of focal adhesion complexes that, in turn, exerts an anti-
migratory effect on cells. Recently, Spry4 was demonstrated to inhibit the migration of human 
prostate cancer cells (Wang et al., 2006). This was followed by the observation that Spry4 





(Tesk1) by binding to it via its C-terminal cysteine-rich region (Leeksma et al., 2002; 
Tsumura et al., 2005). 
 
1.5 Cancer 
The development of cancer is a complex process involving the deregulation of cell signalling 
pathways central to the control of cell growth and cell fate (Fearon and Vogelstein, 1990; 
Sherr, 1996; Hanahan and Weinberg, 2000).  
 
1.5.1 Alterations of three types of genes are responsible for tumourigenesis: 
oncogenes, tumour suppressor genes and stability genes 
Alterations of three types of genes are responsible for tumourigenesis: oncogenes, tumour 
suppressor genes and stability genes (Vogelstein and Kinzler, 2004). These genes are 
implicated in cell proliferation, differentiation, survival and genome integrity and the 
accumulation of alterations in these key cellular genes leads to the deregulation of cell 
signalling pathways central to the control of cell growth and cell fate (Fearon and Vogelstein, 
1990; Sherr, 1996; Hanahan and Weinberg, 2000). The whole process of cell transformation 
has been shown to be somewhat difficult to achieve, due to the intrinsic resistance to 
transformation at both cellular and organism levels; in fact, it may take decades to be 
accomplished through subsequent rounds of clonal selection (Nowell, 2002). Owing to this 
peculiar mechanism, several different combinations of gene inactivations can be found in the 
genome of morphologically similar human cancers, and this phenomenon is potentially 
responsible for the enormous heterogeneity in outcomes of patients with the same clinical 
diagnosis (Sjöblom et al., 2006). To date, only a small fraction of the genes has been 
analyzed. The number and type of alterations responsible for the development of common 
tumour types is unknown (Futreal et al., 2004). Recently, a systemic analysis of the human 
genome sequence has made it possible to identify genetic alterations in cancers in a 
comprehensive and unbiased manner. Analysis of 13,023 genes in 11 breast and colorectal 





in the typical colorectal or breast cancer, respectively. A subset of these genes (average of 14 
and 20, respectively) are expected to contribute to the neoplastic process. These results 
suggest that the number of mutational events occurring during the evolution of human 
tumours is much larger than previously thought (Sjöblom et al., 2006). However, the number 
of genetic hits seems still highly controversial, since majority of mutations identified in 
somatic tumors were ‘passenger mutations’ but not ‘driver mutations’ (Greenman et al., 
2007). 
 
i) Gatekeeper genes: oncogenes and tumour suppressors 
Mutations in oncogenes and tumour suppressor genes and alterations in their signalling 
pathways have been identified to drive the neoplastic process by increasing tumour cell 
number through the stimulation of cell proliferation or the inhibition of cell death or cell-cycle 
arrest (Gan et al., 2003). Oncogenes are mutated in ways to render the gene constitutively 
active or active under the conditions in which the wild-type gene is not. Oncogene activations 
can result from chromosomal translocations, gene amplifications or subtle intragenic 
mutations affecting crucial residues that regulate the activity of the gene product. An 
activating somatic mutation in one allele of an oncogene is generally sufficient to confer a 
selective growth advantage on the cell (Vogelstein and Kinzler, 2004). Tumour suppressor 
genes are targeted in the opposite way by genetic alterations: mutations reduce the activity of 
the gene product. Such inactivations arise from missense mutations at residues crucial for 
activity; from mutations that result in a truncated protein, from deletions or insertions that 
resulted in an altered protein, or from epigenetic silencing (Vogelstein and Kinzler, 2004). 
Generally, mutations in both paternal and maternal alleles of the tumour suppressor genes are 
required to confer selective advantage to the cell. This situation commonly arises through the 
deletion of one allele via a gross chromosomal event, such as loss of an entire chromosome or 
chromosome arm, coupled with an intragenic mutation of the other allele (Knudson, 2002; 
Vogelstein and Kinzler, 2004). Recently, some tumour suppressor genes have been 





the other remains functional (i.e. haplosufficiency) (Santarosa and Ashworth, 2004). 
Mutations in oncogenes and tumour suppressor genes can be classified under 'gatekeeper' 
mutations. Gatekeepers function by directly controlling cell growth, thus inhibiting 
proliferation, leading to apoptosis and/or promoting terminal differentiation. These genes are 
frequently mutated in both sporadic and hereditary tumours, and their functional loss is rate 
limiting for tumour growth of a specific tissue type. Alteration of a particular gatekeeper gene 
can lead to the development of a particular form of predisposition to cancer (Kinzler and 
Vogelstein, 1997; Frank, 2003). p53 gene is one of the most well studied tumour suppressor 
genes. Located on chromosome band 17p13, p53 encodes a 53-kd multifunctional 
transcription factor that regulates the expression of genes involved in cell cycle control, 
apoptosis, DNA repair, and angiogenesis. In breast cancer, most studies have shown that p53 
mutation or down-regulation is associated with an adverse prognosis (Macleod, 2000). 
 
ii) Caretaker genes 
The third class of cancer genes, called stability or 'caretaker' genes are involved in the 
maintenance of genomic stability by reducing the mutation rates in gatekeepers. This class 
includes the mismatch repair (MMR), nucleotide-excision repair (NER) and base-excision 
repair (BER) genes responsible for repairing subtle mistakes made during normal DNA 
replication or induced by exposure to mutagens. Other stability genes control processes 
involving large portions of chromosomes, such as those responsible for mitotic recombination 
and chromosome segregation (for example BRCA1, BLM and ATM). Such genes prevent 
aberrations like aneuploidy and microstatellite instability (Macleod, 2000). Mutations in these 
genes are frequently found in hereditary tumours (Kinzler and Vogelstein, 1997).  
 
Consequently, an altered gatekeeper gene could mainly affect tumour initiation, while a 
caretaker gene could accelerate the tumour progression, even if in certain cases their functions 
may partly overlap; as such the same gene may act either as a gatekeeper or as a caretaker 





1.5.2 Mechanisms of alterations in cancer susceptibility genes 
The marked increase in molecular biological studies within the past three decades has 
revealed that cancer is driven by the progressive accumulation of mutations and epigenetic 
abnormalities in expression of multiple genes that have highly diverse biochemical functions. 
Alterations in these cancer susceptibility genes may result through either genetic or epigenetic 
mechanisms; while the genetic abnormalities are associated with changes in DNA sequence, 
the epigenetic events may lead to alterations in gene expression without changes in DNA 
sequence via various mechanisms. Methylation of DNA and remodeling of chromatin via 
histone proteins, are believed to be the most important epigenetic changes that occur in cancer 
(Weinstein and Joe, 2006). 
 
1.5.2.1 Genetic mechanisms 
Most cancer cells harbour genetic alterations. These genetic alterations consist of abnormal 
chromosome numbers (aneuploidy, polyploidy). The structural changes may occur either at 
the chromosome level (translocations, gains or losses of large parts of chromosomes) or at the 
nucleotide level affecting gene structure and expression (mutations, deletions, gene 
amplifications, microstatellite amplification). The presence of chromosomal abnormalities has 
been shown to correlate with an increased risk of tumour recurrence and cancer progression 
(Croce and Nowell, 1985; Jefford and Irminger-Finger, 2006).  
 
The various types of genetic alterations responsible for tumour development may be divided 
into five groups: 
(a) At the molecular level, subtle sequence changes involved base substitutions, deletions or 
insertions of nucleotides. Mutations of protein-coding genes efficiently render gain- or loss-
of-function of the important proteins involved in tumourigenesis. For instance, 80% of 
pancreatic cancers have missense mutations in the K-Ras gene. 
(b) At the genome level, faulty mismatch repair pathways generate microstatellite instability 





(c) At the chromosomal level, gene amplification may occur. An example of this is the N-myc 
amplification which occurs in 30% of neuroblastoma cells. 
(d) At the chromosomal level, illegitimate mitotic inter- or intra-chromosome recombination 
may result in neomorphic (gain-in-function) or hypermorphic (over-expression) mutations 
that cause neoplasia. Most recombinations in cancers are translocations. In haematological 
malignancies, the phenotype at the molecular level stems from abnormal expression of fusion 
proteins or over-expression of growth related factors when translocations relocate genes in the 
vicinity of high expressing promoters. The best-known example is the Philadelphia 
chromosome in chronic myelogenous leukaemia (CML), whereby a fraction of chromosome 9 
is fused to chromosome 22, causing the aberrant expression of a neomorphic tyrosine kinase 
(BCR-Abl).  
(e) Also at the chromosomal level, most tumours show structural and numerical chromosomal 
rearrangements resulting in gains and losses of large chromosome parts or even whole 
chromosomes leading to aneuploid karyotypes. Numerical and structural aberrations have 
been systematically reported in the Mitelman Database of Chromosome Aberrations in 
Cancer (http://cgap.nci.nih.gov/Chromosomes/Mittelman) (Jefford and Irminger-Finger, 
2006).  
 
1.5.2.2 Epigenetic mechanisms 
Two changes that are integral to epigenetic transcriptional control are DNA methylation and 
covalent modification of histone proteins (Jones and Baylin, 2002; Johnstone, 2002).  
Hypermethylation of short CpG-rich regions, known as CpG islands, was found to occur in 
cancer. These islands, found in the promoter region of about half of the genes, are generally 
unmethylated in normal cells. However, hypermethylation of CpG islands has been observed 
in nearly every type of human tumour, with unique patterns of individual gene methylation 
exhibited by each tumour type (Costello and Plass, 2001; Esteller, 2002). Abnormal 
methylation of CpG islands can efficiently repress transcription of the associated gene in a 





hypothesis for tumour generation (Jones and Laird, 1999; Baylin and Herman, 2000; Jones 
and Baylin, 2002).  
 
DNA methylation interferes with gene expression by direct and indirect mechanisms. First, 
methylation of a CpG site in the recognition sequence of a transcription factor hinders its 
interaction with DNA recognition sequences (Comb and Goodman, 1990; Prendergast et al., 
1991). Secondly, methylation of a region around a transcription regulatory site attracts 
methylated DNA binding domain (MBD) proteins, such as MeCp2, which recruit 
corepressors and histone deacetylases (HDAC) that inactivate the chromatin configuration 
around the gene (Nan et al., 1998a, 1998b). DNA methyltransferases, which are responsible 
for methylation of the DNA, also recruit histone deacetylases, leading to histone deacetylation 
and transcriptional repression. A number of candidate tumour suppressor genes that are not 
commonly inactivated by mutation are transcriptionally silenced by this mechanism (Jones 
and Baylin, 2002).  
 
The second major layer of epigenetic transcriptional control that has been widely studied is 
modification of histone proteins. These proteins serve as building blocks to package 
eukaryotic DNA into repeating nucleosomal units that are folded into higher order chromatin 
fibers. Histones undergo elaborate post-translational modifications on their amino-terminal 
tails, including acetylation, methylation, phosphorylation and ubiquitination (D'Alessio and 
Szyf, 2006). Acetylation has been the most extensively studied and is controlled by histone 
acetyltransferases and histone deacetylases. Acetylation is associated with nucleosome 
remodeling and transcriptional activation, whereas deacetylation is associated with 
transcriptional repression via chromatin condensation. In addition to their histone-modifying 
activity, histone deacetylases may also control gene expression by deacetylating transcription 






The two layers of epigenetic control, DNA methylation and histone acetylation, are integrally 
linked. The discovery of methylated DNA binding proteins and their ability to recruit histone 
modifying proteins to methylated genes led to the conclusion that DNA methylation patterns 
dictate chromatin structure. Recent data, however, suggest that this unidirectional picture 
needs to be revisited and that chromatin structure could also dictate DNA methylation 
patterns (D'Alessio and Szyf, 2006). Proteins that are involved in the silencing of chromatin 
were also shown to recruit DNA methyltransferases to genes (Fuks et al., 2000; Brenner et 
al., 2005; Vire et al., 2006).  
 
1.5.2.3 Transcriptional mechanisms 
Aberrations in the biochemical properties of transcription factors or the regulatory 
mechanisms that fine tune their activity, because of either genetic defects or abnormal 
internal/external cues, can lead to wide gamut of human malignancies (Karamouzis et al., 
2002).  
 
Transcription factors play a pivotal role in the gene transcription process. Regulated 
eukaryotic gene transcription involves the assembly of an initiation complex at the core 
promoter region and the coordinated binding of multiple transcription factors and regulatory 
complexes to the promoter enhancer region. Transcription factors affect the basal 
transcriptional machinery and regulate the transcriptional rate. Hence, they influence the 
expression level of the corresponding gene. Their ultimate action may be positive (activators) 
or negative (repressors). The activity of many of these transcription factors is regulated in a 
number of different ways by distinct signal transduction pathways: by changing the rate of 
synthesis or degradation of the protein, by post-translational modification of the transcription 
factor or by altering its subcellular localization. Since transcription factor mutations and 
perturbations in signal transduction pathways modulating their activity contribute to a wide 





tumourigenesis is of vital importance for the design of new anti-cancer drugs (Karamouzis et 
al., 2002). 
 
Cancer susceptible genes can also be deregulated in gene expression via modifications of 
mRNA stability and/or translational efficiency in cancer. mRNA stability and translation are 
controlled through a complex network of RNA/protein interactions involving recognition of 
specific target mRNAs by RNA-binding proteins (RNA-BPs). Alterations in regulatory 
sequences, RNA-BPs, or in upstream signalling pathways affect the stability and/or 
translational efficiency of mRNAs encoding proto-oncogenes, cytokines, cell cycle regulators 
and other regulatory proteins to promote tumourigenesis and cancer progression (Audic and 
Hartley, 2004).  
 
1.5.3 Implications of alteration in cancer susceptibility genes 
Certain classes of signalling proteins and pathways are targeted much more frequently by 
oncogenic mutations than others (Hunter, 1997; Hanahan and Weinberg, 2000). Proteins 
governing extracellular growth, differentiation and developmental signals, in particular, are 
often mutated in cancers. One illustrative example is provided by receptor tyrosine kinases 
(RTKs), a subclass of transmembrane-spanning receptors endowed with intrinsic, ligand 
stimulatable tyrosine kinase activity. When mutated or altered structurally, RTKs can become 
potent oncoproteins, causing cellular transformation (Blume-Jensen and Hunter, 2001). The 
oncogenicity of such RTKs is mediated by their downstream signalling pathways such as Ras 
and PI3 Kinase (Shaw and Cantley, 2006). The Ras, PI3 kinase signalling pathways form an 
intersecting biochemical network that, when mutated, drive cell growth and tumourigenesis. 
These processes are driven by the phosphorylation of proteins that directly regulate protein 
synthesis, cell cycle progression and metabolism, and through the binding of transcriptional 




















Constitutive activation of RTKs. The most important mechanisms leading to constitutive 
RTK signalling include: over-expression and/or gene amplification of RTKs, genetic 
alterations such as deletions and mutations within the extracellular domain as well as 
alterations of the catalytic site, or autocrine–paracrine stimulation through aberrant growth 
factor loops. Abbreviations: P, phosphorylated tyrosine residue; RTK, receptor tyrosine 
kinase. 
 









1.5.3.1 RTKs as oncogenes 
In normal cells, the activity of RTKs and their mediated cellular signalling is precisely co-
ordinated and tightly controlled. Deregulation of this RTK signalling system, either by 
stimulation through autocrine–paracrine growth factor loops and/or genetic alteration, result 
in deregulated tyrosine kinase activity (Fig 1.5.3.1). Constitutive or strongly enhanced 
signalling capacity of RTKs can result in malignant transformation of cells. Therefore, RTKs 
are frequently implicated in human cancers. In many human cancers, gene amplification 
and/or over-expression of RTKs occur, which might increase the response of cancer cells to 
normal growth factor levels. Additionally, over-expression of a specific RTK on the cell 
surface increases the incidence of receptor dimerization even in the absence of an activating 
ligand. In many cases this results in constitutive activation of the RTK leading to aberrant and 
uncontrolled cell proliferation and tumour formation (Robertson et al., 2000). Another 
important mechanism of constitutive RTK signalling involves autocrine–paracrine stimulation 
through growth factor loops and has been described for the EGFR and insulin-like growth 
factor-I receptor (IGF-IR) families (Derynck et al., 1987; Kaleko et al., 1990). This potent 
mechanism of activation occurs when an RTK is aberrantly expressed or over-expressed in 
the presence of its cognate ligand, or when over-expression of the ligand occurs in the 
presence of its associated receptor. For example, it has been shown in many solid tumours 
that elevated levels of both growth factor receptor and its ligand are expressed concomitantly 
(Salomon et al., 1995). 
 
1.5.3.2 Oncogenes in the Ras-Raf-MEK-ERK pathway  
The intracellular Ras-regulated Raf/MEK/ERK protein kinase signalling cascade has long 
been associated with human cancers and was found to be hyperactivated in ~30% of cancers 
(Hoshino et al., 1999) with activating mutations in Ras occurring in approximately 15%–30% 
of cancers (Bos, 1989). Recent data has shown that B-Raf is mutated in about 7% of cancers 







Since the initial discovery of mutationally-activated Ras genes in human tumours more than 2 
decades ago, much has been established regarding their key roles in oncogenesis and 
regulation of cytoplasmic signalling networks (Shields et al., 2000; Feig and Buchsbaum, 
2002, Feig, 2003; Cox and Der, 2003). Ras proteins control signal transduction pathways 
downstream from transiently activated (ligand-bound) tyrosine kinase receptors and G 
protein-coupled receptors (Carpenter, 2000; Kranenburg and Moolenaar, 2001). The aberrant 
activation of Ras proteins has been implicated in facilitating virtually all aspects of the 
malignant phenotype of the cancer cell, including cellular proliferation, transformation, 
invasion and metastasis (Malumbres and Barbacid, 2003). Additionally, the functions of other 
Ras-related proteins are also regulated by Ras signalling and contribute to oncogenesis.  
 
Mutationally-activated forms of Ras, such as H-Ras, K-Ras and N-Ras, have been shown to 
efficiently transform cells in vitro (morphological transformation, uncontrolled proliferation 
and anchorage-independent growth) and in vivo (tumour formation, invasion and metastasis), 
and such mutations are common in a broad spectrum of human tumours (Bos, 1989). Mutated 
variants of Ras (mutations at codons G12, G13 or G61) are found in 30% of all human 
cancers and are insensitive to GAP stimulation. This greatly impairs the ability of Ras to 
hydrolyze bound GTP and thereby its intrinsic ability to switch off. As a result, mutant 
(GTPase-deficient) Ras proteins constitutively stimulate signal transduction through their 
effector pathways and are constitutively active (Barbacid, 1987; Bos, 1989). Examples of Ras 




For most of their history, Raf proteins have been considered to be important in cancer only 















Tumour type Pathway mutations 
Colon K-Ras (45%), B-Raf (12%) 
Pancreatic K-Ras (90%) 
Ovarian B-Raf (30%) 
Melanoma N-Ras (15%), B-Raf (66%) 
Non-small-cell lung K-Ras (35%) 
Papilary thyroid H-Ras, K-Ras and N-Ras (60%);  
B-Raf (35-60%) 




Human tumours exhibiting activated Ras-MAPK signalling. Abbreviations: ALL, acute 
lymphocytic leukaemia; AML, acute myeloid leukaemia; MAPK, mitogen-activated protein 
kinase. 
 












discovered that B-Raf is also mutated at a high frequency in a wide variety cancers (Table 
1.5.3.2.1) (Davies et al., 2002; Sebolt-Leopold and Herrera, 2004). Over 40 different 
missense mutations in B-Raf, involving 24 different codons, have been identified. Most 
mutations are extremely rare, accounting for 0.1%–2% of all cases. However, a thymidine to 
adenosine transversion at nucleotide 1796, converting valine 599 (V599) to glutamate 
predominates (Davies et al., 2002). It accounts for most (over 90%) of the mutations in 
melanoma and thyroid cancer and for a high proportion of those in colorectal cancer, but is 
comparatively rare in non-small cell lung cancer (Brose et al. 2002; Davies et al. 2002; 
Rajagopalan et al. 2002; Yuen et al. 2002; Fukushima et al. 2003; Kimura et al. 2003; Kumar 
et al. 2003; Nikiforova et al. 2003). V599EB-Raf is one of the most active B-Raf mutants; its in 
vitro kinase activity being ~500 fold greater than that of WTB-Raf (Wan et al., 2004). In 
NIH3T3 cells and murine melanocytes, V599EB-Raf stimulates constitutive ERK signalling, 
induces proliferation and transformation, and allows these cells to grow as tumours in nude 
mice (Davies et al. 2002; Ikenoue et al. 2003; Ikenoue et al. 2004; Houben et al. 2004; Wan 
et al. 2004 and Wellbrock et al. 2004). These data indicate that B-Raf is an oncogene.  
 
1.5.3.3 Tumour suppressors 
Multiple genetic and epigenetic changes are associated with the progression of a normal cell 
to a full-blown metastatic tumour (Payne and Kemp, 2005). The genes affected by these 
changes have been classically defined as either proto-oncogenes, where gain-of-function 
mutations act dominantly, and tumour suppressor genes, which are recessive and are 
inactivated by mutation or loss. Over 30 years ago, Knudson (1971; 2001) advanced a model 
of tumourigenesis stipulating that inactivation of both alleles of a tumour suppressor gene was 
required to promote tumour progression. This model was developed by analysis of the age of 
onset of the hereditary form of retinoblastoma compared to that of the sporadic disease. As 
with several other hereditary cancer syndromes, the predisposition to develop cancer arises as 
a consequence of a heterozygous germ-line mutation of one tumour suppressor gene allele. It 





prompted Knudson to postulate that the inactivation of both tumour suppressor gene alleles 
was required to develop a cancer phenotype (Payne and Kemp, 2005). The early development 
of cancer in hereditary cancer syndromes is because individuals carry a constitutional germ-
line mutation in a tumour suppressor gene and therefore inactivation of the other allele is the 
rate-limiting step. Compared to hereditary cancer, sporadic cancer requires a considerably 
longer time to develop because two mutational events - the inactivation of both alleles of the 
same gene - have to occur. Cancer was caused by disruption of both RB1 alleles, and 
subsequently loss of RB1 protein (Friend et al., 1986). Thus was born the 'two-hit hypothesis'. 
This represented a new class of cancer genes, the recessive anti-oncogenes, now known as 
tumour suppressor genes (Murphree and Benedict, 1984; Knudson, 1988; Knudson, 1993). 
 
While this model has provided a useful conceptual framework for three decades of research, 
recently, it has become clear that mutations in tumour suppressor genes are not always 
recessive. Although originally thought to be of little functional significance, there is now 
considerable evidence suggesting that loss of only one allele of a tumour suppressor might 
contribute to the tumourigenic process (Santarosa and Ashworth, 2004). Haplo-insufficiency 
occurs when one allele is insufficient to confer full functionality produced from two wild-type 
alleles (Fig 1.5.3.3). There are a number of ways haplo-insufficiency of certain tumour 
suppressor genes may be explained: first, haploid levels of a tumour suppressor gene product 
are insufficient to inhibit the activity of critical downstream target proteins involved in 
stimulating growth; second, a tumour suppressor mutation causes it to act in a dominant 
negative manner to block the activity of wild-type tumour suppressor protein; and third, 
expression of the wild-type allele is shut off/reduced as a result of other cooperating 
mutations or epistatic events. As a result, haplo-insufficient tumour suppressor genes also 
contribute to accelerated tumourigenesis, however, without the requirement for inherited 
mutation of one allele (Macleod, 2000; Payne and Kemp, 2005). Indeed, there are now 
numerous examples of functional effects of heterozygous loss-of-function mutations in genes 














Inactivation of tumour suppressor genes. Classic tumour suppressor genes are inactivated 
via ‘two hits’. In the case of inherited cancer susceptibility, one of these ‘hits’ is acquired in 
the germline with the second ‘hit’ being acquired somatically during tumour development. 
Haploinsufficient tumour suppressor genes are compromised by a single ‘hit’, obviating the 
need to sustain ‘two hits’ during the course of tumour development. 
 













(Quon and Berns, 2001; Paige, 2003). The future of tumour suppressor identification is 
therefore likely to involve exceptions to the two-hit model of inactivating mutations. A 
validation criteria for tumour suppressor genes was proposed recently. Proof of a tumour 
suppressor gene will require (i) identification of loss of function in the development of a 
cancer and (ii) demonstration that inactivation of the gene in vivo enhances tumour initiation, 
growth or progression (Paige, 2003).  
 
1.5.4 Tumour markers 
The knowledge of the natural history of cancer progression has advanced in the past decade, 
but has been limited, in part, by the technology available to detect it. Multiple sequential, 
parallel and interconnected changes in cellular machinery over-ride biological regulation, and 
lead to cells becoming neoplastic and invasive. If cancer could be detected at the incipient 
stage and its advance halted, the mortality associated with the disease would be reduced 
(Srinivas et al., 2001). Unfortunately, in many cases, cancer is diagnosed and treated too late, 
when the cancer cells have already invaded and metastasized throughout the body. More than 
60% of patients with breast, lung, colon and ovarian cancer already have hidden or overt 
metastatic colonies. At this stage, therapeutic modalities are limited in their success. 
Therefore, detecting cancers at their earliest stages, even in the pre-malignant state, would 
enable current or future treatment modalities to have a higher likelihood of cure (Petricoin et 
al., 2002).  
 
Detection depends on the identification of reliable tumour markers that provide an indication 
of the transformation of a cell from a non-diseased to a neoplastic phenotype. Tumour 
markers are defined as cellular, biochemical, molecular or genetic alterations by which the 
tumourigenic process can be recognized or monitored. Tumour markers are measurable in 
biological media, such as human tissues, cells or fluids, and can be used to identify 





must have high predictive accuracy, be easily measurable and reproducible, minimally 
invasive and must be able to detect cancer at their earliest stages (Srinivas et al., 2001). 
 
Identifying the molecular alterations that distinguish any particular cancer cell from a normal 
cell will ultimately help to define and predict the nature and pathologic behavior of that 
cancer (prognosis). It will also indicate the responsiveness to treatment of that particular 
tumour. Understanding the profile of molecular changes in any particular cancer will be 
extremely useful as it will become possible to correlate the resulting phenotype of that cancer 
with molecular events. Achieving these goals and knowledge will provide an opportunity for 
discovering new biomarkers for early cancer detection and developing prevention approaches. 
This will also help us identify new targets for therapeutic development (Srinivas et al., 2001). 
 
A large number of molecular markers have been studied to determine their ability to predict 
prognosis or response to therapy, or both. In addition, several classes of tumour markers have 
been used routinely to make treatment decisions in patients with early-stage breast cancer. 
These include markers of proliferation (e.g. Ki-67), hormone receptors, and the human 
epidermal growth factor receptor 2 (EGFR2/HER-2/ErbB2). Ki-67 is used as an important 
prognostic marker to predict tumour proliferation rate; estrogen and progesterone status are 
used to select appropriate hormonal therapy. HER-2/c-ErbB2 is over-expressed in 20-30% of 
breast tumours and such tumours generally have a poorer prognosis. HER-2/c-ErbB2 has been 
used as a marker to establish predictive assays, as clinical trials show the potential benefits of 
Herceptin TM (trastuzumab) therapy for patients with invasive breast carcinomas that over-
express the HER-2/ErBb2 protein. Herceptin therapy consists of a humanized monoclonal 
antibody which targets the HER-2/ErbB2 antigen and inhibits the growth of HER-2/ErbB2 








1.6 Polyoma Middle T antigen (PyMT) as a cancer model 
In this study, we have utilized PyMT as a cancer model in order to test whether Spry proteins 
are capable of inhibiting oncogene-induced cell transformation. 
 
1.6.1 Introduction to Polyoma virus  
The study of viruses has contributed greatly to our understanding of tumour formation. One of 
the first few viruses to be isolated and studied for its tumour transforming potential was the 
mouse polyoma virus (PyV). PyV was discovered by Ludwik Gross over 50 years ago (Gross, 
1953) and was found to cause a variety of tumours when innoculated into mice (Eddy et al., 
1958), leading it to being named polyoma virus. It soon became a popular model to study the 
mechanisms of cell transformation and tumour formation (Dilworth, 2002). 
 
The PyV region expressed early in the lytic cycle encodes 3 proteins or T-antigens: large 
antigen (PyLT), middle T antigen (PyMT) and small T antigen (PyST). These proteins are 
obtained by differential splicing of the mRNA derived from the same genomic DNA sequence 
(Ichaso and Dilworth, 2001). Together, these proteins cause the infected cell to enter the cell 
cycle and so provide a suitable cellular environment for replication of the viral genome. 
Under some circumstances, infection does not kill the cell, but the T-antigens are still 
produced, resulting in the cell becoming transformed and tumourigenic. Most of this 
transforming action is exerted by the middle T antigen, which has the ability to convert 
established cell lines into an oncogenic state (Treisman et al., 1981). 
 
1.6.2 PyMT as a model to study transformation 
Polyoma Middle T antigen (PyMT), the principal transforming component of the polyoma 
virus (DNA virus), is often used as a model to study cell transformation. Polyoma virus 
transforms rat fibroblasts in culture and induces a broad spectrum of tumours when inoculated 
into newborn mice (Tooze, 1980; Gross, 1983). Biochemical and genetic studies in tissue 





established cell lines (Treisman et al., 1981; Raptis et al., 1985). It can also cause a variety of 
tumours in animals, even without the expression of PyLT or PyST (Kiefer et al., 1994). The 
majority of these in vivo tumours are endothelial in origin, but targeted expression can be used 
to form tumours in a variety of cell types, particularly breast tissue (Dankort and Muller, 
2000; Lin et al., 2003).  
 
The membrane bound PyMT has no intrinsic enzyme activity but acts as a scaffolding protein 
that binds and modulates the activities of a number of signalling proteins (Ichaso and 
Dilworth, 2001; Gottlieb and Villarreal, 2001). The ability of middle T antigen to transform 
cells and induce tumours is dependent on its association with and activation of a series of 
signalling molecules that control cell proliferation and contact inhibition of cells. By altering 
normal regulation of cells, cellular transformation would be detected as foci of dense 
morphologically-altered cells among the monolayer of normal cells (Dilworth, 1995; 
Nicholson et al., 2001). Most of the proteins targeted by PyMT are those involved in the 
signalling pathways used to promote cell growth by activated, tyrosine kinase-associated 
receptors. Studies with PyMT have provided great insight into a number of critical signalling 
pathways involved in growth control (Dilworth, 2002). Due to its ability to activate multiple 
signalling pathways commonly activated by growth receptors, in many respects PyMT can be 
considered a permanently active analogue of a growth factor receptor.  
 
1.6.3 General structure of PyMT 
PyMT is 421 amino acids (aa) long (nucleotides 175 to 748 [aa 1 to 191] spliced to 811 to 
1499 [aa 192 to 421]) (Fig. 1.6.3). It has a molecular mass of 55 kDa and contains a tail of 22 
hydrophobic amino acids (aa 394 to 415) at its carboxyl terminus, bound on either side by 
clusters rich in basic residues (Carmichael et al., 1982). There are multiple phosphorylation 
sites throughout PyMT, including the well-studied tyrosines at aa 250, 315 and 322, serines at 
aa 257 and 283, and threonines at aa 160 and 291 (Hunter et al., 1984; Perez et al., 1993). In 





region associated with pp60c-src (aa 185 to 210). While pp60c-src (and other members of the 
src family) serves as tyrosine kinases, protein kinase C and another as yet unnamed kinase 
provide serine phosphorylation (Matthews and Benjamin, 1986). However, in PyMT-infected 
cells, only a small portion of PyMT is phosphorylated; among this fraction, most is serine 
phosphorylation while a significantly lesser portion is tyrosine and threonine phosphorylation 
(Segawa and Ito, 1982).  
 
1.6.4 PyMT signalling pathways 
PyMT transforms cells by activating several key signal transduction pathways, including 
those of the Src family, the Ras/MAPK and the PI3 kinase pathways (Fig. 1.6.4). These same 
pathways are known to be abnormally activated in some human cancers. In a series of 
interactions, PyMT binds first to the A and C subunits of PP2A (Pallas et al., 1990; Walter et 
al., 1990; Ulug et al., 1992), and then associates with and activates one of the src-family of 
tyrosine kinases, pp60c-src, pp62c-yes or pp59c-fyn (Benjamin, 1982; Carmichael et al., 
1982; Courtneidge and Smith, 1983; Kornbluth et al., 1987; Horak et al., 1989; Kypta et al., 
1988). The pp60c-src then phosphorylates at least three residues in the C-terminal half of 
PyMT, which serve as binding sites for SH2 or PTB domain-containing proteins; 
phosphorylated Tyr315 in PyMT binds to the SH2 domain of the 85 kDa component of PI3K 
(Whitman et al., 1985; Kaplan et al., 1986), phospho-tyrosine 322 binds to the SH2 domain 
of PLCγ-1 (Su et al., 1995) and phosphotyrosine 250 interacts with the PTB domain of ShcA 
(Campbell et al., 1994; Dilworth et al., 1994; Blaikie et al., 1997).  
 
The PyMT-associated PI3K, PLCγ-1 and ShcA proteins are in turn tyrosine phosphorylated 
by pp60c-src, resulting in stimulation of PI3K (Coutneidge and Heber, 1987; Kaplan et al., 
1987) and PLCγ-1 (Su et al., 1995) enzymatic activity. Tyrosine phosphorylation on ShcA 
creates binding sites for Grb2 with its associated Sos1 and Gab1 proteins. This activates 
p21ras, and consequently the ERK/MAP kinase cascade (Campbell et al., 1994; Dilworth et 














Schematic diagram of PyMT. PyMT is 421 aa long and is encoded by nucleotides 175 to 
748 (aa 1 to 191) spliced to 811 to 1499 (aa 192 to 421) based upon the sequence numbering 
of the A2 wild-type strain. The membrane-spanning domain consists of hydrophobic aa 
394 to 415. On interaction with the plasma membrane, PyMT associates with (although does 
not directly bind to) src, a tyrosine kinase, resulting in the phosphorylation of tyrosines at aa 
250, 315, and 322 and in the binding of Shc, PI 3-kinase, and PLCγ-1. In addition, PyMT 
contains serine (aa 257 and 283) and threonine (aa 160 and 291) phosphorylation sites. The 
phosphorylation of serine 257 results in the interaction with the 14-3-3 proteins. Finally, 
PyMT associates with both the catalytic subunit C and the regulatory domain A of PP2A at aa 
90 to 120.  
 



























A diagrammatic representation of Shc and PI3-kinase (PI3K) pathways stimulated by 
membrane-bound PyMT. Association of Src family kinases with membrane-bound PyMT 
can result in the phosphorylation of PyMT tyrosines 250 (Y250) and 315 (Y315). 
Phosphorylation of PyMT Y250 can serve as a docking site for Shc, which recruits the Grb2 
adaptor protein, which, in turn, binds the Sos guanine nucleotide exchange factor resulting in 
the activation of Ras. Ras activation can lead to the activation of the Raf-MAP kinase 
cascade, resulting in the phosphorylation of MEK and ERK. Phosphorylation of PyMT 
tyrosine 315 (Y315) results in the binding of the PI3-kinase regulatory p85 subunit and 
subsequent activation of PI3 kinase activity, resulting in the phosphorylation of a number of 
cellular targets including Akt. 
 









Shc and PI3 kinase pathways, which are required for stimulation of cell proliferation and 
survival signalling pathways, respectively (Webster et al., 1998). Removal of either the ShcA 
or the PI3 kinase binding site dramatically decreases transformation induction by PyMT, 
suggesting that MAP kinase activation is a significant factor in PyMT tumourigenesis 




























1.7 Aims of research 
Enhanced signalling by EGF and FGF family members lead to a strong induction of Spry 
mRNA and proteins. Accumulated evidence indicates that Spry proteins provide a means to 
turn off the Ras/MAP kinase pathway and that this process, in coordination with pathway 
activation, may play an important role in modeling branching tissues, such as in development 
of the lung, kidney tubules, vascular system and breast ducts. Ras/ERK pathway is frequently 
deregulated in cancers. Since induction of Spry proteins would predictably impede cancer 
growth, one would expect that down-regulation of Spry would exacerbate the tumourigenic 
effects of enhanced growth factor signalling. This may be manifested in the form of abnormal 
development or in deregulated growth as seen in cancers.  
 
The following questions were therefore asked: 
(1) Is hSpry1 and hSpry2 expression down-regulated in cancers?  
(2) If so, what is the epigenetic, genetic or transcriptional mechanism that mediates down-
regulation of Spry? 



























MATERIALS AND METHODS 
 
2.1 Chemicals and reagents 
Bovine serum albumin (BSA), Luria-Bertani (LB) medium and ampicillin were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  The phosphate-buffered saline (PBS) used in all 
assays was composed of 137 mM NaCl, 2.7 mM KCl, 4.3 mM KH2PO4 and 1.4 mM 
K2HPO4.7H2O at pH 7.3. All other chemicals were purchased from either Sigma (St. Louis, 
MO, USA) or BDH Laboratory Supplies (Poole, England). 
 
2.2 DNA Methodology 
2.2.1 General DNA manipulations 
General recombination DNA manipulations were performed essentially as described by 
Sambrook and Russell (2001). Restriction enzyme digests and other DNA modifications such 
as ligation of DNA and de-phosphorylation of cloning vectors were performed using the 
appropriate buffers specified and supplied by the manufacturers (New England Biolabs, Inc., 
Beverly, MA). Polymerase chain reactions (PCR) were carried out in a thermal cycler 
[Thermal cycler PTC-200 from MJ Research Inc. (Watertown, Massachusetts)] using Expand 
Long Template PCR system (Roche Molecular Biochemicals, Mannheim, FRG) or using high 
fidelity Pfu DNA polymerase (Promega, Madison, WI). DNA fragments from agarose gels 
were purified using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, FRG), according to 
the manufacturer's instructions. Rapid ligation kit from Roche or T4 ligase from New England 
Biolabs were used for DNA ligation. DNA sequencing was carried out with the capillary 
Applied Biosystems sequencers ABI 3730xl and Applied Biosystems Big Dye Terminator 







2.2.2 Preparation of electro-competent cells 
The DH10β E.coli strain was streaked onto an LB (pH 7.5) agar plate (containing 1% bacto-
tryptone, 0.5% bacto-yeast extract, 1% NaCl and 1.5% agar) without antibiotics and incubated 
at 37°C overnight. A single colony was inoculated into 30 ml of LB and grown at 37°C with 
shaking.  7-9 ml of the overnight culture was added to 800 ml of fresh LB broth and grown 
for approximately 3 hr at 37°C with shaking (220 rpm) to an optical density at 600 nm 
(OD600) of about 0.8-0.9. When the appropriate OD reading was obtained, the bacterial culture 
flask was chilled on ice for 15-30 min. From this stage, cells were kept in ice-cold conditions 
throughout the whole process. Cells were harvested by centrifugation at (4000 rpm for 15 min 
at 4°C) and resuspended in ice-cold sterile 10% glycerol (for every 400 ml of initial culture, 
400 ml sterile glycerol was used) and the spin was repeated. The cells were washed an 
additional 3 times with ice-cold 10% glycerol (200 ml, 20 ml, 10 ml) and, after the last wash, 
the pellet was resuspended in 2-4 ml ice-cold 10% glycerol. Subsequently, cells were divided 
into 50 µl aliquots, snap-frozen in liquid nitrogen and stored at -80°C. 
 
For electroporation, 50 µl electro-competent cells were added to no more than 3 µl DNA and 
after gentle mixing, the solution was pipetted into an electroporation cuvette (Gene Pulser 
Cuvette, Bio-Rad, Hercules, CA). The electroporation was carried out with the Micro Pulser 
(Bio-Rad) (program EC2 ; 5.1-5.3 msec). Immediately after the electroporation, 0.5-1 ml of 
SOC media (2% bacto-tryptone, 0.5% bacto yeast extract, 10 mM NaCl, 2 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose) was added, and the whole solution was transferred 
to an Eppendorf tube. Following a recovery for 30 min at 37°C shaking, cells were plated 
onto antibiotic selection LB agar plates. 
 
2.2.3 Purification and analysis of DNA 
Plasmid DNA was purified using the QIAprep procedure (QIAGEN, Hilden, FRG) that is 
based on alkaline lysis of bacterial cells and clearing the lysates under high salt conditions. 





to precipitate, while the plasmid DNA stays in solution. The latter is isolated by adsorption of 
DNA onto silica and subsequent elution in a low salt buffer. The concentration of plasmids 
recovered by this method is usually in the range of 0.1-0.4 mg/ml.  
 
Analysis of DNA was carried out by agarose gel electrophoresis in TAE buffer (40 mM Tris-
acetate, 10 mM EDTA). 0.8-1.2% (w/v) agarose gels were cast in TAE buffer containing 1 
µg/ml ethidium bromide (EtBr). The DNA samples were mixed with DNA loading buffer 
[0.1% Orange G, 30% Ficoll (type 400)] and loaded onto the agarose gel alongside 1 kb DNA 
ladder marker as a molecular weight standard to determine the size of the DNA. The detection 
of the DNA bands was carried out using UV trans-illuminator. 
 
2.2.4 Plasmid constructions 
Wild type full-length constructs of different isoforms of Spry in mammalian expression 
vectors pXJ40FLAG (courtesy of Prof. E. Manser, Glaxo Lab, IMCB), pRK4-FGFR1 have 
been described previously (Yusoff et al., 2002; Fong et al., 2003; Lao et al., 2006). hSpry2 
and hSpry2Y55F cDNA were subcloned into pCMVTag2B vector (Stratagene, San Diego, CA) 
which confers both ampicillin and neomycin resistance, and pBABE vector (courtesy of Prof. 
Joan Brugge Lab, Harvard Medical School) which confers ampicillin and puromycin 
resistance. Human hSprouty1 (hSpry1) and hSprouty4 (hSpry4) cDNA was PCR-amplified 
from adult human embryonic kidney 293T cell line cDNA and subcloned into pXJ40FLAG 
mammalian expression vectors (courtesy of Dr. E. Manser, Glaxo Lab, IMCB). This cloning 
vector confers ampicillin resistance. The N-terminal cDNA fragment of hSpry1 (nucleotide 1-
540) and hSpry2 (nucleotide 1-531) were subcloned into pBluescript KS (-) (Stratagene, San 
Diego, St Louis). Polyoma Middle T antigen, PyMT (A3 strain), derived from J4mT (Webster 








2.2.5 Reverse transcription and polymerase chain reaction (RT-PCR) analysis 
Reverse transcription reactions were performed using 5 µg of DNAse-treated RNA, 1 µl of 
oligo(dT)12-18  and 1 µl SUPERSCRIPT II RNase H-, using the First-Strand Synthesis System 
for RT-PCR kit protocol (Invitrogen Life Technologies, Carlsbad, CA). PCR reactions were 
carried out using 2 µl of cDNA with the following PCR primers:  
 
Constructs Primer Sequence (5' to 3') 
human Spry2 forward 5’ GCGATCACGGAGTTCAG 3’  
reverse 5’ GTGGAGTCTCTCGTGT 3’ 
human Spry1 forward 5’ AGGGCTATCTTCCTAGCA 3’  
reverse 5’ GTGAGAAGCATGGGGT 3’ 
human GAPDH forward 5’ GGTGTGAACCATGAGAAG 3’ 
reverse 5’ CCACAGTTTCCCGGAG 3’ 
human maspin forward 5’ GCTTTTGCCGTTGATCTGTTC 3’ 
reverse 5’ GATCTGACCTTTCGTTTCTTCCA 3’ 
human β-microglobulin forward 5’ CTCGCGCTACTCTCTCTTTCTGG 3’ 
reverse 5’ GCTTACATGTCTCGATCCCACTTAA 3’ 
 
The PCR conditions were as follows: 1 cycle at 96°C for 2min and 35 cycles at 96°C for 30s, 
55°C for 30s, 72°C for 1min. Samples were kept at 72°C for 10 min after the last cycle. The 
β-microglobulin and GADPH genes were co-amplified as internal controls. The PCR products 
were resolved by electrophoresis on 1% agarose gels. 
 
2.2.6 Microarray gene expression data analysis 
Gene expression data based on an earlier study (Chen et al., 2002) was retrieved from the 
Stanford Microarray Database according to the following selection criteria: all non-flagged 





genes with a log (base2) of Red/Green normalized ratio (mean) greater than 3-fold for at least 
4 arrays. The data for 4841 cDNA clones in 75 liver tumour and 72 non-tumour liver tissues 
was retrieved. This data was uploaded onto the web-based microarray data analysis program 
GABRIEL (Genetic Analysis By Rules Incorporating Expert Logic; 
http://gabriel.stanford.edu) for further analysis. 
 
GABRIEL is a rule-based computer program designed to apply domain-specific and 
procedural knowledge systematically for the analysis and interpretation of data from DNA 
microarrays (Pan et al., 2002).  In the study by Chen et al. (2002), both the tumour samples 
(T) and non-tumour samples (N) were compared to a pooled universal cell line reference (U) 
such that expression ratios were represented as log2(T/U) and log2(N/U) respectively.  In 
order to derive more biologically meaningful data, the data was rescaled such that the relative 
T versus N expression ratios (log2 (T/N)) was calculated by log2 (T/U) – log2 (N/U).  If an 
HCC sample did not have a corresponding non-tumour sample, the global mean of the non-
tumour gene expression ratios were used.  The t-score pattern based rule was used to identify 
genes which were significantly differentially expressed between tumour and non-tumour liver 
tissues; the t-score (average/standard deviation) allowed variability among the samples to be 
taken into consideration during the calculation.  To search for genes that have expression 
profiles similar to that of Spry2, the Proband-based analysis function using Spry2 as the 
proband was used.   
 
2.2.7 Quantitative real-time PCR  
Analysis of breast and liver tissue samples was carried out using quantitative real time PCR. 
For each PCR reaction, 2 µl of cDNA was mixed with 500 mM of primers and 4 mM MgCl2 
using the LightCycler-FastStart DNA Master SYBR Green Kit in the LightCycler (Roche, 
Mannheim, Germany) according to manufacturer’s instructions. PCR reactions were carried 
out in triplicates with the human Spry1, Spry2 and GAPDH PCR primers (Section 2.2.5). The 





difference in amplification efficiency of the target and the reference genes. Crossing points of 
Spry (target) amplification products were normalized to the crossing points of GAPDH 
(reference) amplification products. Fold changes in gene expression of hSpry1 and hSpry2 
between normal and tumour tissues were computed.  
 
2.2.8 DNA sequencing 
The PCR sequencing reaction was assembled as follows: 8 µl Big Dye 3 sequencing mix 
(Perkin Elmer, Wellesley, MA), 2 µl DNA template (diluted to 0.1 µg/µl), 1 µl of primer (3 
µM) and 9 µl water. The PCR reaction was carried as recommended by manufacturer’s 
protocol, i.e. 25 cycles of the following steps: (ramp 1°C/sec) 96°C for 10 sec, 50°C for 5 sec 
and 60°C for 4 min. The PCR product was purified by isopropanol precipitation. The 
sequencing data was collected in ABI Prism 377 DNA sequencer (Perkin Elmer). The 
sequences of all plasmids used in this study are verified by ABI sequencing. 
 
2.2.9 Synthesis of [α -32P] dCTP-labeled cDNA 
The N-terminal cDNA fragments of hSpry1 (nucleotide 1-540) and hSpry2 (nucleotide 1-531) 
were purified from pBluescript KS (-) (Stratagene, San Diego, St Louis) by BamHI/XhoI and 
EcoRI/XhoI restriction digestion respectively. The cDNA was labeled by random 
oligonucleotide priming (High Prime DNA Labeling Kit, Roche, Mannheim, Germany) 
according to the manufacturer’s instructions, in the presence of [α-32P] dCTP (6000 Ci/mmol; 
Amersham Pharmacia, Germany). The labeled probes were purified by spin-column 
centrifugation (Probe QuantTM G-50 Micro Columns, Amersham Pharmacia) and attained or 
exceeded the manufacturer's recommendation for specific activity. 
 
2.2.10 Hybridization of cDNA probes to Cancer Profiling Array 
[α-32P] dCTP-labeled hSpry DNA probes were hybridized to the Cancer Profiling Array 





each blot according to the manufacturer’s instructions and exposed to X-ray film at -70°C for 
various lengths of times (24 hr to 3 days). To ensure that cDNA samples were loaded equally 
on the array, the array was stripped and re-probed with human ubiquitin. 
 
2.2.11 Loss of heterozygosity (LOH) 
Genomic DNA was extracted from surgically resected, snap-frozen samples that were 
obtained with patient consent and the appropriate approval from the Institutional Review 
Board at Stanford University.  Paired tumour and non-tumour liver tissues of 12 HCC patients 
were used in this study. 
 




Primer Sequence (5' to 3') 
D13S1263 
 
forward primer 5' TCTCACACTGCACCAGGTTG 3' 
reverse primer 5' GGCCAGAGACTTCCATTTCTTG 3' 
D13S170 
 
forward primer 5' TTGCACTGTGGAGATAAACACATAG 3' 
reverse primer 5' TCACATTGTCTTTTAAGGCAGGAG 3' 
D13S1277 
 
forward primer 5' AATACACACTACTGAGCAAGGA 3' 
reverse primer 5' ACATCAGAGACATTCACGTTA 3'  
D13S266 
 
forward primer 5' CCCTCTGGAGAAACACAC 3' 
reverse primer 5' GGCAGAATTATG CTGCTTA 3' 
 
Genomic DNA from the patient samples was extracted by overnight digestion with Proteinase 
K (Roche; Indianapolis, USA) and purified using Qiagen Genomic tip 20/G (Hilden, 
Germany) according to the manufacturer’s instructions.  A “reduced nucleotide” PCR reaction 
was set up with the following components: 25 µM of all nucleotides except dCTP (4.8 µM), 





and Analytical Sciences; Boston USA), and 0.2 µg genomic DNA in a total volume of 20 µl.  
The PCR protocol was used as follows: denaturation at 95°C for 30 sec, annealing at 65oC for 
45 sec, and amplification at 72°C for 1 min, repeating the cycle for 30 times. The radiolabeled 
PCR products were separated on a 5% TBE-Urea Ready Gel (Biorad, Hercules USA), air 
dried and auto-radiographed.  
 
2.3 RNA extraction and reverse transcription 
Primary breast/liver tumours and adjacent normal-appearing tissue were obtained from 
patients with malignant tumours undergoing surgery. The samples were obtained with 
approval of the appropriate institutional ethics committee and in accordance with the National 
Health and Medical Research Council of Australia guidelines for the conduct of research 
involving humans. Total RNA was extracted from the breast/liver tissues. RNA extraction 
was performed using RNAeasy Kit (Qiagen, GmbH, Hilden, Germany). RNA was treated 
with RNase-free DNase I (Qiagen, GmbH, Hilden, Germany) for 30 min at room temperature.  
 
2.4 Histological analysis 
Human breast/liver cancer tissues and mammary glands were harvested from mice of various 
ages and immediately fixed in 4% paraformaldehdye (PFA) in PBS. PFA-fixed organs were 
then embedded in O.C.T. compound (Sakura Finetek USA Inc., Torrance, CA, USA) and 10 
µm sections were made using a cryostat (Leica Mircosystems). Samples were either subjected 
to in situ analysis or stained with Mayer's hematoxylin-and-eosin B-phloxine (Sigma, St. 
Louis, MO). The samples were examined by microscope (Leica DM4000 B) and 
photographed with a Leica DFC300 FX camera, and the images analyzed with Leica FW4000 
software. 
 
2.5 RNA in situ hybridization analysis 
The N-terminal cDNA sequence of hSpry1 and hSpry2 were subcloned into pBluescript KS (-) 





and used in non-radioactive in situ hybridization as detailed in Chen et al., (2004).  Briefly, 
tissue microarrays were deparaffinized in xylene, and hydrated in graded concentrations of 
ethanol for 5 min each. The slides were then incubated with 1% hydrogen peroxide, followed 
by digestion in 10 µg/ml of proteinase K at 37oC for 30 min, and then hybridized overnight at 
55oC with either sense or antisense riboprobes at 200 ng/ml dilution in mRNA hybridization 
buffer (Dako). Slides were then washed in 2x SSC (300 mM NaCl, 30 mM sodium citrate, pH 
7.0) and incubated with 1:35 dilution of RNase A cocktail (Ambion, Austin, TX) in 2x SSC 
for 30 min at 37oC.  The slides were then stringently washed in 2x SSC/50% formamide 
twice, followed by 0.08x SSC once at 50oC.  Endogenous biotin was blocked using biotin 
blocking reagents from Dako.  For signal amplification, a horseradish peroxidase (HRP)-
conjugated rabbit anti-digoxigenin (DIG) antibody (Dako) was used to catalyze the deposition 
of biotinyl-tyramide, followed by secondary streptavidin complex (GenPoint kit; Dako). The 
final signal was developed with diaminobenzidine (DAB) (GenPoint kit; Dako), and the 
tissues were counterstained in hematoxylin for 15 sec. Arrays were scored using a four-tier 
scale: 0 - negative, 1 - insufficient or equivocal, 2 - weak staining, and 3 - strong staining.  
Tissues with scores of 1 were not included in statistical analysis. 
 
2.6 Immunohistochemistry 
The same tissue sections used for in-situ hybridization were used for immunohistochemistry. 
Cryostat sections (10 µm) were fixed in 4% PFA in PBS for 30 min at room temperature. 
Sections were washed in PBS and incubated for 1 hr with rabbit polyclonal antibodies for 
hSpry2 (produced under contract by Biogenes, Berlin, Germany). After washing in PBS, the 
slides were incubated for 1 hr with biotinylated goat anti-rabbit from Dako LSAB 2 system 
Peroxidase (Dako Corporation, Carpinteria, CA). After one wash in PBS, the slides were then 
incubated for 20 min with streptavidin conjugated to HRP (Vector Laboratories, Burlingame, 
CA) before washing again with PBS for 10 min. Antibody staining was done by treatment 





the incubation and staining steps were performed at room temperature. A negative control 
without primary antibody was performed for all samples.  
 
2.7 Cell culture 
Human 293T, MCF-7, NIH3T3, SNU-449 and T47D cell lines were obtained from American 
Type Tissue Culture Collection (ATCC) (Rockville, MD). The cell lines were cultured in 
RPMI 1640 medium or Dulbecco’s modified Eagle’s medium (DMEM) high glucose 
medium, supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Hyclone 
Laboratories, Logan, UT), 10 mM HEPES (pH 7.4), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine. Cells were cultured at 37°C and 5% CO2. All other 
tissue culture materials were obtained from Sigma Chemical Co. (St Louis, MO) unless 
otherwise stated. NIH3T3 cells were cultured in DMEM media supplemented with 10% calf 
serum (Gibco) in place of FBS, but with all other supplements as above. 
 
2.7.1 Transfection of mammalian cells 
293T or MCF-7 cells were seeded at ~1 x 106 cells/well onto 100 mm culture plates for 16 hr 
before transfection. These adherent cells at ~80% confluency were rinsed with serum-free 
medium and transfected with plasmid DNA by liposome mediated transfection with 
LipofectamineTM 2000 reagent (3 µl per 1 µg DNA) (Gibco-BRL). At 4-6 hr post-treatment, 
the transfection reagent was aspirated and the cells were incubated for another 24-36 hr in 
complete growth medium before they were harvested. 
 
2.7.2 Treatment of cells with 5-aza-deoxycytidine and trichostatin  
Cells were seeded at a density of 5x105 per well in 100 mm dishes. 5-aza-deoxycytidine (5-
azaDC) (Sigma Chemical Co., St Louis, MO) was freshly prepared in deionized water and 
filter-sterilized. Trichostatin was freshly prepared in ethanol and filter-sterilized. 24 hr after 
seeding, cells were treated with 2.5 µM 5-aza-DC (24-72 hrs) or treated with 300 nM of 





every 24 hr. In instances where cells were doubly treated, cells were subjected to 96 hr of 5-
azaDC treatment and 300 nM of trichostatin was added in the last 24 hr.  After treatment, 
cells were washed with PBS and total RNA was isolated for RT-PCR. 
 
2.7.3 Stable transfection 
The hSpry2Y55F expression construct for stable transfection was created by subcloning the full 
length hSpry2Y55F cDNA into the BamHI-XhoI sites of the constitutive mammalian 
expression vector pCMVTag2B (Stratagene, San Diego, CA) to generate the pCMV-
hSpry2Y55F (FLAG-tagged) construct. The MCF-7 cell line was transfected with pCMV-
hSpry2Y55F, under the control of a CMV promoter for constitutive expression. For control 
purposes, the MCF-7 cell line was transfected with a vector control. Cell lines were 
established as MCF-7-hSpry2Y55F, and MCF-7 control cells. 
 
The SNU-449 cell line was transfected with pCMV-hSpry2 and pCMV-hSpry2Y55F. For 
control purposes, the SNU-449 cell line was also transfected with a vector control. SNU-449 
and MCF-7 cells stably expressing hSpry2 and hSpry2Y55F were selected by using up to 1 
mg/ml of geneticin (Gibco) in culture media.   
 
The NIH3T3 stables were prepared by transfecting in pBABE-hSpry2-FLAG and pBABE-
hSpry2Y55F-FLAG and selecting for positive clones with puromycin. For control purposes, the 
same cell line was transfected with a vector control. Cell lines were established as NIH3T3-
hSpry2, NIH3T3-hSpry2Y55F and NIH3T3 control cells. 
 
2.7.4 Proliferation assay 
MCF-7 cells stably expressing Spry2Y55F and MCF-7 control cells were seeded (1x104/well) in 
a 96-well plate in triplicates. After incubation at 37°C in 5% CO2 for 12 hr, the number of 
living cells was measured using a CellTiter 96 Aqueous One Solution Cell Proliferation 





Aqueous Assay uses the novel tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and the electron 
coupling reagent, phenazine methosulfate (PMS). MTS is chemically reduced by cells into 
formazan, which is soluble in tissue culture medium. The measurement of the absorbance of 
the formazan can be carried out using 96 well microplates at 492 nm. The assay measures 
dehydrogenase enzyme activity found in metabolically active cells. Since the production of 
formazan is proportional to the number of living cells, the intensity of the produced color is a 
good indication of the viability of the cells. 
 
Assays were performed with addition of a small amount of the CellTiter 96 Aqueous One 
Solution Reagent directly to culture wells, incubated for 2 hr at 37°C in 5% CO2, following 
which the absorbance was read at 485 nm with a 96-well plate reader. The quantity of 
formazan produced as measured by the amount of 485 nm absorbance is directly proportional 
to the number of living cells in culture.  
 
SNU449 cells stably expressing Spry2 or Spry2Y55F were seeded into 96 well plates at a 
density of 3x103 cells per well.  The following day, the culture media was replaced with 
serum-free media and incubated for 48 hr before obtaining a day zero absorbance reading (at 
485 nm) using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay according to 
the manufacturer’s instructions.  HGF (50 ng/ml) was added to the wells and left to incubate 
for another 2 days, before the cell proliferation assay was repeated.  
 
2.7.5 Transformation assays 
5x105 cells of each cell line (NIH3T3-hSpry2, NIH3T3-hSpry2Y55F and NIH3T3 control cells) 
were plated onto a 10 cm dish. Each plate was transfected with 5 µg purified PyMT (A3 
strain), using Lipofectamine 2000 reagent as recommended by the manufacturer. The plates 
were maintained at 37°C and 5% CO2 for 2 weeks with media changes every 3 days. The cells 






2.7.6 Staining for foci formation 
Plates were rinsed with PBS and then fixed with 5 ml of 10% formaldehyde in PBS for 30 
min at room temperature. The formaldehyde was removed and the foci were stained with 
crystal violet at room temperature for 10 min. The stain was removed and plates were washed 
with 70% ethanol to remove background staining. The results shown are representative of 2 
independent experiments. 
 
2.7.7 Soft agar colony formation 
MCF-7-hSpry2Y55F and MCF-7 control cells were cultured in 6-well plates pre-covered in a 
soft agar layer (RPMI 1640 with 0.5% agar and 10% FBS). Another top layer of agarose was 
overlaid on the pre-existing soft agar layer and it consisting of 5x103 cells in RPMI 1640 with 
0.35% agar and 10% FBS. Medium was added to the top layer to prevent drying of the 
agarose gel.  After 14 days the colonies were stained with 3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich), which are shown as purple. 
 
2.7.8 In vivo tumour formation 
5x105 MCF-7-hSpry2Y55F or MCF-7 control cells were suspended in 200 µl matrigel (BD 
Biosciences) and injected into the mammary (axillary) fat pad of BALB/c nude mice, which 
simultaneously received a 60-day release pellet containing 0.72 mg of β-estradiol (Innovative 





2.7.9 siRNA knock down 
For the siRNA knock-down assay, Spry2 siRNA duplexes (D1 to D4) and a negative control 






Target areas of the mouse Spry2 synthetic siRNA were: 
siRNA duplex 1, sense: (665-683bp) UGAAAGGUCUCUUCUAUCA 
siRNA duplex 2, sense: (287-305bp) CCUCGCAGGUCCAUUCUUC 
siRNA duplex 3, sense: (23-41bp) GCAACGGGUCGCAGCCUUU 
siRNA duplex 4, sense: (78-96bp) GGAGCCGGAUCCAAGAGAU  
 
The control siRNA oligomer used was a non-targeting, negative siRNA control pool that was 
transiently transfected into cells using siPORT Amine (Cat no. 1631; Ambion, Austin TX) 
according to the manufacturer’s instructions (Dharmacon). 
 
2.7.10 Adenovirus System 
The AdEasy Adenoviral Vector System was purchased from Stratagene (La Jolla, USA).  
Spry2 was cloned into the NotI and XhoI restriction sites of pShuttle-IRES-hrGFP1 and 
subsequently recombined with the adenovirus vector pAdEasy-1 to form viable adenoviruses.  
Production of Spry2 adenoviruses was performed in AD293 cells (Stratagene, La Jolla) 
following Bio-safety level 2 guidelines.   
 
2.8 Protein methodology 
2.8.1 Preparation of extracts from cells 
Cultured cells were rinsed twice with cold PBS before lysis in cold HEPES lysis buffer [20 
mM HEPES (pH 7.5); 140 mM NaCl; 10% Glycerol; 1% Triton X-100; 1.5 mM MgCl2; 1 
mM EGTA (pH 8.0); cocktail of protease inhibitors: Complete (1 tablet/50 ml; Roche, 
Mannheim, FRG); 1 mm sodium orthovanadate (Na3VO4)] and the cells were collected by 
manual scraping with a cell scraper (Costar, Corning, NY). Whole cell lysates were clarified 
by centrifugation at 14000 rpm for 15 min at 4°C and the cell pellet was discarded. 
 





Proteins were typically analysed by means of a one-dimensional sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini-Protean II system, 
according to standard protocols (Sambrook and Russell, 2001). To prepare the samples for 
SDS-PAGE, equal volumes of protein samples and 2x Laemmli buffer [125 mM Tris-HCl 
(pH 6.8), 4% (v/v) SDS, 10% (v/v) β-mercaptoethanol, 20% glycerol and 0.4% (w/v) 
bromophenol blue] were mixed thoroughly and boiled at 95°C for 5 min before loading into 
the wells. The components of the electrophoresis buffer were 25 mM Tris-HCl (pH 8.3), 192 
mM glycine and 0.1% SDS. The separated proteins were visualised either by direct staining 
with Coomassie Brilliant Blue Solution [0.2% (w/v) Coomassie Brillant Blue in 45% (v/v) 
methanol and 10% (v/v) acetic acid][destaining solution: 40% (v/v) methanol and 10% (v/v) 
acetic acid] or by immunodetection (Section 2.8.5), and their sizes were estimated using 
molecular size markers from Bio-Rad.  
 
2.8.3 Antibodies and immunoprecipitation reagents 
HRP-conjugated anti-phospho-tyrosine (PY20), mouse anti-panERK, mouse anti-c-Cbl, 
mouse anti-Grb2 and mouse anti-ERK2, mouse anti-SOS1 were obtained from Transduction 
Laboratories (Lexington, KY). Monoclonal anti-phospho-ERK1/2 (p42/44), rabbit anti-
phospho-Akt-Thr308, rabbit anti-PP2A-C and rabbit anti-PP2A-C were purchased from Cell 
Signalling TECHNOLOGYTM (Beverly, MA). Monoclonal antibodies against FLAG epitopes 
and Protein A-agarose were purchased from Roche Molecular Biochemicals (Indianapolis, 
IN). Secondary anti-mouse and anti-rabbit conjugated to horseradish peroxidase were 
purchased from Sigma Aldrich (St Louis, MO). Rabbit anti-Grb2, rabbit anti-FGFR1, mouse 
anti-Myc, rabbit PLCγ, rabbit ShcA and rabbit 14-3-3 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Rabbit anti-Spry was purchased from Upstate 
Biotechnology Ltd (Lake Placid, NY). 
 





Approximately, 2.5 µg of the appropriate antibody (for immunoprecipitation) was added to 
~300 µg of proteins from total cell lysates, and incubated at 4°C for 2-18 hr. Subsequently, 30 
µg of protein G/A agarose suspension beads were added to capture the immunocomplex for 
an additional 2 hrs. The pelleted immunoprecipitates were washed thrice in RIPA buffer and 
the bound proteins were eluted with 2x Laemmli buffer, boiled at 95°C for 5 min and then 
subjected to SDS-PAGE. 
 
2.8.5  Western transfer and immunodetection 
Eluted proteins were resolved by SDS-PAGE and electrophoretically transferred onto 
Immuno-BlotTM  PDVF membranes (pre-activated with methanol) (Bio-Rad) using western 
transfer apparatus (Bio-Rad Trans-Blot systems) in a transfer buffer containing 25 mM Tris-
base (pH 8.3), 192 mM glycine, 10% SDS and 20% methanol for 1 hr at 4°C. Subsequently, 
the membranes were incubated in blocking buffer [PBS containing 1% (w/v) BSA and 0.1% 
(v/v) polyoxyethylene-sorbitan monolaurate (Tween 20)] for at least 1 hr at room 
temperature. The membranes were then incubated for 1 hr at room temperature with primary 
antibody (0.1-1 g/ml). Unbound antibodies were removed by extensive washing in wash 
buffer (PBS containing 0.1% Tween-20). Membranes were then incubated with 0.5 µg/ml 
horseradish peroxidase-conjugated (HRP) secondary antibody for at least 1 hr at room 
temperature and then washed in wash buffer 3 times. Membranes were then developed using 
an enhanced chemiluminescence (ECL) kit (GE Healthcare) for 1 min. HRP catalysed-
oxidative degradation of luminal occurs, resulting in light emission at a wavelength of 428 
nm, which was detected on an autoradiography film (GE Healthcare). 
 
 
CHAPTER 3  






The primary objective of this study was to investigate whether the expression of the various 
Sproutys (Sprys) were deregulated in a variety of human cancers, and then to further examine 
consistencies in the patterns of expression in a particular cancer by analyzing paired clinical 
samples. Ramaswamy et al. (2001) created a public microarray database containing the gene 
expression profiles of 218 human tumours and 90 normal tissues samples, representing 14 
common human cancer classes. This database is known as the Global Cancer Map (GCM) 
(www-genome.wi.mit.edu/MPR/GCM.html) and it was utilized to identify changes in levels 
of Spry genes in various cancers.  
 
3.1 RESULTS: hSpry1 and 2 expression is down-regulated in breast cancer  
3.1.1 Microarray database 
The GCM microarray database was analysed to determine the levels of expression of hSprys. 
In the analysis of the gene array data (Fig. 3.1.1), the gene expression levels in cancer tissues 
were compared to levels in normal healthy tissue. In this database, only data for the Spry 1 
and 2 isoforms were present. Hence, only these two isoforms were evaluated. Several other 
genes that are known to influence the expression of Sprys were analyzed concurrently with 
Spry genes. 
 
Fibroblast growth factor 8 (Fgf8) was selected since the mammalian expression pattern of 
Sprys in early embryonic development shows close correlation with known sites of Fgf8 
signalling and FGF signalling is known to induce the expression of Spry genes (Minowada et 
al., 1999; Chambers et al., 2000). Fibroblast Growth Factor Receptor 1 (FGFR1) was 
included since Spry2 has been shown to inhibit the activation of the Ras/MAPK downstream 












Spry2 is down-regulated in breast and uterine cancer. Analysis of microarray database 
(Global Cancer Map) comparing the expression of Spry1 and 2 in human cancers with respect 
to normal tissues. Tumour tissues, spanning 12 common tumour types, and unmatched normal 
tissues were subjected to oligonucleotide microarray (Affymetrix GeneChips) gene expression 
analysis. The gene expression for the individual tumour tissues were compared to the mean 
values of that of the normal tissue. The panel shows the expression of hSpry1 and hSpry2 in 
human cancers, with respect to normal tissues.  
 
(Explanation of scale: Red indicates an up-regulation in gene expression in tumours with 
respect to normal tissue. Green indicates a down-regulation in gene expression in tumours 








various FGFRs, have been found to be over-expressed in numerous cancers (Morrison et al., 
1994; Lappi et al., 1995). The expression of these genes was compared alongside that of 
hSprys. Previous work from our laboratory showed that c-Cbl binds to hSpry2 (Fong et al., 





ubiquitination and endosome sorting pathway (Hall et al., 2003; Rubin et al., 2003). It was 
therefore interesting to investigate the expression levels of c-Cbl. Spry1 and 2 levels were 
deregulated in most cancers (Fig. 3.1.1). In glioblastomas and central nervous system (CNS) 
medulloblastoma, Spry1 expression was up-regulated. Many cancers show a down-regulation 
of Spry1 and 2. However, the most profound down-regulation was seen with Spry2's 
expression in breast and uterine cancer.  
 
3.1.2 Matched normal and tumour tissue cDNA array studies 
To further confirm these results, the expression of Spry1 and 2 was investigated using a 
commercially available cDNA array (Cancer Profiling Array) (Fig. 3.1.2A) that had matched 
normal and tumour tissue cDNA spotted in equal amounts onto a blot.  
 
The hSpry2 probe was prepared and tested for specificity (Fig. 3.1.2B) before subjecting it to 
hybridization with the Cancer Profiling array. On the resultant blot, a high proportion of the 
breast cancer samples were observed to have a diminished expression of Spry2. However, 
Spry2 expression remained unchanged between normal and tumour uterine tissue (Fig. 
3.1.2C). Using densitometry, the intensity of the radioactive probe signal from each cDNA 
sample was quantitated. Signals from breast tumour cDNA were compared with those of 
normal breast tissue cDNA from the same individual. The breast cancers which showed at 
least a 50% decrease in levels of Spry2 with respect to that of normal tissue, were deemed to 
have a significant down-regulation of Spry2 in breast tumours. (A two-fold down- or up-
regulation of gene expression is generally considered a significant result). 48 out of 50 (96%) 
of the paired samples showed a down-regulation of hSpry2. Similarly, when the hSpry1 probe 
was hybridized to the Cancer Profiling Array, the same trend was observed: 39 out of 50 
(78%) of the paired samples showed a down-regulation of hSpry1 (Fig. 3.1.2D).  
 
To demonstrate that the sample population of breast cancer tumours in the blot was a true 





ErbB2. ErbB2 is a prognostic marker for breast cancer and collated data indicates it is over-
expressed in 25-30% of breast cancers (Slamon et al., 1987). The ErbB2 probe was prepared 
and hybridised to the Cancer Profiling Array. The breast cancers showing at least an arbitrary 
2-fold up-regulation in signal were considered to exhibit an up-regulation in expression of 
ErbB2. ErbB2 was found to be over-expressed in 25 out of 50 (50%) breast cancer tumour 
samples, as compared to normal samples (Fig. 3.1.2E). This is higher than the 30% typically 
observed in many breast cancer samples but deemed to be within acceptable limits. To ensure 
equal loading of cDNA samples on the membrane, the membrane was re-probed with a 
human ubiquitin control probe provided by the manufacturer (Fig. 3.1.2F) and equal loading 
of cDNA in the Cancer Profiling Array was demonstrated. 
 
While the cDNA array used does not encompass a wide range of cancers, and some of the 
paired samples are not present in statistically relevant numbers, the evidence that hSpry1 and 
hSpry2 are comprehensively down-regulated, specifically in breast cancers, was compelling 



















Layout of the commercially available cDNA array (Cancer Profiling Array) (purchased 
from BD Clontech, Palto Alto) 
This cDNA array contained pairs of cDNAs generated from matched tumour and normal (T= 
tumour; N = normal) tissue samples from individual patients, spotted side by side on a nylon 
membrane. All samples on these arrays were normalized to two different housekeeping genes: 
β-actin and ubiquitin. On the left side of the blot, there are 50 matched pairs of normal and 
tumour cDNA from 50 breast cancer patients. Where three spots are boxed, they are (in 
clockwise direction) normal, tumour and metastatic tissue (figure adapted from BD Clontech, 
























hSpry1 and hSpry2 cDNA probes are specific for their respective Spry isoforms. A dot 
blot consisting of the cDNA of full length hSpry1, hSpry2, hSpry3 and hSpry4 was prepared 
by spotting 10ng of cDNA on a nitrocellulose membrane (Hybond, GE Healthcare). The blot 































hSpry2 is down-regulated in breast cancer.  [α-32P]-labeled N-terminal half of hSpry2 
































hSpry1 is down-regulated in breast cancer.  [α-32P]-labeled N-terminal half of hSpry1 































Expression levels of ErbB2 in breast tumours demonstrate that the sample population of 
breast tumours in the blot is a true representation of the population of breast cancers. 
The cDNA array was stripped of the cDNA probe that was previously hybridized to it and re-






































The cDNA samples in the Cancer Profiling Array are equally loaded. The cDNA array 
was stripped of the cDNA probe that was previously hybridized to it and re-probed with 







3.1.3 Quantitative real-time PCR studies 
In order to confirm the data from the GCM and Cancer Profiling Array, matched clinical 
samples were obtained and analyzed by an alternative method. Matched normal and tumour 
breast samples consisting of 18 ductal and 1 lobular carcinomas (courtesy of Wayne A. 






quantitative PCR. The breast tumours analyzed were classified into various stages of breast 
cancer as follows: 1 stage I, 14 stage II, and 2 stage III breast carcinomas (2 samples were not 
classified).  
 
The expression level of the Spry genes in each normal tissue sample (control) was set at 100% 
and the expression level in the matching tumour sample was reflected as a percentage of the 
control.  Each sample was analyzed three times and a mean value was calculated. 18 out of 19 
(94.7%) of the tumour samples showed a significant down-regulation in hSpry2 (Fig. 3.1.3A) 
and hSpry1 (Fig. 3.1.3B) expression. A 2-100 fold down-regulation of hSpry1 and hSpry2 
was observed in the breast tumours. Within the sample population of 19 patients, the extent of 
down-regulation of Sprys did not correlate with the staging of cancer, indicating that Sprys 
were down-regulated in the early stages of breast cancer. As before, the expression levels of 
ErbB2 were analyzed to show that the 19 breast cancer samples used were from a 
representative patient population. 11 of the 19 samples (57.8%) showed a significant over-
expression of ErbB2 (Fig. 3.1.3C), which is comparable with the values obtained from the 
Cancer Profiling Array and previously documented reports (Slamon et al., 1987).  
 
In summary, there was a profound down-regulation in levels of hSpry1 and hSpry2 in breast 
tumours. The results obtained from the three methods of analysis (microarray, cDNA array 
and real-time PCR) were essentially in accordance with each other, although real time 
quantitative PCR analysis showed a higher percentage of samples with reduced Spry1 levels. 













Spry1 and 2 are down-regulated in breast tumours. 
(A) The expression of hSpry2 in 19 malignant breast tumours and paired normal tissue was 
analyzed by quantitative real time PCR The expression of hSpry2 in the normal tissue was 
averaged and deemed to be 100% (solid horizontal line) and the standard error of mean (SEM) 
is demarcated with the dotted lines. The tumour samples were expressed as a percentage of the 
mean expression of hSpry2 in normal tissues. Each sample was analyzed three times and a 
mean value ± SEM was calculated.  
(B) The expression of hSpry1 in 19 malignant breast tumours were analyzed in a similar 
















Expression levels of ErbB2 were analyzed to show that the sample population of breast 
tumours used was from a representative breast cancer patient population. In a similar 
manner to Fig. 3.1.3A and B, the expression of ErbB2 in 19 malignant breast tumours was 
















as breast cancer-specific tumour markers in the diagnosis and clinical management of breast 
cancer.  
 
3.2 Expression of mSpry1 and mSpry2 in developing mouse mammary gland 
The FGF signalling pathway has been shown to be crucial in mammary gland development. 
FGFR2b is expressed on mammary epithelial cells and, together with stromal Fgf10, is 
required for forming embryonic mammary placodes (an area of thickening in the embryonic 
epithelial layer from which the mammary gland later develops). Knock out of the Fgf10 and 
FGFR2b genes in mice has been shown to disrupt the formation of 4 out of 5 mammary 
placodes (Mailleux et al., 2002). In addition, mammary-targeted conditional ablation of 
FGFR2b causes a severe delay in adolescent ductal development (Sternlicht, 2006).  
 
The mammary gland has the unique physiological function of producing and delivering 
adequate amounts of milk from mother to newborn, in part by forming an extensive network 
of branched ducts (Sternlicht, 2006). This strategy of forming a branched system in order to 
pack a large epithelial surface area into an otherwise limited tissue volume is clearly not 
unique to the mammary gland. Rather, it is seen in many other organs, from the trachea and 
air sacs of insects to the lungs, kidneys and salivary glands of higher organisms. The key 
mechanisms that underlie branching are conserved among these branched organs. However, 
tissue-specific mechanisms must also apply, as all of these organs clearly differ in form and 
function (Affolter et al., 2003). Unlike other organs, the mammary gland is a unique organ 
because it exhibits most of its development during adolescence rather than embryonic 
development. Its morphogenesis begins in utero, pauses between birth and puberty, and 
resumes in response to ovarian estrogens which stimulate the breast ducts to invade the 
mammary fat pad, forming an open ductal tree that eventually fills the entire mammary fat 
pad of the young adult (Sternlicht,  2006) (Fig. 3.2.1). The final developmental fate of the 
mammary gland is fulfilled only when pregnancy and lactation occurs. There is a further 









Mouse mammary gland development during puberty, pregnancy and lactation.   
Schematic (Aa–d) and whole mount (Ba–d) presentation of the different stages of mammary 
gland development. Rudimentary ductal design within the mammary fat pad is visible at birth, 
which grows at the same rate as the animal until the onset of puberty. During puberty, the 
cyclical production of ovarian estrogen and progesterone promotes and accelerates ductal 
outgrowth (Aa, Ba). At this stage, conspicuous club-shaped structures (terminal end buds 
(TEB), where the highest levels of cell division occur, appear at the ductal tips. In the mature 
virgin, the entire fat pad is filled with a regularly spaced system of primary and secondary 
ducts, with side branches that form and disappear in each estrous cycle (Ab, Bb). Hormonal 
changes that occur when pregnancy begins increase cell proliferation and the formation of 
alveolar buds (Ac, Bc), which grow and differentiate into milk-secreting alveoli at the end of 
pregnancy (Ad, Bd). During lactation, alveoli are fully matured and the luminal cells 























Phases of mammary gland development. Proliferative development in virgin animals is 
represented by the linear portion of the diagram. Cyclical development initiated by pregnancy 













that occurs to prepare for lactation. The "open" architecture of the tree-like mammary gland 
fills up with milk-producing alveoli which can be likened to leaves growing on otherwise bare 
branches of a tree. Following weaning, the secretory epithelium involutes by apoptosis until 
the gland once again resembles that of a virgin (Wiseman and Werb., 2002; Smalley and 
Ashworth., 2003; Sternlicht, 2006). A summary of the various different phases of mammary 
gland development is shown in Fig. 3.2.2. 
 
Similar to the manner by which Spry negatively regulates lung branching, Spry may also 
negatively regulate mammary gland branching via the inhibition of FGF signalling. It 
appeared from the accumulated data (section 3.1) that Spry1 and 2 are expressed in normal 
human breast tissue. Currently there has been no data published on the expression or the roles 
of Spry1 and 2 during mammary gland development. Thus, an investigation was carried out to 
evaluate the expression of Spry1 and 2 during mammary gland development. The temporal 
and spatial localization of Sprys would provide some understanding as to the role of Sprys in 
mammary gland development. While it is appreciated that there are differences between 
human and murine mammary gland development, mouse mammary gland tissues were used 
as it was difficult to obtain normal human mammary gland tissues. Mouse mammary gland 
tissue sections were analyzed to identify the localization of mSpry1 and 2 over the various 
stages of mammary gland development. 
 
In situ hybridizations were carried out as described in ‘Materials and Methods’ and 
representative results are shown in Fig. 3.2.3. Spry2 is highly expressed in developing 
mammary ducts in 2 and 6 week old females and appears to be confined specifically to the 
epithelial lining of the mammary ducts and absent in the stroma and adipose tissues (Fig. 
3.2.3A). It is also strongly expressed in the male mouse mammary gland tissue at 6 weeks 
(Fig. 3.2.3B). The level of expression began to decrease as the mice developed beyond sexual 
maturity, as evidenced by the lower levels of Spry expression at 16 weeks in female mice 





alveoli (Fig. 3.2.3C). Spry2 expression then diminishes in the lactating female and appears to 
be totally absent during the involution phase. Based on Fig. 3.2.3A & C, a bar graph 
representation of the qualitative expression of Spry2 over the various stages of mammary 
gland development is shown in Fig. 3.2.3D. Fig. 3.2.3E shows the sense control probe for 
mSpry2 hybridized to a section of the mammary gland from a pregnant mouse, showing a lack 
of non-specific staining. 
 
In summary, it appeared that Spry2 is expressed in mammary development during the stages 
of tissue modeling when the epithelial breast ducts are proliferating and branching (puberty), 
and later when the alveoli are actively proliferating (pregnancy). Such a developmental 
scenario parallels the tissue modeling in the Drosophila trachea and mammalian lung 
formation, whereby tubular epithelium is remodeled into a branching system under the 
regulatory influence of the various Sprys. Therefore, Sprys have the potential to negatively 
regulate branching morphogenesis in the developing mammary gland. 
 
Similar studies were carried out for Spry1 to examine the expression and localization in breast 
tissue. mSpry1 was found to be co-localized with mSpry2, albeit at lower expression levels in 
a pregnant mouse (Fig. 3.2.3F). This evidence hints that the two isoforms of Spry may have 


















mSpry2 is highly expressed in developing mammary ducts in 2 and 6 week old females 
and appears to be confined specifically to the epithelial lining of the mammary ducts. 
H&E staining and in situ staining of mSpry2 expression in female mouse mammary glands 






mSpry2's localization in 6 week old male mouse mammary gland was found to be similar 
to that observed in 6 week old female mouse mammary gland. H&E staining (left) and 
in situ staining (right) of mSpry2 expression in male mouse mammary glands that were 6 












In pregnant mice, the expression of mSpry2 becomes elevated again in actively 
proliferating alveoli. mSpry2 expression then becomes diminished in the lactating female 
and appears to be totally absent during the involution phase. H&E staining and in situ 
staining of mSpry2 expression in female mouse mammary glands of mice that were 







A bar chart qualitative representation of the levels of Spry2 during the various stages of 













mSpry2 sense probe control demonstrates a lack of non-specific staining. mSpry2 sense 










Co-localization of the two Spry isoforms, specifically in the luminal epithelial cells of the 
mammary ducts of a pregnant mouse. In situ staining for mSpry2 (left) and mSpry1 (right) 




mSpry2 sense (20X) 
mSpry2 (20X)  mSpry1 (20X) 







3.3 In situ analysis of human breast tissue showed the down-regulation of Spry 
isoforms in breast cancer 
Having studied the expression pattern of Spry in mouse mammary gland tissue, the next step 
was to compare the expression of Spry isoforms in normal and cancerous human breast 
tissues. First, the basal expression level of Spry in normal breast tissue was ascertained. As it 
was difficult to obtain normal human breast tissue, normal tissue (unaffected by cancer) that 
was removed during cancer surgery was used. The normal tissue was stained for hSpry2 and 
Fgf8 (Fig. 3.3.1). The staining clearly shows that both Spry2 and Fgf8 co-localized in 
epithelial cells lining the breast ducts. When the tumour-encompassing tissue (invasive ductal 
carcinoma, grade 3) from the same sample was analyzed, both Spry2 and Spry1 expressions 
were undetectable, although Fgf8 expression was still apparent. Fgf8 has been previously 
shown to be up-regulated in breast cancer (Marsh et al., 1999) and was used as a positive 
control to demonstrate the integrity of the mRNA in the breast cancer tissue (Fig. 3.3.2A). 
The same observations were noted for another breast cancer specimen, which was an invasive 
























hSpry2 and hFgf8 are co-localized in the epithelial lining of normal breast ducts. In situ 
staining for hSpry2 (left) and hFgf8 (right) in a normal section of tissue found in a human 






hSpry2 (20X)      hFgf8 (20X) 











Spry1 and 2 are down-regulated in human breast cancer tissues. 
(A) H&E and in situ staining of for hSpry1, hSpry2 and hFgf8 in a human ductal carcinoma 
(grade 3).  
(B) H&E and in situ staining of for hSpry1, hSpry2 and hFgf8 in a human invasive ductal 











3.4 Immunohistochemistry analysis of human breast tissue showed the down-
regulation of Spry isoforms in breast cancer 
Immunohistochemistry was then performed to correlate the Spry gene expression levels to 
that of protein levels. In a segment of healthy breast tissue, Spry2 was shown to be present in 
epithelial cells that line the lumen of mammary ducts (Fig. 3.4A). Correspondingly, in the 
cancerous breast tissue of the same individual (invasive ductal carcinoma, grade 3), there is 
little or no Spry2 protein present (Fig. 3.4B).  In the same cancerous tissue, both ErbB2 
(stained with Neu-2 antibody) and Fgf8 are present in relatively high amounts (Fig. 3.4B). 
Both ErbB2 (Slamon et al., 1987) and Fgf8 (Marsh et al., 1999) have been previously shown 
to be up-regulated in breast cancer and have been used as positive controls to demonstrate the 
integrity of the tissue. 
 
Taken together, the expression level and spatial localization of Spry1 and Spry2 proteins 
indicate that both Sprys are present in normal mammary epithelial tissue. However, when this 
tissue becomes cancerous, Spry mRNA and protein levels decrease substantially in a high 





















Immunohistochemical analysis of human breast tissue showed that Spry2 localizes 
specifically in the epithelial lining of the breast ducts. Immunohistochemical staining of 





Immunohistochemical analysis of human breast tissue showed that Spry2 expression is 
down-regulated in breast cancer. Immunohistochemical staining of hSpry2, ErbB2 (using 
Neu antibody) and Fgf8 in an invasive ductal carcinoma (grade 3). In the same tissue, both 
ErbB2 and Fgf8 were present in relatively high amounts. ErbB2 and Fgf8, which have been 
previously shown to be up-regulated in breast cancer, have been used as positive controls to 
demonstrate the integrity of the tissue. 
 
 
H&E (20X)  α-Fgf8 (20X) 







3.5 Expression of Spry2 in breast cancer cell lines 
The results shown in Sections 3.1-3.4 indicate that Spry1 and Spry2 were down-regulated in 
breast cancer tissues. The next step was to evaluate the expression of Spry2 in breast cell lines 
and to confirm earlier observations. Breast cancer cell lines with low Spry2 expression levels 
were selected to investigate the mechanisms of down-regulation of Spry2 (Section 3.6). 
 
Northern blot analysis was employed to compare the mRNA expression of Spry2 in normal 
and tumour breast cell lines. Normal Human Mammary Epithelial Cells (HMEC) showed 
moderate expression of Spry2 mRNA (Fig. 3.5). This result correlated with the earlier data 
which showed that Spry2 is expressed specifically in the mammalian mammary epithelial 
cells (Section 3.2 and Fig. 3.3.1). Nine human breast cancer cell lines were studied. Five cell 
lines showed no or low expression of Spry2: T-47D (infiltrating ductal carcinoma), MCF7 
(adenocarcinoma), ZR-75-1 (ductal carcinoma), Sk-BR-3 (adenocarcinoma), BT-454 
(invasive ductal carcinoma) whereas four breast cancer cell lines showed moderate or high 
levels of expression of Spry2: MDA-MB-231 (adenocarcinoma), MDA-MB-435S (ductal 
carcinoma), BT-549 (ductal carcinoma), and Hs578T (breast carcinoma).  
 
Clearly, the expression profile of Spry2 in breast cancer cell lines did not correlate fully with 
the earlier findings of Spry2 being down-regulated in a high percentage human breast cancer 
samples. High Spry2 expression in some breast cancer cells could not be explained by the ER, 
EGFR or FGF status of these cells (Breast Cancer Cell Line Database: 
http://www.mdanderson.org/departments/cancerbiology/dIndex.cfm?pn=31062032-B0EB-
11D4-80FB00508B603A14). It is debatable whether breast cancer cell lines are representative 
of the tumours from which they originated. While numerous similarities have been found 
between cell lines and tumours, recent technical advances, including the use of microarrays 
and comparative genetic analysis, have brought new data to the discussion.  There is evidence 












Spry2 mRNA expression in various normal and tumour breast cell lines. [α-32P]-labeled 
N-terminal half of hSpry2 cDNA probe was hybridized to a membrane containing total RNA 
from various cell lines (Northern Blot analysis). HMEC (normal Human Mammary Epithelial 
Cells) show moderate expression of Spry2 mRNA. 5 breast cancer cell lines showed no or 
low expression of Spry2 and 4 breast cancer cell lines showed moderate high levels of 
expression of Spry2. RNA size markers are indicated to the left. β-actin gene expression was 















misclassified and are therefore not representative of breast cancer cells (Ross et al., 2000; 
Thompson et al., 2004; Rae et al., 2006). 
 
3.6 Down-regulation of hSpry2 in breast cancer was not due to epigenetic silencing  
In Section 3.1, an exceptionally high percentage (94.7%) of breast cancers showed down-
regulated levels of Spry1 and Spry2. Alterations in Spry genes may result through either 
genetic or epigenetic mechanisms; while genetic alterations are associated with changes in 
DNA sequence, the epigenetic alterations evoke changes in gene expression without changes 
in DNA sequence.  
 
A loss of Spry expression could occur with genetic aberrations such as chromosomal deletions 
and mutations. Homozygosity for loss of tumour suppressor gene function is frequently 
achieved by the inherited or somatic mutation of one allele together with a chromosome 
deletion of the region containing the other allele. Mutations in the coding region of the SPRY 
genes may alter splicing of the mRNA (splice site mutation), or cause a shift in the reading 
frame (frame shift), both of which can significantly alter the gene product. Alternatively, 
nonsense mutations in the SPRY2 gene may code for a premature stop codon in the Spry2 
mRNA and result in the production of a truncated mRNA and protein.  
 
A literature search was conducted to determine whether high incidences of LOH occur in the 
chromosomal regions where hSpry1 (4q28.1) and hSpry2 (13q31.1) are located. The results 
failed to find any evidence of high incidences of loss of heterozygosity (LOH) occurring in 
these chromosomal regions (Miller et al., 2003). Hence, down-regulation of Spry1 and 2 in 
breast cancer is unlikely to be caused by genetic changes such as chromosomal rearrangements 
and deletions. In order to examine whether mutations of the SPRY2 gene were responsible for 
the loss in Spry2 mRNA transcript in breast cancers, sequencing was carried out in the coding 
region, the 5'UTR and 3'UTR of SPRY2 gene in the breast cancer cell lines analyzed earlier in 





gene. This result corroborates with recent studies that identified genetic alterations in breast 
and colon cancers in a comprehensive and unbiased manner. SPRY mutations were found in 
neither breast nor colon cancers (Sjöblom et al., 2006; Wood et al., 2007). 
 
Although the importance of genetic mutations in cancer has long been recognized, the role of 
epigenetic events has been increasingly emphasized in the recent years. Methylation of DNA 
and remodeling of chromatin via histone proteins are the epigenetic molecular mechanisms 
that have been known to be involved in cancer onset and progression (Macaluso et al., 2003). 
Methylation of DNA is the covalent modification that can occur at cytosines within the CpG-
rich regions DNA and is catalyzed by DNA methyltransferase (Chen and Li, 2006). Such 
addition of methyl groups can prevent binding of basal transcriptional machinery and 
transcriptional factors (Ducasse and Brown, 2006). DNA methylation also suppresses 
transcription because methylated DNA binding proteins bind methylated DNA and recruit 
histone deacetylases (HDAC) and histone methyltransferases to regulatory regions of genes 
resulting in chromatin inactivation (Rountree et al., 2001; Robertson, 2002). The SPRY2 gene 
has an extensive CpG rich region encompassing approximately 500bp of 5' upstream 
sequence, the 5' UTR first exon and extending into the adjacent intron region. This putative 
CpG island (referred to as CpG I) fulfills the stringent criteria proposed by Takai and Jones 
(2002) with a predicted OBSCpG/EXPCpG ratio of 0.92 and GC content of 67.5% in the 
Grail/EXP analysis (http://menu.hgmp.mrc.ac.uk/menu-bin/nix). Located approximately 1.2kb 
upstream of CpG I, a second GpG island was predicted with an OBSCpG/EXPCpG ratio of 
0.84, containing 31 CpG repeats and is referred to as CpG II (Fig. 3.6.1A).  
 
To address whether hypermethylation was involved in silencing Spry2 expression, T47D (a 
breast cancer cell line where previous analysis had shown low Spry2 levels) was challenged 
with the DNA methyl-transferase inhibitor, 5-aza-deoxycytidine (5-aza-DC) and the histone 
deacetylase (HDAC) inhibitor, trichostatin and Spry2 mRNA was assayed. The expression of 





cancers (Maass et al., 2002), was monitored as a positive control. The results demonstrated 
that whereas Maspin expression increases when cells are treated with 5-aza-DC, there was no 
increase in the expression of Spry2 (Fig. 3.6.1B). Likewise, Maspin expression increases when 
cells are treated with trichostatin but there was no concurrent increase in the expression of 
Spry2 (Fig. 3.6.1B). To further confirm that methylation is not responsible for the silencing of 
Spry2 expression in breast cancer, bisulphite PCR methods were employed to sequence the 
CpG-rich islands (CpG island I) of the hSPRY2 gene in a human breast cancer specimen. The 
cytosine residues in these CpG-rich dinucleotides were not found to be methylated. 
 
These results demonstrate that the decreased expression levels of hSpry2 seen in breast cancers 
are neither due to DNA methylation nor histone hypoacetylation. Taken together, it is likely 
that there is enhanced Spry2 mRNA degradation or reduced Spry2 mRNA transcription arising 
from the loss/ mutation of transcriptional factors responsible for mediating transcription of 
Spry2 mRNA. Gross et al (2003) highlighted Spry1 as the downstream transcriptional effector 
of WT1 in the developing kidney. The consistent down-regulation of Sprys in breast cancer is 
unlikely to be caused by the level of expression of WT1 in breast cancer. WT1 was found to be 
up-regulated in breast cancer (Loeb et al., 2001). When the WT1 probe was hybridized to the 
Cancer Profiling Array, no difference in WT1 expression was observed between normal and 
tumour breast tissue samples (Fig. 3.6.2). Further characterization of the transcriptional 
mechanism of the Spry genes in normal versus cancerous breast tissue is required to shed light 






















Schematic representation of the hSPRY2 gene structure highlighting the positions of the 
two CpG islands (CpG I and CpG II) relative to the transcription start site (adapted from 
































Epigenetic silencing is not responsible for the down-regulation of Spry2 expression in 
breast tumours. Treatment of T47D breast cancer cells with 2.5µM 5-azaDC and/or 300nM 
trichostatin did not up-regulate the expression of hSpry2. In instances where cells were doubly 
treated, cells were subjected to 96hr of 5-azaDC treatment and trichostatin was added in the 
last 24hr. Maspin is a gene known to be silenced by hypermethylation and/or histone 
deacetylation. Treatment with either 5-aza-DC and/or trichostatin is known to up-regulate its 
expression. It has been used as a positive control to show that both treatments were effective. 


























WT1, an upstream transcriptional effector of Spry1, is not the cause of down-regulation 













3.7 Inhibiting Spry’s function in MCF-7 cells results in cells proliferating faster and 
exhibiting anchorage-independent growth 
A central question arises when the gene that plays a pivotal role in a major signal transduction 
pathway shows consistently aberrant expression in a particular cancer; is the change 
contributing to the tumourigenic process? Spry1 and 2 are highly expressed during periods 
where the breast undergoes extensive changes in ductal patterning. The expression of Sprys in 
actively proliferating breast tissue may play a surveillance role against inappropriate cell 
growth or movement. It may be postulated that down-regulation of Sprys in cancer allows for 
uncontrolled proliferation due to unchecked upstream hyper-activation of the Ras/ERK 
pathway thereby permitting onset of the tumourigenic process. To test this hypothesis, the 
down-regulation in expression of Sprys in breast cancer was simulated. The function of 
endogenous wild-type Sprys was quenched by over-expressing the Y55F mutant of hSpry2 in 
MCF-7 cells and the tumourigenic potential of Spry2Y55F MCF-7 cells was compared with that 
of wild type cells in nude mice. There have been several reports that the tyrosine 
phosphorylation of Y55 on hSpry2 is necessary for its Ras/MAP kinase inhibitory function 
(Sasaki et al., 2001, Hanafusa et al., 2002; Fong et al., 2003). Some reports provide 
compelling evidence that the Spry2Y55F mutant functions as a dominant negative factor in 
inhibiting Sprys' functions (Sasaki et al., 2001, Hanafusa et al., 2002). This is consistent with 
the evidence that Spry proteins function as part of a higher-order complex through hetero 
and/or homodimerization (Sasaki et al., 2001, Hanafusa et al., 2002), as the presence of a 
Spry conserved tyrosine mutant protein may inactivate the complex, resulting in the 
abrogation of the physiological function of the wild-type protein (Mason et al., 2006).  
 
Furthermore, there is a distinct possibility that hSpry1 and hSpry2 may play redundant roles 
fulfilling the general function of Spry. Hence, a cell line over-expressing hSpry2Y55F will 
nullify the effect of both wild-type Spry1 and Spry2 since the tyrosine residue is highly 





residue will be blocked by an over-expression of such a point mutant, irrespective of its 
isoform. 
 
hSpry2Y55F-transfected stable MCF-7 cell lines were generated as described in ‘Materials and 
Methods’ and as an initial analysis, the effect of over-expression of hSpry2Y55F was assessed 
based on the proliferation rate of the cells.  The hSpry2Y55F-transfected clones showed a 
significant 22% increase in proliferation over control MCF-7 cells (p = 0.0034) (Fig. 3.7A), 
indicating that nullifying the effect of wild-type Sprys impacts on the growth rate of the 
MCF-7 cells. 
 
Next the anchorage-independent growth of the stable hSpry2Y55 cells in the formation of 
colonies was assessed using the soft agar assay. In comparison with the control MCF-7 cells, 
hSpry2Y55-transfected clones formed larger and greater numbers of colonies compared to 
control MCF-7 cells (Fig. 3.7B), indicating that the abrogation of the function of wild-type 
Sprys in MCF-7 cells promotes cell transformation, resulting in the loss of contact inhibition 
























Inhibiting Spry’s function causes MCF-7 cells to proliferate faster and exhibit 
anchorage independent growth  
(A) Proliferation assays. MCF-7 hSpry2Y55F stable and control cells were seeded and cultured 
in 10% serum for 12hr. The number of living cells was measured using CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI). The quantity of formazan 
product is measured by the amount of 485nm absorbance is directly proportional to the 
number of living cells in culture. The values correspond to the average absorbance at 485nm 
± SEM derived from triplicates of a representative experiment. The experiment was repeated 
3 times with similar results being obtained.  
(B) Colony forming assays. MCF-7 hSpry2Y55F stable and control cells were cultured in 6-
well plates first covered in soft agar. After 14 days, the colonies were stained with 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye. The experiment was 









3.8 Inhibiting Spry’s function in MCF-7 cells results in the formation of larger 
tumours 
The in vivo tumourigenic potential of the stable cells was assessed using an in vivo animal 
model of breast cancer that involves the growth of MCF-7 xenografts in nude mice. To avoid 
individual variation, hSpry2Y55 MCF-7 and control MCF-7 cells were injected into both sides 
of each nude mouse. The progression of tumours was followed at weekly intervals over 9 
weeks after which the animals were sacrificed and the tumours extracted and weighed. It was 
immediately apparent that the hSpry2Y55F cells caused a significantly larger tumour mass 
when compared with the control cells (p = 0.0001). An image of a typical mouse is shown in 
Fig. 3.8A.  The respective tumours from 15 different animals were weighed and the results 
displayed in the bar chart shown in Fig. 3.8B. The values correspond to the average weight of 
tumours ± SEM derived from 15 mice. The average weight of hSpry2Y55F tumours was 2.9 
times greater than control tumours. To confirm that hSpry2Y55F is still consistently expressed 
in the xenograft tumours excised from the nude mice, proteins from both tumours were 
extracted and hSpry2Y55F (FLAG-tagged) expression was confirmed using western blotting 
techniques (Fig. 3.8C). 
 
These experiments indicate the down-regulation or elimination of wild-type Spry function 
may contribute to the transformation of cells, resulting in the hyper-proliferation of cells and 
the larger tumour masses observed with hSpry2Y55F tumours. The results suggest a previously 



















Inhibiting Spry’s function causes MCF-7 cells to have greater in vivo tumourigenic 
potential. 
(A) Xenograft assays in nude mice. To compare the in vivo tumourigenic potential of the 
MCF-7-hSpry2Y55 cells with that of the control MCF-7 cells, both types of cells were injected 
separately into each side of the nude mice. The animals were sacrificed at 9 weeks and both 
tumours were extracted and weighed.  
(B) Graph showing the respective tumours from 15 different animals, which were weighed 
and tabulated. The values correspond to the average weight of tumours ± SEM derived from 
15 mice. The hSpry2Y55F cell line formed significantly larger (2.9X) tumour masses compared 
with the control MCF-7 cell line (* p = 0.0001). The experiment was repeated 2 times with 




















Expression of hSpry2Y55F in the xenograft tumours excised from the nude mice. To 
confirm that hSpry2Y55F is still consistently expressed in the xenograft tumours, proteins from 
both tumours were extracted and hSpry2Y55F (FLAG-tagged) expression was confirmed using 

















The expression of Sprys in various types of cancer was analyzed and Spry1 and 2 were found 
to be significantly down-regulated in more than 90% of breast cancers. hSpry1 and 2 are 
expressed abundantly in normal breast tissues and there is a 2-100 fold down-regulation in the 
expression of both genes in malignant breast cancer. Patient data accurately matched the 
prediction and preliminary data for the down-regulation of hSpry2 in breast cancer; this also 
indicates that the down-regulation of hSpry1 may be close to that of Spry2.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
In this study, the possible mechanisms by which the Sprys may be down-regulated in breast 
cancer was examined. Epigenetic causes, which are a relatively common reason for the 
observed down-regulation of genes in cancer, were ruled out. WT1 is unlikely to be 
responsible for down-regulation of at least hSpry1 in breast cancer since it has been 
established that WT1 is up-regulated in breast cancer (Loeb et al., 2001) and no difference in 
WT1 expression was observed between the normal and tumour breast tissue samples in the 
Cancer Profiling Array. Only the detailed analysis of the transcriptional mechanism of the 
Spry genes in normal versus cancer cells is likely to shed any light on the observed consistent 
down-regulation.  
 
The co-localization of both isoforms in the normal breast tissue as well as the observed 
simultaneous down-regulation of both isoforms in breast cancer indicate that Spry1 and 2 are 
likely to be similarly regulated and that there is possibly a redundancy in their physiological 
functions. To further clarify whether there is a functional redundancy between the expressed 
proteins, a comparison of the phenotype of single and double Spry knockout mice should be 
undertaken. 
 
The expression of Spry was examined in the mammary glands of mice at different life stages. 
The Sprys were found to be expressed abundantly in actively developing mammary gland, as 





had ceased to branch or proliferate. Given the evidence that Spry is an antagonist of tracheal 
branching morphogenesis, Sprys may play a role in the negative regulation of the branching 
of breast ducts. It appears that the expression of Spry genes precludes random branching of 
ducts and most likely promotes branching at an active apical site. This suggests that Sprys 
may have a tumour suppressor role in breast cancer. Although observed down-regulation of 
Spry in breast cancer is not the direct result of genetic or epigenetic causes (such as 
mutation/deletion/methylation), the profound difference in Spry expression between normal 
and malignant breast tissue at least mimics Knudson’s two hit hypothesis modified to 
accommodate haploinsufficiency (Cook and McCaw, 2000). 
 
While it is accepted that the causes of cancers are multifactorial, and due to certain genes 
(oncogenes and tumour suppressors), the deregulation of genes involved in growth and 
differentiation have a more significant impact. Conversely, the status of certain tumour 
suppressor genes such as p53 and Rb are important for their central surveillance and 
regulatory roles in cell cycle, such that the loss-of-function of these genes would relieve cells 
of the inhibitions that normally hold the cell cycle in check. It is possible that because of its 
critical role in the negative regulation of the Ras/MAP kinase pathway, Spry could be deemed 
a putative tumour suppressor gene and loss of expression or function may allow the cell to be 
insensitive to anti-growth signals. To examine this possibility, the hSpry2Y55F mutant was 
over-expressed in MCF-7 cells. Over-expression of the putative dominant negative hSpry2Y55F 
mutant quenches the function of endogenous wild-type Spry in MCF-7 cells and causes cells 
to proliferate faster, exhibit anchorage-independent growth and loss of contact inhibition. As a 
result hSpry2Y55F MCF-7 cells form larger tumours in the in vivo nude mice assay compared 
to control MCF-7 cells. The consistent down-regulation of Spry1 and 2 in breast cancer and 
the experimental evidence utilizing a dominant-negative hSpry2Y55F indicates that Spry 
proteins may actively maintain tissue integrity that runs amok when their expression is 
decreased below normal threshold levels. Spry1 and Spry2 may play tumour suppressive roles 





the adult and undergoes cyclical morphological changes with respect to fluctuations in 
hormonal levels. This suggests a previously unrecognized role for Sprys in cancer 
development.  
 
Future studies would investigate whether Spry gene silencing might augment the signalling 
defects in cancers. Given the high frequency of Spry1 and Spry2 silencing in breast cancer 
and the high rate of HER-2/ErbB2 amplification in this disease (Slamon et al., 1987), it is 
likely that a subset of tumours will have a very active RTK-Ras-ERK signalling axis owing to 
the presence of two oncogenic lesions in the same genetic pathway. Further studies would be 
needed to examine whether patients with the loss of Spry expression in breast cancers have a 
poorer prognosis and whether restoration of Spry gene expression is sufficient to cause 
cellular apoptosis and growth arrest of breast tumours. If so, the molecular mechanisms of 
how Spry genes are silenced in cancers has to be fully investigated and drugs can be 
developed to target a protein or block/alter a particular molecular pathway that is responsible 
for down-regulation of Spry gene expression. Spry genes can then be used as molecular 
markers to screen for patients that demonstrate loss in expression of these genes and for 
predicting the subset of cancer patients that may potentially respond to therapeutic treatments 
which restore the expression of Sprys in breast tissues. 
 
Although the loss of Spry expression is detected even in the early stages (Stage I) of breast 
cancers, the use of Spry as a molecular marker to detect for breast cancer requires the 
resection of a small amount of normal and tumour breast tissue.  Spry mRNA expression in 
the tumour tissue would be compared to that in the normal tissue in order to assay for down-
regulation of the expression of Spry in breast tumours. This is a far more invasive procedure 
compared to the current methods of diagnosis of breast cancers and can only be carried out in 






Current diagnostic methods for breast cancer involves physical examination (palpation for 
lumps in the breast) and examination of nipple discharge for cancer cells (ductal lavage). In 
addition to a physical examination, blood and imaging tests may be performed. Imaging tests 
may include one or more of the following: diagnostic mammography, ultrasonography or 
magnetic resonance imaging. Based on these examinations, the physician will then decide 
whether further tests are needed. If a breast lump or mass is indicative of cancer, a physician 
will perform a biopsy to remove cells or tissue from the breast tissue so that a pathologist can 
determine if cancerous cells are present in the breast lump. Blood tests can only be used in 
conjunction with other clinical observations for diagnosis of certain cancers. Tumour markers 
such as prostate specific antigen (PSA) are associated with the likelihood of prostate cancer 
being present.  
 
Spry proteins are unlikely to be used as molecular markers in the detection of breast cancer as 
less invasive methods of diagnosis of breast cancer currently exist. There is no evidence that 
Spry proteins are secreted by cells into the blood stream. Thus, it would be difficult to design 
a blood assay to detect the loss of Spry expression occurring in the development of breast 
tumours. Sprys are more likely to be used as molecular markers in breast cancers for the 























DOWN-REGULATION OF SPROUTY2 IN LIVER CANCER 
 
4.1 Introduction to Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC), the primary adult liver malignancy, is the fifth most 
common cancer, and the third leading cause of cancer deaths worldwide (Block et al., 2003). 
The major risk factors (accounting for 70-85% of all cases) of HCC are chronic infections 
with hepatitis B virus (HBV) or hepatitis C virus (HCV), although other non-viral causes 
(such as environmental carcinogens, e.g., aflatoxin B1; alcohol abuse; inherited disorders, 
e.g., hemochromatosis, Wilson disease, alpha1-antitrypsin deficiency, tyrosinemia) also play 
a role (Suriawinata and Xu, 2004; Szabo et al., 2004). Once predominant in Asian and 
African countries due to endemic HBV infections, the incidence of HCC is steadily on the 
rise in Western countries due to HCV infections and non-viral causes (Block et al., 2003; El-
Serag, 2002). Although the etiology of HCC is more well-defined than other types of cancers, 
the underlying molecular mechanisms leading to hepatocarcinogenesis remain incompletely 
understood despite current research efforts into the molecular genetics and pathogenesis of 
HCC.   
 
Extensive studies have demonstrated that the development of HCC from preneoplastic lesions 
are associated with complex and heterogeneous genetic or chromosomal abnormalities such 
as loss of heterozygosity (LOH), microsatellite instability, gene alterations, and aberrant 
global gene expression profiles (Suriawinata and Xu, 2004). Additionally, there is convincing 
evidence that HBV and HCV, the prominent etiological factors of HCC, are involved directly 
in the carcinogenic process (Kioke et al., 2002). There are fundamental differences between 
HBV and HCV: HBV is a Hepadnavirus with a double-stranded DNA genome whereas HCV 
is a Flaviviridae virus with a single-stranded RNA genome; HBV DNA is integrated into the 





similarities exist in the pathways of HBV and HCV induced hepatocarcinogenesis (Szabo et 
al., 2004).  Most notably, the product of the HBV X gene (HBx protein) and the core protein 
of HCV have been demonstrated to have oncogenic potential (Kioke et al., 2002), and to 
activate the Ras / extracellular signal-regulated kinase (ERK) signalling cascade (Hayashi et 
al., 1999; Giambartolomei et al., 2001; Hayashi et al., 2000; Yun et al., 2004; Doria et al., 
1995). Indeed, ERK expression and activity both have been found to be activated in HCC, 
suggesting an important role of this signalling pathway in hepatocarcinogenesis (Ito et al., 
1998; Schmidt et al., 1997; Schmidt et al., 1999; Huynh et al., 2003). ERK is a key molecule 
that transduces signals from convergent pathways into the nuclei, resulting in multiple cellular 
responses such as proliferation and differentiation (Ito et al., 1998). Additionally, it is a 
protein serine/threonine kinase which can be activated by a number of growth factors and 
receptors, among which and pertinent to the liver is the hepatocyte growth factor (HGF) and 
its receptor the c-met proto-oncogene (Lee et al., 1998; Ueki et al., 1997). 
 
Given the significance of the MAPK pathway in HCC, which can be activated by important 
etiological factors (HBV and HCV) and mitogenic growth factors, modulation of this pathway 
in HCC could have profound effects on the development or progression of HCC.  Because of 
the implied significance of Spry2 in human HCC, the functional role of Spry2 in HCC was 
investigated.   
 
4.2 RESULTS: Spry2 transcript is down-regulated in HCC 
4.2.1 Microarray studies 
In an earlier gene expression study of HCC, Spry2 was one of the top 600 genes observed to 
be differentially expressed in HCC as compared to non-tumour liver tissue (p<0.01 by 
Student’s t test with Bonferroni correction) (Chen et al., 2002). To verify this observation, a 
more stringent and biologically relevant analytical approach was employed: first, the data was 
rescaled so that the relative tumour (T) versus non-tumour (N) expression ratios (log2(T/N)) 





the microarray study.  If an HCC sample did not have a corresponding non-tumour sample, 
the global mean of the non-tumour gene expression ratios were used.  Genes satisfying the 
pattern of being down-regulated in tumour, compared to non-tumour, were then assessed 
using a t-score pattern-based algorithm, for samples with a t-score less than -2.  The t-score is 
a measure of variability (average/standard deviation), and thus provides an indication of the 
consistency of the expression values across all samples. Of the genes investigated, 1557 genes 
satisfied this defined pattern of t-score < -2, with a false positive rate of 0.008 and false 
negative rate of 0.002.  Spry2 (t-score = -8.023) was among the top 7% of the genes with 
absolute t-score > 8, suggesting that it is consistently (69/75, 92% of matched samples) and 































Figure 4.2.1  
Spry2 transcript is down-regulated in Hepatocellular carcinoma (HCC). Microarray 
analysis of the relative expression of Spry1 and Spry2 in tumour compared to non-tumour 
liver.  Of the total of 75 patients, 57 are matched HCC and non-tumour liver samples.  In the 
study by Chen et al. (2002), both the tumour samples (T) and normal tissue samples (N) were 
compared to a pooled universal cell-line reference (U) such that expression ratios were 
represented as log2 (T/U) and log2 (N/U) respectively.  The relative T vs. N expression ratios 
[log2(T/N)] depicted here is calculated by log2(T/U) – log2(N/U).  If an HCC sample did not 
have a corresponding non-tumour sample, the global mean of the non-tumour gene expression 
ratios were used.  The relative abundance of transcripts of each gene is represented by the 
color scale at the bottom right corner with red representing strongly over expressed and green 
























4.2.2 Quantitative real-time PCR studies 
The observed gene expression data was verified using semi-quantitative real-time PCR to 
measure the transcript levels of Spry2 in 11 matched tumour and non-tumour liver tissues, and 
it was consistently observed that Spry2 is down-regulated in HCC compared to non-tumour 
liver (8/11, 73%) (Fig. 4.2.2A). Unlike in breast cancer, Spry1 was not significantly down-
regulated in HCC (Fig. 4.2.1 and 4.2.2B). 
 
4.2.3 In situ and immunohistochemistry studies showed that Spry2 is differentially 
expressed in normal, cirrhotic, and HCC liver tissues 
In situ hybridization was employed on liver tissue microarrays to confirm that the Spry2 
transcript expression levels were less in HCC. The tissue microarrays consists of an 
independent set of patients from those included in the microarray and real-time PCR study, 
thereby allowing independent confirmation of the gene expression data. In total, there were 17 
normal livers, 14 cirrhotic livers, and 67 malignant HCCs, among other control tissues. Tissue 
arrays were constructed as previously described (Kononen et al., 1998; van de Rijn et al., 
2002), with each core being 1.6 mm on one array and 2 mm on the other array.  
 
Consistently, the Spry2 transcript was detected in a larger percentage of normal and benign 
liver tissues than in malignant HCC (Table 4.2.3A).  Differential staining between non-
tumour liver and malignant HCC was significant at p < 0.01, whereas staining between 
cirrhotic liver and malignant HCC was significant at p < 0.05.  Interestingly, cirrhotic liver 
stained the most strongly for Spry2 compared to normal or malignant HCC liver (Fig. 
4.2.3A).  By immunohistochemistry, the expression of Spry2 protein showed a similar pattern 
(Fig. 4.2.3B), although differential expression levels were less significant than when 
calculated at the transcript level: p = 0.088 between non-tumour liver and malignant HCC, 














Spry2 but not Spry1 is significantly down-regulated in HCC. Real-time PCR measurement 
of (A) Spry2 and (B) Spry1 in 11 paired tumour/non-tumour samples. The mean expression of 
Sprys in normal tissue was averaged and deemed to be 100% (dotted line). The expressions of 
Sprys in tumour samples were expressed as a percentage of the expression of Sprys in normal 
tissue. Each sample was analyzed three times and the mean value ± SEM was calculated. 
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Non-tumour liver 2 14 < 0.01 
Cirrhotic liver 3 11 < 0.05 
Malignant HCC 47 19  
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Non-tumour liver  8 7 0.088 
Cirrhotic liver  6 8 0.029 
Malignant HCC  47 18  
 
Table 4.2.3  
Spry2 expression is relatively higher in normal and cirrhotic liver compared to HCC 
liver. (A) in-situ hybridization and (B) immunohistochemistry was used to detect Spry2's 











Spry2 expression is relatively higher in normal and cirrhotic liver compared to HCC 
liver. (A) in-situ hybridization and (B) immunohistochemistry was used to detect the 










4.3 Down-regulation of Spry2 in HCC is not due to loss of heterozygosity 
Due to the implied role of Spry2 as a tumour suppressor gene, and also because Spry2 is 
located on 13q [a chromosomal region that is frequently deleted in HCC (Levy et al., 2002)], 
it was next investigated whether the down-regulation of Spry2 could result from loss of 
heterozygosity (LOH).  Using the microsatellite markers D13S170, D13S1263, D13S1277 
and D13S266 (Fig. 4.3A), LOH was not observed in 12 pairs of HCC tumour/non-tumour 
tissues.  The microsatellite markers D13S1277 and D13S266 were chosen since up to 47% of 
prostate cancer samples exhibit LOH at these loci (McKie et al., 2005). The LOH result for 
microsatellite marker D13S1263 is shown in Fig. 4.3B; other microsatellite markers gave 
similar results.  These results correlated with a recent study by Pineau et al. (2003), where no 





























Loss of Heterozygosity (LOH) does not cause the down-regulation of Spry2 in HCC. 
(A) Schematic representation of microsatellite markers flanking the Spry2 gene loci. Diagram 
is not drawn to scale.   
(B) LOH assay of 12 pairs of normal (N) and HCC samples (T) was performed as described 
in Materials and Methods. The radiolabeled PCR products were separated in 5% TBE-Urea 












4.4 Hypermethylation of promoter is not responsible for down-regulation of Spry2. 
Methylation of the Spry2 promoter region (or of genes upstream of Spry2) was next assessed 
as a possible mechanism for the silencing of Spry2 in HCC.  Hypermethylation of promoter 
regions is a common mechanism of gene silencing.  This process works in concert with 
histone deacetylation to repress gene transcription (Rountree et al., 2001; Robertson, 2002). 
Two HCC cell lines that express Spry2 at low levels (SNU449 and HepG2) and moderate 
levels (Hep3B; about 4 fold higher) were selected for treatment with the DNA methyl-
transferase inhibitor 5-aza-deoxycytidine (5-aza-DC) according to the protocol by McKie et 
al. (2005). Real-time PCR analysis of Spry2 mRNA levels in these cell lines showed that the 
levels of Spry2 did not up-regulate after 5-aza-DC treatment. Instead, a slight reduction of 
Spry2 levels was observed (Fig. 4.4, left panel).  RASSF1A is one of the most frequently 
inactivated genes described thus far in human solid tumours (Dammann et al., 2000) and its 
inactivation commonly involves methylation of the promoter and CpG islands, and can be up-
regulated by 5-aza-DC treatment.  It was used here as a positive control for the 5-aza-DC 


























Epigenetic silencing via methylation of Spry promoter (or the promoter of genes 
upstream of Spry) is not responsible for the down-regulation of Spry2 expression in liver 
tumours.  Treatment of Hep3B, HepG2, SNU449 liver cancer cells with 5-aza-deoxycytidine 
(5-aza-DC) (25 µM) for 6 days (on alternate days) did not up-regulate the expression of 
Spry2. RASSF1A is a gene silenced by hypermethylation and was used as a positive control to 
show that the 5-aza-DC treatment was effective. All real-time PCR analysis was normalized 






















4.5 Spry2 inhibits HGF-stimulated ERK and exerts an anti-proliferative effect in 
the hepatoma cell line SNU449 
As seen in the earlier results (Fig. 3.7 and 3.8), functional inhibition of Spry2 enhanced 
proliferation of the breast cancer cell line MCF-7, suggesting that Spry2 has a growth 
inhibitory role in breast cancer.  To test whether this functional implication of Spry2 is also 
observed in liver cancer, stably expressing clones of Spry2 and its reported dominant-negative 
mutant Spry2Y55F were generated using the human HCC cell line SNU449.  In the absence of 
any growth stimulatory factors, inhibition of Spry2 function in the SNU449 cells stably 
expressing Spry2Y55F mutant resulted in an enhanced proliferation rate compared to the 
control parental cell line (Fig. 4.5A).  The growth inhibitory effect of over-expressing Spry2 
was evident only in the presence of HGF (50 ng/ml); this effect is significant at p = 0.03 
(student t-test from 3 independent experiments).  
 
In order to elucidate the molecular mechanism in which Spry2 mediated its growth inhibitory 
effect, the ERK activity in HCC cells upon HGF stimulation was evaluated. Recombinant 
adenoviruses carrying the Spry2 gene were generated using the AdEasy Adenoviral Vector 
System (Stratagene, La Jolla USA).  This provided an infection efficiency close to 100% in 
SNU449 cells.  Following HGF stimulation, ERK activation was found to be inhibited at 
earlier time points when compared to uninfected SNU449 control cells (Fig. 4.5B).  This is 
consistent with a previous study (Lee et al., 2004) where Spry2 was shown to inhibit ERK 
activation in a leiomyosarcoma cells.   
 
4.6 Knocking down Spry2 levels transforms NIH3T3 cells in the presence of FGF 
stimulation 
The current liver and breast cancer studies suggest that a reduced level of Spry2 may play a 
central role in enabling certain stages of tumour progression. To further address this, Spry2 
levels in the NIH3T3 cells were knocked down using siRNA and the cells assessed for foci 





transformation by activation of the Ras signal transduction pathway (Li et al., 2004), which 
Spry proteins are known to regulate (Yusoff et al., 2002; Gross et al., 2001).  The siRNA 
duplexes (Dharmacon) were first transfected into mouse Neuro2A cells (which exhibits 
higher transfection efficiency) and real-time PCR analysis showed approximately 50 percent 
knock-down for each of the 4 duplexes (D1 to D4; Fig. 4.6A).  The siRNAs were then 
subsequently transfected into NIH3T3 cells which were either left unstimulated or stimulated 
with basic FGF (20 ng/ml) for 2 weeks with regular replacement of the media and ligand 
every 3 days.  FGF was used as NIH3T3 cells do not respond to HGF stimulation, probably 
due to low expression levels of endogenous Met receptors.  Crystal violet stained dishes 
indicated no difference in cell morphology among the unstimulated dishes (Fig. 4.6B).  A 
slight but readily apparent transforming phenotype was observed for cells transfected with 
Spry2 siRNA duplexes when the FGF ligand was added.  This suggests that a lower Spry2 
level coupled with a high concentration of growth factor can indeed facilitate the 






















Spry2 inhibits HGF-stimulated ERK and exerts an anti-proliferative effect in the 
hepatoma cell line SNU449. 
(A) Proliferation of SNU 449 cells stably expressing Spry2, Spry2Y55 and control cells. The 
figure represents the percentage increase in living cells that were either unstimulated (no 
HGF) or treated with HGF (at 50 ng/ml) and is representative of 3 independent experiments; 
error bars indicate + standard error mean.  Asterisk (*) indicates p < 0.05 (student’s t-test).  
(B) The phosphorylated-ERK level was assayed in both control cells and Spry2 infected 
SNU449 cells. SNU449 cells were seeded into 4 well plates at a density of 3 X 103 cells per 
well and left to culture overnight.  On the next day, a dose of Spry2 adenovirus sufficient to 
give a MOI (multiplicity of infection) of 5 was added to the wells.  After 4 days, the cells 
were stimulated with HGF (50 ng/ml) for various durations and harvested for western 
blotting.  













Knocking down Spry2 levels, in the presence of FGF stimulation, enhances 
transformation in NIH3T3 cells  
(A) Real time PCR analysis of the levels of Spry2 after Spry2 siRNA duplexes (D1 to D4) 
were transfected into Neuro2A cells. The expression of Spry2 in siRNA-treated cells was 
expressed as a percentage of the expression of Spry2 in cells treated with negative control 
siRNA. Each sample was analyzed three times and the mean value ± SEM was calculated. 
Transcript quantification was reported relative to human ribosomal 18S.  
(B) Transformation assay. NIH3T3 cells were transfected with either a negative control 
siRNA (C) or Spry2 siRNA duplexes 1 to 4 (D1 to D4).  2 days after transfection, the cells 
were split into two 60 mm diameter dishes and left unstimulated or stimulated with basic FGF 
(20 ng/ml) for 14 days, with regular replacement of media and ligand every 3 days.  The 








A consistent under-expression of Spry2 was observed in the majority of HCC livers compared 
to their matched normal livers, implying a potential diagnostic value of Spry2 in HCC.  On 
the other hand, Spry1 did not show any consistent down-regulation in tumour vs. non-tumour 
liver samples, based on either gene expression or real-time PCR data which is in contrast to 
the previous study of its level in breast cancer (chapter 3). The down-regulation of Spry2 in 
HCC may confer a proliferative advantage for tumour cells by allowing unchecked activation 
of the Ras/ERK pathway, which would normally be controlled by relatively higher expression 
levels of Spry2 in normal liver.   
 
Validation using in-situ hybridization and immunohistochemistry on an independent set of 
archived liver tissues confirmed the presence of Spry2 transcript and protein in normal liver 
tissues and their absence in HCC liver tissues. Interestingly, the level of Spry2 transcript and 
protein were the highest in cirrhotic liver. Cirrhosis is characterized anatomically by 
widespread nodules in the liver combined with fibrosis, which together causes distortion of 
the normal liver architecture, interference with blood flow through the liver, and disruption of 
the normal biochemical functions of the liver.  Cirrhosis can result from almost any chronic 
liver disease that causes damage to the liver cells. In patients with chronic hepatitis, the 
development of cirrhosis increases their risk of developing HCC. In general, HCC in livers 
with cirrhosis tend to be less well differentiated than HCC in livers without cirrhosis, and the 
presence of cirrhosis in turn portends a poorer prognosis (Nzeako et al., 1996). The 
abundance of Spry2 in cirrhosis raises the interesting possibility that it could serve as an early 
marker heralding later onset of HCC.  Potentially, high levels of Spry2 may be expressed due 
to the increased tissue remodeling during cirrhosis and is necessary to prevent uncontrolled 
cellular proliferation.  It will be interesting to monitor the levels of Spry2 in cirrhotic samples 






The mechanisms regulating Spry2 expression in various types of cancer are incompletely 
understood. As in breast cancer, the possibility of DNA methylation of promoter sites 
contributing to the observed silencing of Spry2 in HCC has been ruled out. This is in contrast 
to the study of Spry2 in prostate cancer where McKie et al. (2005) found a high proportion of 
samples methylated.  Similarly, no LOH was observed in the microsatellite markers flanking 
the Spry2 gene locus in HCC unlike that in prostate cancer (McKie et al., 2005).  Genetic 
variability between the different cancers may account for the differences observed in the 
mechanisms of down-regulation of Spry2 in various cancers.  In the case of HCC, the Spry2 
exon2 loci was previously checked for homozygous deletion in HCC cell lines by Pineau et 
al. (2003) but none was found.  In addition, Jou et al. (2004) had scanned for minimal deleted 
regions (MDR) in HCC and found the cytogenetic loci 13q13.1 to 13q22.1 (MDR regions 
D13S171 to D13S156) and 13q31.3 to 13q32.2 (MDR regions D13S265 to D13S159) to be 
deleted.  The Spry2 loci is located at chromosome 13q31.1 and is therefore between these two 
MDR regions. Thus, the earlier observations that LOH is not responsible for the down-
regulation in Spry2 in HCC (section 4.3) is in agreement with these studies. 
 
Recent functional studies of the promoter region of human Spry2 uncovered the presence of 
binding sites for numerous transcription factors that could modulate the basal and tissue-
specific expressions of Spry2 (Ding et al., 2003).  It is likely that the complex interactions of 
multiple transcription factors together control the expression of Spry2 in a cell- and context-
specific manner, eventually accounting for deregulation of Spry2 in human cancers.  Further 
studies would evaluate whether the loss of activators or increased activity or levels of 
repressors acting on the Spry2 promoter is involved in the down-regulation of Spry2 in HCC. 
 
Despite unknown mechanisms regulating Spry2 expression in HCC, Spry2 has been observed 
to play functionally important roles in HCC, including the inhibition of HGF-stimulated 
proliferation and HGF-activated ERK pathway in HCC cell lines.  The inhibition of an over-





being exploited: a recent clinical trial investigated the use of a Raf kinase inhibitor (BAY 43-
9006) to treat HCC by arresting proliferation and angiogenesis resulting from inappropriate 
signalling in the RAF/MEK/ERK and VEGFR-2/PDGFR-β cascades respectively (El-Serag et 
al., 2002).   
 
HCC is a hypervascular lesion with a rich supply of blood vessels; the angiogenic switch is 
regulated by various angiogenic growth factors and inhibitors, most commonly vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and insulin-like 
growth factor II (Kim et al., 2002).  Recently, new angiogenic pathways and regulators of 
these pathways have been discovered, which includes Sprouty (Bicknell and Harris, 2004).  
Specifically, mouse Spry4 was shown to inhibit angiogenesis (Lee et al., 2001), apparently 
via inhibition of receptor tyrosine kinase signalling upstream of or at the level Raf (Sasaki et 
al., 2003).  A reduction in both basal and bFGF or VEGF-induced ERK phosphorylation by 
Spry4 was postulated, resulting in the reduction of proliferation, migration, and differentiation 
during angiogenesis.  Whether other Sprouty proteins have similar anti-angiogenic properties 
is still unknown; this topic warrants further investigation as it can offer valuable insights into 
the molecular pathogenesis of HCC, as well as point towards novel approaches of therapeutic 
intervention.  
 
Finally, the use of Spry2 siRNA to knock down the expression levels in Spry2 in NIH3T3 
cells suggests that knock down of Spry2 expression levels results in a lowered threshold for 
cell transformation. By mimicking the high levels of growth factor environment where the 
liver tumour may be exposed to, the reduction of Spry2 protein in the siRNA duplex 
transfected dishes induces a mild transforming phenotype in the presence of basic FGF.  This 
suggests that Spry2 may play a role in preventing cell transformation and a down-regulation 






In conclusion, this study clearly indicates a role for Spry2 in HCC.  Further studies into the 
functional roles of Spry2 in the progression to liver cancer will not only enhance our 
understanding of the intricate molecular pathophysiology of this malignancy, but also help in 






























EVIDENCE FOR THE ROLE OF SPROUTYS IN CANCER 
 
Recent work done in other laboratories show that expression of the Sprouty family of proteins 
is deregulated in cancers including prostate tumours, melanoma, gastrointestinal stromal 
tumours (GISTs) and lung tumours. These additional data that substantiate the involvement of 
Spry proteins in cancer is discussed in this chapter, together with the recent evidence that 
Spry proteins can act to suppress the tumourigenesis process, at least in certain tumours (K-
Ras induced lung tumours). This chapter is adapted from a review written by me (Lo et al., 
2006) and includes the additional reports that have emerged recently. 
 
5.1  Down-regulation of Sprys in prostate cancer 
There are four studies that have found Sprys 1, 2 and 4 to be down-regulated in prostate 
cancer.  
 
In the first study, a tissue microarray containing samples from 407 cases of prostate cancer 
and matched normal peripheral tissues were analyzed for Spry1 immunoreactivity (Kwabi-
Addo et al., 2004). In normal prostate tissue, Spry1 was found to be expressed in epithelial 
and smooth muscle cells, with some staining of fibroblasts. Spry1 was found to be decreased 
in 39% of the prostate cancer samples.  However, amongst these 407 cases of prostate 
cancers, a significant fraction had a higher level of expression of Spry1 in cancer tissues than 
in the corresponding normal prostate epithelium. Primary prostate epithelial cells were also 
found to have higher levels of Spry1 protein compared to prostate cancer cell lines, thereby 
supporting the tissue microarray data. Real-time PCR data showed that the expression of 
Spry1 was up to 1.9 fold higher in the normal tissue, compared to that in cancer tissues. 





contributing factor for suppressed Spry1 expression in prostate cancer (Kwabi-Addo et al., 
2004). 
 
More recently, McKie et al. (2005) observed that Spry2 expression in invasive prostate cancer 
cell lines and high-grade clinical prostate cancer was reduced compared to benign prostatic 
hyperplasia (BPH) and well differentiated tumours. In order to understand the causes for the 
difference in Spry2 expression in these types of tumours, a study was conducted to determine 
which mechanisms are responsible. To address whether methylation is responsible for 
silencing of Spry2 expression, prostate cancer cell lines were challenged with 5-aza-DC. 
Spry2 expression, which is normally low in prostate cancer cell lines, was re-activated upon 
treatment with 5-aza-DC. Extensive methylation of the proximal CpG island I (Fig. 3.6.1A, 
page 94) was observed in 76-82% of high grade invasive prostate cancers while control BPH 
tissues were predominantly unmethylated. Furthermore, suppressed Spry2 expression 
correlated with methylation of the CpG regions in clinical samples of prostate cancer. There 
was no evidence of Spry2 mutations in prostate cancer tissues and cell lines. Chromosomal 
deletion around the hSPRY2 gene locus was assessed by PCR-based loss of heterozygosity 
(LOH) analysis using markers flanking the hSPRY2 gene locus. A moderately low incidence 
(27-40%) of LOH was detected using 2 markers tightly flanking the hSPRY2 gene. Hence, the 
authors conclude that epigenetic inactivation of Spry2 is the main mechanism for the down-
regulation of the hSpry2 gene in prostate cancer (McKie et al., 2005). 
 
Fritzsche et al. (2006) observed diminished expression of both Spry1 and Spry2 mRNAs 
using both microarray analysis of microdissected prostate cancers and quantitative RT-PCR 
of macrodissected specimens. However, they found that down-regulation of both Spry1 and 
Spry2 was only moderate. While Fritzsche et al. (2006) found a significant, but an average of 
only 2-fold reduction of Spry2 expression in prostate cancers, McKie et al. (2005) reported an 
8-fold difference in Spry2 mRNA expression between cancerous and normal prostate 





(2004) was in line with the findings of Fritzche et al. (2006). Thus, in spite of the quantitative 
difference, the three studies taken together indicate a concomitant, albeit moderate, down-
regulation of Spry1 and Spry2 in prostate cancers. 
 
Fritzsche et al. (2006) also observed that the decrease in Spry1 and Spry2 mRNA expression 
paralleled each other and that the expression levels of both genes were significantly lower in 
cancers that recurred within the average follow-up period of 32 months. DNA methylation 
was not found to be responsible for the down-regulation of Spry1 and 2 genes. Although 
methylation had been reported previously by McKie et al. (2005) in the CpG island I (Fig. 
3.6.1A) (encompassing the promoter and first exon) of SPRY 2, analysis of the 5' end of this 
CpG island did not yield any evidence of methylation (Fritzsche et al., 2006). They postulated 
that down-regulation of Spry2 in prostate cancers occurs independently of DNA methylation 
as reported for breast (Chapter 3) and liver cancers (Chapter 4). 
 
The last study conducted by Wang et al. (2006) showed via in situ hybridization that Spry4 is 
expressed in normal prostatic epithelial cells and the expression is decreased in a subset of 
prostate cancers. Quantitative RT-PCR confirmed that Spry4 expression was decreased in 
approximately one-half of prostate cancers. Analysis of the 5' promoter region of SPRY4 
revealed the presence of a CpG island approximately 1kb upstream of the transcriptional 
initiation site, the proximal region of which was preferentially methylated in prostate cancer 
tissues. More than half of all prostate cancers were methylated in this region, and methylation 
correlated significantly with decreased Spry4 expression as determined by RT-PCR (Wang et 
al., 2006).  
 
Accumulated evidence from all four studies indicates that Spry isoforms 1, 2 and 4 are down-
regulated in prostate cancer. However, the mechanisms for down-regulation of Sprys have not 
been fully elucidated. Genetic (loss of heterozygosity) and epigenetic (methylation) 





reports as to whether methylation is responsible for silencing of Spry2 in prostate cancer. 
Therefore, a general consensus on the mechanisms responsible for Spry2 down-regulation in 
prostate cancer has not been reached. 
 
5.2 Evidence for Sprouty isoforms as tumour suppressors  
The first evidence of Spry's ability to interfere with the tumourigenic process was shown in a 
study where over-expression of Spry2 in an osteosarcoma cell line, LM8, was found to inhibit 
tumour growth and metastasis (Miyoshi et al., 2004). Spry2 had been shown to inhibit FGF-
induced and serum-induced ERK activation as well as serum- and chemokine-mediated 
migration in these cells (Miyoshi et al., 2004). When Spry2 over-expressing LM8 cells were 
injected into nude mice, tumour growth and metastasis were suppressed. To rule out the 
possibility that the Spry2-expressing cells could be less metastatic because of slower tumour 
growth, tumour cells were directly injected intravenously into nude mice. Again, a high level 
of metastasis was observed with LacZ expressing cells but not with Spry2 expressing cells. 
This data points to the possibility that Spry2 inhibits tumour growth and metastasis, possibly 
via the inhibition of Ras/ERK activation and cell migration (Miyoshi et al., 2004).  
 
 In subsequent studies, numerous in vitro cell-based assays demonstrated that Sprys inhibit 
cell proliferation, migration, invasion as well as anchorage independent cell growth. Over-
expression of Spry1 in prostate cancer cell lines has an inhibitory effect on cell proliferation 
and colony formation (Kwabi-Addo et al., 2004). Similarly, over-expression of Spry2 
inhibited hepatocyte growth factor (HGF)-stimulated ERK activation and exerted an anti-
proliferative effect in HGF-responsive cell lines (Lee et al., 2004; Section 4.5). In addition, 
over-expression of Spry2 also inhibits anchorage-independent cell growth as well as cell 
migration in in vitro invasion assays (Lee et al., 2004). On the other hand, knocking down the 
endogenous levels of Spry2 in NIH3T3 cells caused a mild transformation, indicating that 
Spry2 is a potential tumour suppressor (Section 4.6). The knockdown of Spry2 protein using 





Correspondingly, increased cell cycle progression and decreased apoptosis was observed in 
these cells. These results indicate that Spry2 acts as a negative regulator of endothelial cell 
proliferation and survival (Paik et al., 2007). 
 
Recently, Shaw et al. (2007) showed that in K-RasG12D-induced lung tumourigenesis, Spry2 is 
up-regulated and functions as a tumour suppressor. Compared to K-RasG12D; Spry2 wild type 
control mice, K-RasG12D; Spry -/- mice developed more tumours and have a larger total tumour 
area. Immunohistochemical analysis of the tumours demonstrated a slight increase in the 
number and intensity of phosphorylated ERK-positive tumours in K-RasG12D; Spry -/- mice 
compared to the control mice. These results support the notion that Spry2 functions to inhibit 
K-RasG12D-induced tumour development by antagonizing Ras/ERK signalling and inhibiting 
tumour formation (Shaw et al., 2007).  
 
Alternatively, Spry2 could potentially suppress tumour development by triggering oncogene-
induced senescence (Courtois-Cox et al., 2006). While early studies suggest that senescence 
is mediated by sustained hyper-activation of Ras/ERK signalling, one recent study proposed 
that the global suppression of Ras signalling pathways, in part through the induction of Spry 
proteins, triggers the senescence response (Courtois-Cox et al., 2006). Of note, this study 
used NF1 knockdown and B-Raf mutant cells. In mouse embryonic fibroblasts (MEFs) 
expressing endogeneous K-RasG12D, Spry2 was similarly induced but senescence was not 
observed to occur in these cells (Shaw et al., 2007). Future efforts will focus on determining 
whether Spry proteins function as tumour suppressors by simply restraining excessive cellular 
proliferation or by enabling a senescence program. 
 
5.3 Sprouty as a potential  tumour marker  
5.3.1 Melanoma 
The Ras/ERK pathway is constitutively activated in melanoma due to either oncogenic 





B-Raf occur in nearly 70% of melanomas. It is also found at a significant frequency in other 
cancers, including cancers of colorectal, ovarian and thyroid origin. Over 30 different 
missense mutations have been identified, with the majority positioned in the kinase domain of 
B-Raf and with 90% of the mutations corresponding to a V599E substitution (Wellbrock et 
al., 2004). B-Raf activity is enhanced by this mutational change presumably because the 
negative charge of the glutamate residue effectively mimics the phosphorylation that occurs 
within the activation loop (Wan et al., 2004). B-Raf mutants exhibit increased ERK activation 
via sustained MEK phosphorylation or interaction with C-Raf (Wan et al., 2004). This can 
result in growth transformation of rodent fibroblasts and melanocytes (Wellbrock et al., 
2004). The functional knocking down of B-Raf activity in melanoma with small interfering 
RNA has confirmed its oncogenic activity in mediating ERK signalling, induction of 
proliferation and protection from apoptosis (Wan et al., 2004).  
 
Tsavachidou et al. (2004) analyzed the gene expression changes between a panel of 
melanomas with wild-type (WT) B-Raf and a group of melanoma cells with the B-Raf V599E 
mutation. Spry2 expression was found to be up-regulated in melanoma cells with B-Raf 
mutations, compared to melanocytes with WT B-Raf. Similarly, when Bloethner et al. (2005), 
analyzed the gene expression profile of a melanoma cell line with a B-Raf mutation and 
compared it with that of melanoma cell lines with the common Q61R mutation in the N-Ras 
gene as well as cell lines with no mutations, Spry2 was found to be up-regulated in the cells 
containing mutations of either B-Raf or N-Ras genes. Interestingly, Spry2 has an inhibitory 
effect on ERK signalling in melanocytes and WT B-Raf melanoma cells, but not in cell lines 
with the V599E mutation (Tsavachidou et al., 2004). Data from both groups suggests that 
V599E mutant melanoma cells have higher levels of Spry2, which is likely due to the 
increased ERK activity in these cells. Tsavachidou et al. (2004) showed that Spry2 and 4 
bound to WT B-Raf but not with mutant V599E and other exon 15 B-Raf mutants. Although 
there was no demonstration that binding of Spry to B-Raf is important for the inhibition of 





Spry2 to bind to B-Raf is associated with a loss in its ability to inhibit ERK signalling in B-
Raf mutant melanoma cells. This is a significant finding and may imply that in melanomas 
with the V599E mutation, aberrant ERK signalling is unchecked because Spry isoforms are 
rendered functionally ineffective (Tsavachidou et al., 2004). 
 
5.3.2  Gastrointestinal stromal tumours (GISTs) 
Nielsen et al. (2002) analyzed the gene expression patterns of 41 soft tissue tumours by 
microarray in order to identify gene clusters that distinguish the different tumour classes. The 
tumours included synovial sarcomas, gastrointestinal stromal tumours, neural tumours and 
leiomyosarcomas. Spry1 and Spry4 were among the genes that showed specific expression in 
gastrointestinal stromal tumours (GISTs). 
 
Within this group of soft-tissue tumours, receptor tyrosine kinases that could potentially 
induce Spry expression were identified. c-Kit was also identified among the cluster of genes 
that were highly expressed and specific to GISTs. c-Kit is a proto-oncogene which encodes 
for the RTK, c-Kit, also known as stem cell factor receptor. Aberrant c-Kit activity derived 
from activating c-Kit mutations is deemed to be important for the transformation of GISTs. 
The mutations, usually involving exon 11, are gain-in-function mutations, resulting in a 
constitutively phosphorylated and activated c-Kit (Nielsen et al., 2002).  
 
Spry has been shown to be induced by aberrant c-Kit activation (Frolov et al., 2003). This was 
demonstrated in a study that involved treating GIST cells with an inhibitor of c-Kit, Imatinib 
mesylate (Gleevec, STI-571). Imatinib has been shown to be an in vitro inhibitor of c-Kit 
phosphorylation and tumour cell proliferation, while at the same time inducing apoptosis in a 
human GIST cell line. Frolov et al. (2003) identified genes that were altered in response to the 
treatment using microarray analysis. Spry4 was identified and confirmed as one of the most 
significant Imantinib-responsive genes that were consistently down-regulated upon treatment 





loss of the phosphorylated forms of c-Kit, Akt and ERK1/2. Within 3 hr of inhibition of c-Kit, 
Spry4 levels were considerably decreased and lost by 6 hr. To further confirm that Spry4 
expression was regulated by an ERK-dependent pathway, GIST cells were treated with the 
MEK inhibitor, U0126. Spry4 showed a similar pattern of down-regulation to Imatinib-treated 
cells, indicating that Spry4 was downstream of ERK signalling activated by c-Kit.  
 
Spry4 was found to be a reliable marker with respect to the clinical response of patients to 
Imatinib treatment. The authors found that in patients responsive to the drug, Spry4 levels 
were dramatically decreased. However, in non-responsive patients, Spry4 levels did not 
decrease. Furthermore, in patients that initially responded but subsequently relapsed, Spry4 
levels decreased dramatically in the tumour biopsy taken during clinical response but returned 
back to pretreatment levels upon clinical relapse (Frolov et al., 2003).  
 
5.3.3  clear cell Renal Cell Carcinomas (ccRCC) 
While Sprouty is a potential marker of aberrant MAPK signalling in the above-mentioned 
cancers, in other cancers, it has surprisingly been found to be a marker for good clinical 
prognosis. Takahashi et al. (2001) studied the expression profiles of 29 ccRCC and isolated 
51 genes that effectively discriminated between patients with good and poor outcome. Spry1 
was found to be up-regulated exclusively in the good outcome group.  
 
5.3.4 Lung tumours induced by K-Ras  
Spry2 and, to a much lesser extent, Spry1 were found to be up-regulated in mouse lung 
tumours which were induced by oncogenic K-RasG12D. Individual lung tumours were isolated 
from 3- to 4-month old mice harboring a "latent" (LA2) K-RasG12D allele (Johnson et al., 
2001). This allele is sporadically activated following a spontaneous recombination event, 
leading to the expression of oncogenic K-Ras and lung tumour formation in 100% of the 
experimental animals. In six out of the seven tumours examined, the degree of Spry2 up-





levels inversely correlated with levels of phosphorylated ERK which is consistent with Spry-
mediated inhibition of Ras/ERK signalling (Shaw et al., 2007).  
 
5.4 Summary 
Spry genes have been shown to be down-regulated in breast, liver and prostate cancers but up-
regulated in melanoma, gastrointestinal stromal tumours and K-Ras induced lung tumours. 
The up-regulation of Spry expression in certain tumours (GISTs, melanoma, lung tumours) is 
often induced by the presence of oncogenic lesions, such as mutation in c-Kit, B-Raf, K-Ras, 
which cause the constitutive activation of the Ras/ERK pathway. Recently, Sprouty proteins 
were discovered to be upregulated in the early phase of Ras activation, as part of the 
multifaceted negative feedback signaling network that terminates the oncogenic signal and 
participates in the senescence response to limit tumor development (Courtois-Cox et al., 
2006). 
 
Although numerous oncogenes are also activated in breast, liver and prostate cancers, the 
same phenomenon of up-regulation of Spry genes is not observed in these tumours. Instead, 
down-regulation of Spry genes is observed in these tumours. The mechanisms of down-
regulation of Spry genes have not been completely elucidated in these cancers but at least for 
prostate cancers, a few genetic (loss of heterozygosity) and epigenetic mechanisms 
(methylation) have been identified to be responsible for silencing of Spry genes (McKie et al., 
2005; Wang et al., 2006). 
 
Spry genes have the potential to be used as molecular markers to aid cancer diagnosis and 
treatment. Up-regulation of Spry genes can be used concurrently with other molecular 
markers to distinguish the different tumour classes. Alternatively, up-regulation of Spry genes 
can also be used concurrently with other molecular markers as an aid for prognosis or to 





of cancer, up-regulation of Spry genes can either be a marker for good (ccRCC) or bad (lack 





































SPROUTY2 INHIBITS RAS/ERK ACTIVATION AND TRANSFORMATION 
DOWNSTREAM OF POLYOMA MIDDLE T ONCOGENE 
 
In cancer, multiple growth factor systems, including FGF, EGF, VEGF and IGF families 
contribute to tumourigenesis (Djakiew, 2000). Given that Sprys are inducible physiological 
inhibitors of many RTK pathways including FGF, VEGF, GDNF and HGF, Sprys would be 
expected to play an important role in counter-balancing such abnormal signalling activities. 
Hence, suppressed expression or function of Spry would potentiate aberrant signalling in 
tumourigenesis.  
 
This study sought to investigate whether Sprys have the ability to suppress oncogene-induced 
transformation. Spry2 was placed in the presence of Polyoma Middle T antigen (PyMT) 
oncogene to test whether Spry2 was capable of inhibiting cell transformation induced by 
PyMT.  
 
6.1 PyMT as a model to study transformation 
Polyoma Middle T antigen (PyMT), the principal transforming component of the polyoma 
virus (DNA virus), is used as a model system to study cell transformation (Fig. 6.1). An 
introduction to PyMT can be found in section 1.6. The following section will discuss the 
association of PyMT with cellular components in a defined series of binding reactions that are 
responsible for the transforming effect. Each interaction will be considered in the order that 
they probably would occur in the cell. 
 
6.1.1 Membrane binding 
PyMT is associated with most cellular membranes (Dilworth et al., 1986), though localization 
















Schematic diagram of PyMT. PyMT is 421 aa long and is encoded by nucleotides 175 to 
748 (aa 1 to 191) spliced to 811 to 1499 (aa 192 to 421) based upon the sequence numbering 
of the A2 wild-type strain. The membrane-spanning domain consists of hydrophobic aa 
394 to 415. On interaction with the plasma membrane, PyMT associates with (although does 
not directly bind to) src, a tyrosine kinase, resulting in the phosphorylation of tyrosines at aa 
250, 315, and 322 and in the binding of ShcA, PI 3-kinase, and PLCγ-1. In addition, PyMT 
contains serine (aa 257 and 283) and threonine (aa 160 and 291) phosphorylation sites. The 
phosphorylation of serine 257 results in the interaction with the 14-3-3 proteins. Finally, 
PyMT associates with both the catalytic subunit C and the regulatory domain A of PP2A at aa 
90 to 120.  
 















and then attaches to membranes via the 22 hydrophobic amino acids (aa) at the C-terminal 
tail. The basic amino acid (aa) is known to influence membrane location (Dahl et al., 1992; 
Elliott et al., 1998). Without these amino acids, PyMT loses its ability to bind to the 
membranes and fails to associate with most of the cellular proteins that it normally binds. As 
a result, it fails to cause transformation. However, this hydrophobic region does more than 
simply mediate membrane interaction, as its replacement with the membrane targeting 
domains of vesicular stomatitis virus glycoprotein G (Templeton and Eckhart, 1984), 
cytochrome b5 (Zhu et al., 1998), or myristylation signal of pp60c-src (Elliott et al., 1998) all 
locate PyMT to the membrane site but fail to restore transformation. In addition, mutations 
within the hydrophobic domain can also abolish transforming activity without disrupting 
membrane binding (Markland and Smith, 1987). 
 
6.1.2 Binding to PP2A 
PyMT, as well as PyST with which it shares extensive amino acid homology, contains a 
PP2A binding domain (aa 90 to 120) that allows it to mimic the cellular PP2A regulatory B 
subunit and bind to the core PP2A dimer composed of the A (regulatory) and C (catalytic) 
subunits (Pallas et al., 1990; Mumby, 1995). Mutations of a number of these highly conserved 
residues, notably two conserved cysteine motifs (Cys-X-Cys-X-X-Cys) found twice at the 
centre of the N-terminus of PyMT, eliminate binding to PP2A. PyMT interacts with the 
HEAT repeats 2 to 8 of PP2A A subunit (though the presence of the C subunit of PP2A can 
further improve binding) (Ruediger et al., 1992). The function of the complex between PyMT 
and PP2A is still unclear but it seems that PyMT-PP2A complexes may be responsible for 
dephosphorylating critical target proteins (Mullane et al., 1998). PyMT mutations that affect 
PP2A association and also prevent interaction with most other proteins that bind wild type 
PyMT, with the exception of Hsc70, and possibly 14-3-3. These mutants also show a 






PP2A normally consists of a trimer, an AC core dimer plus a variable B subunit that is 
thought to influence substrate specificity and subcellular distribution of the phosphatase 
(Mumby, 1995; Janssens and Goris, 2001). If PyMT is acting as a virally encoded B subunit, 
it is feasible that substrate specificity is altered as a consequence of binding to PyMT (Ichaso 
and Dilworth, 2001). However, there is no evidence yet that the phosphatase activity of PP2A 
associated with PyMT acts on any protein outside, or even inside, the PyMT complex. The 
binding of PP2A subunits A and C to PyMT is required for the stable association of the Src 
family kinases, and in the absence of the binding of these PP2A subunits, none of the PyMT 
tyrosines are phosphorylated and the cellular growth signal transduction pathways are not 
activated (Ichaso and Dilworth, 2001).  
 
6.1.3 Src binding  
PyMT is associated with three src-family members in fibroblast cells; pp60c-src (Courtneidge 
and Smith, 1983), pp62c-yes (Kornbluth et al., 1987) and pp59c-fyn (Cheng et al., 1988; 
Kypta et al., 1988; Horak et al., 1989), though only one polypeptide is bound to each PyMT 
molecule. All the associations seem to occur in the same manner, so pp60c-src will be used 
generically. Analysis of a number of PyMT mutants indicated that the complex with src was 
necessary but insufficient for cellular transformation (Bolen et al., 1984; Courtneidge et al., 
1985; Cheng et al., 1986; Markland et al., 1986; Grussenmeyer et al., 1987). 
 
It seems that prior association with PP2A is required for PyMT to bind pp60c-src, as the triple 
complex contains equimolar amounts of PyMT, PP2A and src-family polypeptides (Glover et 
al., 1999) and all the PyMT mutants that disrupt PP2A binding also fail to interact with 
pp60c-src. A region of the PyMT (aa 185 to 210) containing the N-terminal part of PyMT 
unique sequences, is also required for pp60c-src binding but has no effect on the interaction 
with PP2A (Brewster et al., 1997). Point mutagenesis shows that two motifs in this area are 
involved in pp60c-src association, each containing a basic patch followed by either a serine or 





probably have to be in the dephosphorylated state, so it is tempting to speculate that the PP2A 
bound to PyMT is required to keep these residues in this state (Ichaso and Dilworth, 2001). 
The membrane-bound N-terminal end of PyMT binds to and activates the cellular Src tyrosine 
kinase family resulting in the phosphorylation of a number of important PyMT tyrosine 
residues (Ichaso and Dilworth, 2001; Gottlieb and Villarreal, 2001) at aa 250, 315 and 322 
(Schaffhausen and Benjamin et al., 1981; Harvey et al., 1984; Hunter et al., 1984). 
 
6.1.4 Crucial PyMT-stimulated signalling pathways that mediate transformation of 
cells 
Two of the principal signalling pathways that are stimulated by the PyMT are the Ras/ERK 
mitogen-activated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PI3K) 
cascades (Fig 6.1.4). The membrane-located PyMT binds PP2A and Src, which results in the 
phosphorylation of several tyrosine residues in the carboxyl-terminal end of PyMT. 
 
Phosphorylated tyrosine 250 (Y250) of PyMT binds the Src-homology 2 (SH2) domain-
containing transforming protein A (ShcA), which in turn becomes tyrosine phosphorylated, 
creating binding sites for growth-factor-receptor-bound protein 2 (Grb2) and its associated 
protein, son of sevenless (SOS). The guanine nucleotide exchange factor activity of 
membrane-located SOS activates Ras, which then interacts with, and activates, Raf, PI3K, 
RALGDS, and possibly Rin1 and/or AF6. Raf then phosphorylates MAPK kinase (MEK), 
which in turn phosphorylates and activates extracellular signal-related kinases (ERKs; also 
generically known as MAPKs), leading to cell proliferation (Dilworth, 2002). 
 
Phosphorylated PyMT Tyr315 binds to the SH2 domains in the 85-kDa component of PI3K, 
activating the kinase activity of the p110 subunit, which then phosphorylates the D3 position 
of the lipid phosphatidylinositol (4,5) bisphosphate [PtdIns (4,5) P2] to form 
phosphatidylinositol (3,4,5) triphosphate [PtdIns (3,4,5) P3]. Membrane-bound PtdIns (3,4,5) 


















A diagrammatic representation of ShcA and PI3-kinase (PI3K) pathways stimulated by 
membrane-bound PyMT. Association of Src family kinases with membrane-bound PyMT 
can result in the phosphorylation of PyMT tyrosines 250 (Y250) and 315 (Y315). 
Phosphorylation of PyMT Y250 can serve as a docking site for ShcA, which recruits the Grb2 
adaptor protein, which binds the SOS guanine nucleotide exchange factor resulting in the 
activation of Ras. Ras activation can lead to the activation of the Raf-MAP kinase cascade, 
resulting in the phosphorylation of MEK and ERK. Phosphorylation of PyMT tyrosine 315 
(Y315) results in the binding of the PI3-kinase regulatory p85 subunit and subsequent 
activation of PI3-kinase activity resulting in the phosphorylation of a number of cellular 
targets including Akt.  
 









dependent protein kinase-1 (PDK1), Akt and possibly PDK2. PDK1 and PDK2 then 
phosphorylate and activate Akt, which can then phosphorylate several substrates, culminating 
in an inhibition of apoptosis. Substrates that are phosphorylated by Akt include MDM2, 
which when phosphorylated prevents p53-driven apoptosis; BCL-2-associated death agonist 
(BAD), which restores the anti-apoptotic effects of the BAD-binding protein BCL-XL; 
caspase-9, which inhibits its apoptotic protease action; FHKR, a member of the forkhead 
family of transcription factors that prevents stimulation of pro-apoptotic gene transcription; 
and IkappaB kinase (IKK), which stimulates transcription of anti-apoptotic factors by nuclear 
factor kappa B (NF-κB). Akt can also control proliferation by phosphorylation and inhibition 
of glycogen synthetase kinase-3β (GSK3β) to allow the accumulation of cyclin D1, and cell 
growth by phosphorylating mTOR, a protein kinase that acts to control protein synthesis 
through p70 S6 kinase. Other molecules that are involved in tumourigenesis, such as Rac1, 
Cdc42, protein kinase C (PKC) and serum/glucocorticoid regulated kinase (SGK), are also 
stimulated by PI3K activity in an Akt-independent fashion (Vivanco and Sawyers, 2002). 
 
Other signalling events are stimulated by PyMT, including the activation of PLCγ-1 and the 
binding of the 14-3-3 group of proteins, although how these proteins contribute to 
tumourigenesis is unclear (Dilworth, 2002). PyMT also induces ARF, and consequently, p53, 
as a result of inappropriate induction of one or more of the growth stimulatory pathways it 
activates (Lomax and Fried, 2001; O'Shea and Fried, 2005). As a result, PyMT will not 
transform primary mouse cells or any cells which possess an intact ARF-p53 pathway 
(Lomax and Fried, 2001). However, PyMT will transform these cells if either p53 or ARF are 
inactivated (Mor et al., 1997; Lomax and Fried, 2001). PyMT will also transform primary 
mouse cells or any cells in which PyLT and PyST are co-expressed (Rassoulzadegan et al., 







6.2 RESULTS: Spry2 inhibits PyMT-induced transformation in NIH3T3 cells 
An in vitro transformation assay was used to test whether Spry2 was able to inhibit cell 
transformation induced by PyMT. NIH3T3 cells have been shown to be transformed by over-
expression of PyMT (Dilworth, 1995), and this was reproducible as seen in Fig. 6.2.1. 
NIH3T3 hSpry2 and hSpry2Y55F (mutation of Tyr55 to Phe55) stable cell lines were prepared 
by transfecting NIH3T3 cells with pBABE-hSpry2-FLAG and pBABE-hSpry2Y55F-FLAG and 
selecting for positive clones with puromycin. For control purposes, the same cell line was 
transfected with a vector control. Cell lines were established as NIH3T3-hSpry2, NIH3T3-
hSpry2Y55F and NIH3T3 control cells. The stable expression of Spry2 that was observed 
during western blotting analysis is shown in Fig 6.2.2A. Each stable line was transformed 
with 5 µg purified PyMT (A3 strain) in a 10 cm dish and left for 2 weeks for foci formation. 
The foci were fixed and stained with crystal violet as shown in Fig. 6.2.2B. NIH3T3-hSpry2 
cells were more resistant to transformation by PyMT as compared with NIH3T3 control cells. 
NIH3T3-hSpry2 developed less colonies upon transformation (Fig. 6.2.2B), indicating that 
the over-expression of Spry2 in NIH3T3 cells inhibited colony formation. NIH3T3 control 
cells developed 478.7 ± 98.6 colonies upon transformation whereas NIH3T3-hSpry2 
developed 78.7 ± 24.3 colonies (p <0.5, student’s t test). In contrast, NIH3T3-hSpry2Y55F 
stable cells were not as resistant to transformation as NIH3T3-hSpry2 cells and developed 
272 ± 60.5 colonies upon PyMT transformation (Fig. 6.2.2C); this indicates that the Tyr 55 in 
Spry2 was important for Spry2's ability to inhibit transformation downstream of PyMT.  
 
6.3 Elucidation of Spry2's mechanism of inhibition of PyMT-induced 
transformation 
To study Spry2's mechanism of action in inhibiting foci formation, the effect of Spry proteins 
on the activation of signalling pathways downstream of PyMT was examined. There are 
several ways Spry2 may interfere with PyMT-mediated tumourigenesis. PyMT-mediated 
























NIH3T3 fibroblast cells form foci upon transformation by PyMT. 
NIH3T3 cells were transformed with 5µg purified PyMT (A3 strain) in a 10cm dish and left 
















































Spry2 is able to inhibit PyMT-induced transformation whereas Spry2Y55F could only 
partially inhibit PyMT-induced transformation. 
(A) NIH3T3 Spry2-FLAG, Spry2Y55F-FLAG and control cells were established by 
transfecting in pBABE-hSpry2-FLAG and pBABE-hSpry2Y55F-FLAG into NIH3T3 cell lines 
and selecting for positive clones with puromycin. For control purposes, the same cell line was 
transfected with a vector control. Whole cell lysates (WCL) of each stable cell line were 
subjected to western blotting analysis to detect FLAG (Spry2) expression. 
(B) NIH3T3 Spry2, Spry2Y55F and control cells were transformed with PyMT (A3 strain) in a 
10cm dish and left for 2 weeks for foci formation to develop. The foci were fixed and stained 



































































Spry2 is able to inhibit PyMT-induced transformation whereas Spry2Y55F could only 
partially inhibit PyMT-induced transformation. 
The number of foci formed in each plate, for each of the 3 cell lines, was counted. The values 














1998) and Spry2 proteins are known to be negative regulators of the Ras/ERK pathways 
(Gross et al., 2001; Impagnatiello et al., 2001; Yusoff et al., 2002). Therefore, it was highly 
possible that Spry2 could mediate its inhibitory effects on PyMT-induced transformation via 
the inhibition of the Ras/ERK pathway (covered in section 6.3.1). Alternatively, Spry2 may 
impact on PyMT signalling via novel mechanisms that have not been previously documented.  
 
Other than the Ras/ERK pathway, there are potentially other pathways that Spry2 may 
impinge upon to cause the inhibition of PyMT-induced foci formation. Firstly, Spry2 may 
inhibit the PI3 kinase (covered later in Section 6.3.5) signalling downstream of the PyMT. 
Alternatively, Spry2 may interfere with the binding of PP2A to PyMT. Spry2 has been shown 
by our laboratory to interact with PP2A (Lao et al., 2007) and PP2A binding to PyMT has 
been shown to be crucial for the subsequent binding of pp60c-src to PyMT (Glover et al., 
1999). pp60c-src plays an important role in phosphorylating Tyr residues on PyMT, which 
serve as binding sites for PI3K (Whitman et al., 1985; Kaplan et al., 1986),  PLCγ-1 (Su et 
al., 1995) and ShcA (Campbell et al., 1994; Dilworth et al., 1994; Blaikie et al., 1997). The 
PyMT-associated proteins are in turn tyrosine phosphorylated by pp60c-src, resulting in 
stimulation of PI3K (Courtneidge and Heber, 1987; Kaplan et al., 1987) and PLCγ-1 (Su et 
al., 1995) signalling pathways and activation of the Ras/ERK MAPK cascade (Campbell et 
al., 1994; Dilworth et al., 1994; Blaikie et al., 1997). Hence, Spry2 may interfere with 
PyMT's interaction with PP2A, thus abrogating all possible signalling from PyMT. The 
experiments that evaluated this possibility are covered in Section 6.3.4. 
 
6.3.1 Spry1, 2 and 4 inhibit Ras/ERK MAPK downstream of PyMT  
To demonstrate that PyMT is able to activate the Ras/ERK MAPK in 293T cells in a dose-
dependent manner, PyMT was transfected into 293T cells in increasing doses and whole cell 
lysates (WCL) were subjected to western blotting analysis to detect phosphorylated-ERK1/2. 
A corresponding dose-dependent increase in ERK activation was observed with increasing 













Spry isoforms 1, 2 and 4 inhibit phospho-ERK1/2 activation 
293T cells were transfected with plasmids encoding PyMT, various Spry-FLAG isoforms and 
mutants, and empty vector constructs. Expression of these constructs was ascertained by 
immunoblot analysis with anti-FLAG or anti-PyMT. The PyMT construct was expressed in 
increasing amounts of 2.5, 3, 3.5 and 4µg. Whole cell lysates (WCL) were subjected to 
western blotting analysis to detect phospho-ERK1/2. The same blot was stripped and re-






















The various Spry isoforms were then tested for their ability to inhibit PyMT-activated ERK 
phosphorylation in 293T cells. As seen in Fig. 6.3.1A, Spry isoforms 1 (lane 10 and 12), 2 
(lane 6) and 4 (lane 8) inhibit phospho-ERK1/2 activation by PyMT. This observation that all 
3 isoforms of Spry inhibit PyMT signalling is dissimilar to that observed for the FGF 
signalling. Lao et al. (2006) found that, amongst the various isoforms of Sprys, Spry2 was the 
most potent inhibitor of FGF signalling. Spry2's inhibitory activity stems from its ability to 
bind to the N-terminal SH3 domain of Grb2 via its C-terminal proline-rich PxxPxR sequence 
upon FGF stimulation (Fig. 6.3.1B). The PxxPxR motif in the C-terminus of Spry2 is cryptic 
in unstimulated cells and biochemical results suggest that it is revealed upon activation of 
FGFRs as Grb2 only binds under FGF-stimulated conditions (Lao et al., 2006). This 
interaction between Spry2 and Grb2 derails the connection to proteins downstream of the 
ERK pathway by diverting Grb2 away from the FGFR-FRS2-Shp2-Grb2 complex. 
Comparatively, Spry1 and Spry4 do not inhibit ERK activation as strongly as Spry2, as they 
do not have the C-terminal proline-rich PxxPxR sequence and are therefore unable to bind to 
Grb2 and sequester it away from the FGFR1-FRS2-Shp2-Grb2 complex (Lao et al., 2006). 
Since all three Spry isoforms mediate inhibition of the Ras/ERK pathway in PyMT signalling, 
it was highly likely that Spry isoforms mediate their inhibitory effects on the Ras/ERK 
pathway via a different mechanism from that utilized in FGF signalling.  
 
6.3.2 Comparison of the protein interactions of Spry isoforms in PyMT versus FGF 
signalling 
Besides Grb2, the best characterized protein that interacts with Spry2 in the context of FGF 
signalling includes c-Cbl. The interaction of Spry2 with E3 ubiquitin ligase, c-Cbl, is 
important for regulation of Spry's activity (Hanafusa et al., 2002; Fong et al., 2003; Hall et 
al., 2003; Rubin et al., 2003; Mason et al., 2004). In the presence of FGF stimulation, 
tyrosine phosphorylation on the conserved N-terminal tyrosine of Spry1 (Tyr53) and 2 




















Domain map of Spry and its conserved motifs/sequences 
Spry2's inhibitory activity in FGF signalling stems from its ability to bind to Grb2's SH3 
domain via its C-terminal proline-rich PxxPxR sequence upon FGF stimulation. The 
conserved N-terminal tyrosine residue in the Spry isoforms lies in a conserved NxYxxxP 
motif. Phosphorylation of the conserved tyrosine (Y55) of Spry2 is necessary for its ability to 
inhibit RTK-dependent Ras/ERK signalling. The PxxPxR motif on the C-terminus of Spry2 is 
















interact with c-Cbl (Fong et al., 2003; Lao et al., 2006). The binding of c-Cbl to Spry2 has 
several potential downstream effects. Firstly, c-Cbl binding to Spry2 enables it to target it for 
destruction via ubiquitination and degradation by the proteosome, terminating Spry2's 
Ras/ERK inhibitory activity (Hall et al., 2003; Rubin et al., 2003). Secondly, the binding of 
Spry2 to c-Cbl is known to sequester c-Cbl away from its physiological targets and affect c-
Cbl's ability to ubiquitinate its physiological targets (Tsygankov et al., 2001). Lastly, c-Cbl 
has been implicated as a positive regulator of some signalling pathways such as insulin 
signalling. Cbl phosphorylation by the insulin receptor leads to the recruitment of Crk-C3G 
complex to the receptor where C3G, a guanyl nucleotide exchange factor, activates the small 
G protein TC10. The activation of TC10 has been shown to be crucial to insulin-stimulated 
GLUT4 translocation (Liu et al., 2003). 
 
The conserved N-terminal tyrosine (located in a NxYxxxP motif) of Spry proteins has not 
only been shown to be also crucial for Spry2's interaction with c-Cbl, it has been shown to be 
of importance in mediating Spry2's interaction, albeit indirectly, with Grb2 (Hanafusa et al., 
2002; Fong et al., 2003; Hall et al., 2003; Rubin et al., 2003; Mason et al., 2004; Lao et al., 
2006) (Fig. 6.3.1B). Sprys need to be tyrosine phosphorylated in order for them to possess 
inhibitory activity. Phosphorylation of the tyrosine (Y55) of Spry2 is necessary for its ability 
to inhibit FGF-dependent Ras/ERK signalling (Hanafusa et al., 2002; Fong et al., 2003; 
Mason et al., 2004; Lao et al., 2006). Lao et al. (2007) showed that upon FGF stimulation and 
phosphorylation of tyrosine 55 of Spry2, PP2A was found to bind more strongly to Spry2 at 
amino acids (aa) 50-60. PP2A dephosphorylates at least 2 conserved Ser residues (S112 and 
S115) in the Spry2 protein and mediates the change in the Spry2 tertiary protein structure. 
This allows Grb2 to bind to the proline-rich PxxPxR motif in Spry2 and for Spry2 to serve as 
a Ras/ERK pathway inhibitor in FGF signalling (Lao et al., 2007).  
 
 
The following experiments (section 6.3.2.1-6.3.2.4) address the following questions: Do Spry 





stimulation? Are Spry proteins phosphorylated in the presence of PyMT stimulation? Is the 
conserved tyrosine in the Spry isoforms important for their inhibitory activity on the Ras/ERK 
pathway? 
 
6.3.2.1 Spry2 does not interact with c-Cbl in the presence of PyMT 
To investigate whether Sprys bind to c-Cbl in the presence of PyMT, Sprys were 
immunoprecipitated in the presence of PyMT. The binding of Spry2 to c-Cbl in the presence 
of FGFR1 activation (Lao et al., 2006) was included in the experiment as a positive control 
(lane 8). As seen in Fig 6.3.2A, none of the Spry isoforms bound to c-Cbl in the presence of 
PyMT activation (lane 3-5). This would imply that c-Cbl was not involved in the regulation of 
Spry2 levels in PyMT signalling and further suggest that Sprys were not mediating their 
inhibitory effect on the Ras/ERK signalling in PyMT by influencing c-Cbl's ability to 
ubiquitinate other physiological targets. 
 
6.3.2.2 Spry2's inhibition of ERK is not mediated by Grb2 sequestration 
To determine whether Spry2 inhibits phosphorylated ERK in PyMT signalling in a similar 
mechanism to that observed in FGF signalling, the binding of endogenous Grb2 to Spry2 in 
the presence of PyMT stimulation was investigated. 293T cells were transfected with PyMT 
or FGFR1 as a control, in the presence of Spry2. Endogenous Grb2 was precipitated and the 
lysates subjected to western blotting and probing for Spry2 and ShcA proteins (Fig. 6.3.2B). 
It can be seen that Grb2 interacts with Spry2 in the presence of FGFR1 activation, correlating 
with the results obtained by Lao et al. (2006). However, in the presence of PyMT, Grb2 does 
not interact with Spry2, indicating that Spry2 inhibits ERK activation by PyMT in a different 




















Spry isoforms 1, 2 and 4 are not phosphorylated and do not interact with c-Cbl in the 
presence of PyMT activation 
293T cells were transfected with plasmids encoding PyMT or FGFR1 and FLAG-Spry2 and 
empty vector constructs. Expression of these constructs was ascertained by immunoblot 
analysis with anti-FLAG, anti-PyMT or anti-FGFR1 (bottom). The WCL was subjected to 
immunoprecipitation (IP) with anti-FLAG (top). Bound proteins are separated by SDS-PAGE 































Spry2 does not interact with Grb2 in the presence of PyMT  
293T cells were transfected with plasmids encoding PyMT or FGFR1, FLAG-Spry2 and 
empty vector constructs. Expression of these constructs was ascertained by immunoblot 
analysis with anti-FLAG, anti-PyMT, anti-FGFR1 and anti-PY20 (bottom). The WCL was 
subjected to immunoprecipitation (IP) with anti-Grb2 and protein agarose beads (top left) or 
beads only as control (top right). Bound proteins were separated by SDS-PAGE and then 


















In order to further verify that Spry2's mechanism of inhibiting Ras/ERK in PyMT signalling 
is not mediated via binding to Grb2's SH3 domain and sequestering Grb2 away from the 
FGFR1-FRS2-Shp2-Grb2 complex, a Spry2 mutant that shows decreased binding to Grb2 was 
tested for its ability to inhibit Ras/ERK activation. Spry2R309A (mutation of Arg309 to Ala309) 
has a point mutation in the C-terminal proline-rich PxxPxR region that is crucial for Grb2 
binding. As a result, Spry2R309A is less potent (than wild-type Spry2) in its ability to inhibit 
ERK activation downstream of FGF stimulation (Lao et al., 2006). As seen in Fig 6.3.2C, 
Spry2R309A was equally potent at inhibiting ERK activation downstream of PyMT (lane 8) as 
compared to wild-type Spry2 (lane 6 and 7), further confirming the lack of involvement of 
Grb2.  
 
ShcA proteins are known to be upstream of Grb2 in both PyMT and FGFR1 signalling. ShcA 
binds to tyrosine phosphorylated residues in the PyMT and FGFR1 upon activation of these 
proteins/receptors and they in turn become tyrosine phosphorylated, creating binding sites for 
Grb2. To examine whether Spry2 inhibits the interaction between ShcA and Grb2, ShcA 
isoforms (52 and 46 kDa) were co-immunoprecipitated with Grb2 upon both PyMT and 
FGFR1 activation of Ras/ERK signalling pathway. As seen in Fig. 6.3.2B, the presence of 
Spry2 did not affect the ShcA-Grb2 interaction, indicating that Ras/ERK signalling is not 
disrupted upstream of Grb2 in both PyMT- and FGFR1-induced Ras/ERK signalling.  
 
The accumulated data indicates that Spry inhibits the Ras/ERK downstream of PyMT 
activation. However, Spry2 does not inhibit Ras/ERK pathway downstream of PyMT 
activation by the same mechanism of action as that in the FGF signalling - via sequestration 
of Grb2. Spry2 also does not interfere with the interaction of ShcA with Grb2 within the 



















Conserved residues N53 and Y55 in Spry2 are important for Spry2's ability to inhibit 
the Ras/ERK in PyMT signalling. 
293T cells were transfected with plasmids encoding PyMT, FLAG-Spry2 wild-type, FLAG-
Spry2 mutants and empty vector constructs. Expression of these constructs was ascertained by 
immunoblot analysis with anti-FLAG or anti-PyMT. The PyMT construct was expressed in 
increasing amounts of 2.5, 3, 3.5 and 4 µg. Whole cell lysates (WCL) were subjected to 
western blotting analysis to detect phosphorylated-ERK1/2. The same blot was stripped and 
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6.3.2.3 Conserved N-terminal tyrosine in Spry isoforms is necessary for the ability of 
Spry isoforms to inhibit the Ras/ERK signalling downstream of PyMT 
To determine if the N-terminal tyrosine residue in the various Spry isoforms is necessary for 
the ability of Sprys to inhibit activated ERK downstream of PyMT, tyrosine point mutants 
Spry1Y53F, Spry2Y55F and Spry4Y53F were co-expressed with PyMT and examined for changes 
in ERK phosphorylation. As seen in Fig 6.3.1A, tyrosine point mutants Spry1Y53F (lane 11 
and 13), Spry2Y55F (lane 7) and Spry4Y53F (lane 9) lose their ability to inhibit phosphorylated-
ERK downstream of PyMT. These results indicate that the conserved N-terminal tyrosines of 
Sprys are necessary for their ability to inhibit PyMT-induced Ras/ERK signalling. 
 
6.3.2.4 Spry isoformss are not phosphorylated in the presence of PyMT 
To investigate whether phosphorylation occurs on the conserved Tyr residues in the various 
Sprys, Sprys 1, 2 and 4 were immunoprecipitated and examined for changes in 
phosphorylation in the presence of PyMT activation. As Sprys 1, 2 and 4 have been shown to 
be phosphorylated in the presence of FGFR1 activation (Fong et al., 2003; Lao et al., 2006), 
FGFR1 stimulation was included as a positive control (lane 7-9). As seen in Fig 6.3.2A, none 
of the Spry isoforms were phosphorylated in the presence of PyMT activation (lane 3-5), 
suggesting that Spry isoforms do not have to undergo tyrosine phosphorylation in order to 
function as inhibitors of the PyMT-induced Ras/ERK signalling pathway. This result 
indicates that the conserved tyrosine residues of Sprys are extremely important for 
maintaining Sprys' tertiary protein structure and replacement of the conserved tyrosine residue 
with phenylalanine would result in Spry proteins losing their inhibitory activity. 
 
6.3.3 Asn53 and Tyr55 residues in the aa 50-60 region of Spry2 is necessary for 
mediating Spry2's ability to inhibit Ras/ERK signalling downstream of PyMT 
In FGF signalling, the aa 50-60 region of Spry2 has been shown to be important for binding 
of Spry2 to c-Cbl and PP2A (Fong et al., 2003; Lao et al., 2007). Mutation of the Asn53, 





activation, indicating that the residues surrounding the Tyr55 are of importance in mediating 
Spry2's Ras/ERK inhibitory activity (Fong et al., 2003; Lao et al., 2006). 
 
In a subsequent experiment, Spry mutants (Spry2N53A, Spry2Y55A and Spry2P59A) were tested 
for their ability to inhibit Ras/ERK pathway, in the presence of PyMT. The aim was to see if 
the same residues in the conserved N-terminal region of Spry2, that were previously shown to 
be important for inhibition of the FGF-induced ERK activation, are important for inhibition of 
PyMT-induced ERK activation. As seen in Fig 6.3.2C, only Spry2P59A retained its ability to 
inhibit ERK activation downstream of PyMT (lane 10) whereas the inhibitory activity of 
Spry2N53A and Spry2Y55A was lost (lane 12 and 11, respectively), indicating that only Asn53 
and Tyr55 are important for Spry2's function as a Ras/ERK inhibitor downstream of PyMT. 
This observation indicates that the amino acid residues crucial for mediating Sprys' inhibitory 
effect on the Ras/ERK signalling downstream of PyMT, differs from that required for 
mediating inhibitory effect on the Ras/ERK signalling downstream of FGF stimulation. It is 
possible that these amino acids are necessary for the binding of PP2A or other unidentified 
signalling molecules that mediate Spry2's inhibitory activity on the Ras/ERK signalling 
downstream of PyMT. 
 
The accumulated evidence indicates that all Spry proteins inhibit PyMT-induced Ras/ERK 
signalling. Spry isoforms are not phosphorylated and do not interact with Grb2 or c-Cbl, in 
the presence of PyMT stimulation, indicating that Spry isoforms have a different mechanism 
of action in their inhibitory roles in the PyMT signalling pathway. These results differ from 
the biochemical findings of Spry proteins in FGF signalling where Spry2 was found to be the 
strongest inhibitor of Ras/ERK signalling and that Spry2 interacted with c-Cbl and Grb2, in 








6.3.4 Spry isoforms do not inhibit the interaction between PyMT and its associated 
signalling proteins 
The next step in the study was to examine whether Spry2 inhibits other PyMT signalling 
pathways besides the Ras/ERK pathway. To study whether Spry proteins can inhibit the 
interaction between PyMT and its immediately associated signalling proteins, PyMT was 
transfected into 293T cells, together with the various Spry isoforms. PyMT was 
immunoprecipitated from the whole cell lysates and its interactions with immediate 
downstream interaction partners such as PP2A (A and C) and 14-3-3 were ascertained. As 
seen in Fig 6.3.4.1, Spry isoforms did not interfere with the interaction between PyMT and its 
immediate partners [14-3-3 or PP2A (A and C subunits)]. The PyMT was also observed to be 
phosphorylated in 293T cells, presumably by pp60c-src and the presence of Spry isoforms did 
not affect this.   
 
From the same cell lysates, endogeneous PLCγ was immunoprecipitated and its interaction 
with PyMT was ascertained. As seen in Fig 6.3.4.2, Spry isoforms also did not interfere with 
the interaction between PyMT and PLCγ. In the presence of PyMT, PLCγ was observed to be 
phosphorylated and the presence of Spry isoforms also did not affect this. PyMT that was 
bound to PLCγ was also observed to be phosphorylated, regardless of Spry's presence. These 



















Spry isoforms 1, 2 and 4 do not inhibit the interaction between PyMT and its associated 
signalling proteins  
293T cells were transfected with plasmids encoding PyMT, Spry-FLAG isoforms and empty 
vector constructs. Expression of these constructs was ascertained by immunoblot analysis 
with anti-FLAG and anti-PyMT (bottom). The WCL was subjected to immunoprecipitation 
(IP) with anti-PyMT and protein agarose beads (top) or beads only as control (top right). 
Bound proteins were separated by SDS-PAGE and then immunoblotted with anti-PyMT, anti-
























Spry isoforms 1, 2 and 4 do not inhibit the interaction between PyMT and PLCγ 
293T cells were transfected with plasmids encoding PyMT, Spry-FLAG isoforms and empty 
vector constructs. Expression of these constructs was ascertained by immunoblot analysis 
with anti-FLAG and anti-PyMT (bottom). The WCL was subjected to immunoprecipitation 
(IP) with anti-PLCγ and protein agarose beads (top) or beads as control (top right). Bound 



















6.3.5 Spry isoforms do not inhibit PI3 kinase signalling downstream of PyMT 
To determine whether Spry isoforms inhibit PI3 kinase signalling downstream of PyMT, 
293T cells were transfected with plasmids encoding PyMT, Myc-Akt, FLAG-Spry isoforms 
and empty vector constructs. As seen in Fig 6.3.5, PyMT expression causes the activation of 
phosphorylated Akt at residue Thr 308. The presence of the various isoforms of Spry did not 
affect the phosphorylation status of Akt. The same blot was stripped and re-probed with anti-
Myc to confirm equal expression of Myc-Akt. This indicates that Spry isoforms do not inhibit 



















































Spry isoforms 1, 2 and 4 do not inhibit PI3 kinase signalling downstream of PyMT. 
293T cells were transfected with plasmids encoding PyMT, Akt-Myc, Spry-FLAG isoforms 
and empty vector constructs. Expression of these constructs was ascertained by immunoblot 
analysis with anti-FLAG and anti-PyMT. Whole cell lysates (WCL) were subjected to 
western blotting analysis to detect phosphorylated-Akt Thr 308. The same blot was stripped 























In this study, Spry was placed in the presence of an oncogenic stimulus (PyMT) to study if 
Spry2 is capable of inhibiting oncogene-induced tumourigenesis. Using an in vitro 
transformation assay, Spry2 was demonstrated to be able to inhibit foci-formation induced by 
PyMT. 
 
PyMT-mediated tumourigenesis requires activation of both ShcA and PI3 kinase pathways, 
which are required for stimulation of cell proliferation and survival signalling pathways, 
respectively (Webster et al., 1998; Dahl et al., 1996). In section 6.3.1, there is evidence that 
Spry2 can inhibit PyMT transformation via inhibition of the activation of the Ras/ERK 
signalling pathway. The current understanding of the mechanism of how Spry2 inhibits the 
Ras/ERK pathway in FGF signalling was used as a guideline in the evaluation of the 
mechanism of how Spry isoforms inhibit Ras/ERK pathway induced by PyMT. The study has 
shown that Spry2 is not phosphorylated in the presence of PyMT activation. This is in 
contrast to the findings that Spry2 is phosphorylated upon FGF stimulation and that tyrosine 
55 phosphorylation is necessary for Spry2 to inhibit FGF signalling (Lao et al., 2006). Spry2 
was found to interact with Grb2 upon FGF activation and this interaction sequesters Grb2 
away from the FGFR1-FRS2-Shp2-Grb2 complex and derails the connection to proteins 
downstream of the ERK pathway (Lao et al., 2006). However, this observation was not 
mirrored in the PyMT context, indicating that Spry2's mechanism of action in inhibition of 
Ras/ERK activation in PyMT signalling differs from that in the FGF signalling. Spry2 also 
did not interact with c-Cbl upon PyMT activation, indicating that c-Cbl is not responsible for 
regulating and terminating Spry2's activity in the PyMT signalling pathway. The 
accumulating data indicates that the mechanism of action of Spry2 and the regulatory 
mechanisms that control its activity differ between the PyMT and FGF signalling pathways.  
 
Spry isoforms 1, 2 and 4 were found to inhibit the Ras/ERK signalling pathway in the PyMT 





signalling pathway downstream of activated FGFR (Lao et al., 2006). Although all Sprys are 
not phosphorylated in the presence of PyMT activation, the conserved tyrosine residue in 
Spry isoforms is essential for the ability of Sprys to inhibit Ras/ERK signalling pathway. 
Spry2Y55F is unable to inhibit Ras/ERK signalling pathway and is unable to inhibit 
transformation induced by PyMT.  
 
Further studies would aim to find the particular signalling molecule in the Ras/MAP kinase 
pathway that Spry interacts with to facilitate the inhibition of Ras/ERK signalling pathway. 
One of the prime candidates is PP2A. A recent study has shown that PP2A has an important 
role in the activation of the Ras/ERK pathway in PyMT signalling. A mutant PyMT protein 
(known as MTA) which is truncated at its C-terminus, is severely inhibited in its associated 
Src kinase activity and is unable to interact with Shc proteins. However, this mutant is able to 
cause the activation of Ras/ERK pathway in a PP2A-dependent manner (Rodriguez-Viciana 
et al., 2006). PP2A has been found to interact with Spry2 in the FGF signalling pathway. Lao 
et al. (2007) postulated that PP2A may be the phosphatase that dephosphorylates Ser residues 
in Spry2, enabling Spry2 to act as a Ras/ERK inhibitor in FGF signalling. Future studies 
should investigate whether Sprys can inhibit PP2A-mediated Ras/ERK pathway activation 
downstream of PyMT. 
 
Besides evaluating the biochemical mechanisms of action of Sprys, physiological studies can 
be carried out to test if Spry2 can inhibit tumourigenesis mediated by the PyMT in vivo. 
Breast cancer transgenic mouse models (Lin et al., 2003) whose oncogenesis is induced by 
expression of the polyoma virus middle T oncoprotein (PyMT mice, Jackson Labs) could be 
used to test if Spry2 can slow down tumour progression mediated by the PyMT. In this 
model, the expression of the oncoprotein, PyMT, is under the control of mouse mammary 
tumour virus LTR (MMTV LTR) and is therefore restricted to the mammary epithelium. 
Mammary hyperplasia is detected in this model as early as 4 weeks and most importantly, a 





appearance of pulmonary metastases (Lin et al., 2003). Mice homozygous null for the Spry2 
allele (Spry2–/–) will be crossed with mice that were transgenic for the polyoma virus middle T 
(PyMT) antigen. Female offspring from this cross that are PyMT+/–; wild type for the Spry2 
allele and PyMT+/–; Spry2–/– would be saved for analysis. If Spry2 has tumour suppressor 
properties, loss of Spry2 should accelerate the tumourigenesis process in PyMT mice. 
Alternatively, Spry2 transgenics, expressing the Spry2 specifically in the mammary 
epithelium will be produced and then crossed with mice that were transgenic the polyoma 
virus middle T (PyMT) antigen. If Spry2 has tumour suppressor properties, it should inhibit 



























SUMMARY & FUTURE PERSPECTIVES 
  
7.1 Spry expression is deregulated in various cancers 
The objective of this work was to investigate whether Spry proteins play a role in cancer. The 
study started out by comparing Spry1 and 2 expression levels between normal and tumour 
tissues. In chapters 3 and 4, Spry levels were demonstrated to be down-regulated in breast 
cancer (Spry1 and 2) and liver cancer (Spry2). Others have expanded on the knowledge about 
Spry expression in cancer by demonstrating that Sprys are down-regulated in prostate cancer 
(Spry1, 2 and 4) and up-regulated in melanoma (Spry2), GISTs (Spry1 and 4) and K-Ras 
induced lung tumours (Spry2 and, to a much lesser extent, Spry1). 
 
7.2 The mechanism of down-regulation of Sprys in different cancers is cancer-
specific 
Analysis of the possible genetic and epigenetic mechanisms whereby Spry genes are down-
regulated have yielded some answers. McKie et al. (2005) found evidence of LOH occurring 
around the Spry2 gene locus in prostate cancers. However, based on other pieces of evidence, 
there is still some uncertainty as to whether epigenetic silencing of Spry2 by methylation is 
predominantly responsible for the down-regulation of Spry2 in prostate cancers (McAkie et 
al., 2005; Fritzsche et al., 2006). In breast and liver cancers at least, methylation was not 
found to be responsible for the down-regulation of Spry1 and Spry2 genes, implying cancer-
specific genetic and epigenetic mechanisms of down-regulation of Sprys.  
 
Further thorough investigation would be required to examine whether mechanisms such as 
enhanced mRNA degradation or reduced mRNA transcription, arising from loss of or 
mutations in transcriptional factors, or up-regulation of miRNAs, are responsible for the 





of the various Spry isoforms would be needed in order to have a better understanding of the 
mechanisms of deregulation of Spry in different types of cancers. 
 
7.3 Spry as a tumour suppressor? 
When a gene is found to be deregulated in a significant number of cancers (in the reported 
cases Spry2 is consistently down-regulated in several cancers) two important questions arise: 
(1) Is the down-regulation a cause or effect of the cancer? (2) Does the change in gene 
expression have a value in cancer diagnosis, prognosis or monitoring of treatment? In tumour 
development, it would be expected that a number of genes become suppressed, causing 
normal cells to become malignant. These include genes involved in cell cycle arrest and 
apoptosis. However, certain genes represent critical points in cell cycle regulation. A number 
of these, such as p53 and Rb are currently the best characterized tumour suppressors. The 
position of Spry2 in the Ras/ERK pathway suggests that, in certain contexts, it may have a 
tumour suppressive function.  
 
In multicellular organisms, RTKs are involved in the control of fundamental aspects of cell 
physiology, ranging from cell migration to survival, growth, proliferation and differentiation, 
during both embryonic and adult development. The execution of these programs requires 
signals of adequate strength to be delivered for the appropriate time within precise spatial 
boundaries. Several RTK inhibitors have been identified in invertebrate and mammalian 
organisms. Because they are involved in fine-tuning and termination of receptor signals, 
negative regulators of RTK activity fulfill a significant and fundamental role in the control of 
receptor signalling. One example of such negative regulators are the Spry isoforms. Spry has 
been demonstrated to regulate branching morphogenesis in lung and kidney via the inhibition 
of the RTK-induced Ras/ERK signalling pathway. ERK signalling has been shown to be 
important in the regulation of proliferation, migration and differentiation during branching 
morphogenesis. Spry2 targeted expression in the ureteric bud of mice caused the inhibition of 





In vitro studies involving over-expression of Spry have shown that Spry inhibits proliferation 
and migration of cells via the inhibition of ERK activation (Gross et al., 2003; Lee et al., 
2001; Impagnatiello et al., 2001; Lee et al., 2004; Miyoshi et al., 2004). Even in post-
developmental stages, Spry2 was found to be expressed in the epithelial lining of ducts in the 
lung (Warburton and Bellusci, 2004; Perl et al., 2003) and mammary gland. Its expression is 
observed to be up-regulated when these epithelial cells are actively proliferating and 
branching in the mammary gland. These findings, coupled with the evidence that Spry is up-
regulated in the actively proliferating neointimal vascular smooth muscle cells (VSMCs) after 
vascular injury, suggest that Spry has a role in opposing the actions of growth factors in 
modulating growth and migration under physiological and pathological conditions (Zhang et 
al., 2005).  
 
Cancer occurs when a normal cell accrues enough genetic changes to be able to grow 
continuously and kill the host. Usually, cancer is thought of as a disease that progresses 
through the gradual accumulation of multiple successive genetic "hits". Each genetic change 
confers a proliferative advantage, causing cells to progress from a normal state to a fully 
malignant, metastatic state (Paige, 2003). Gatekeeper genes are very often mutated in cancers 
and they include oncogenes as well as tumour suppressors. Gatekeeper proteins are located at 
nexus points in signalling pathways and they integrate incoming signals to regulate cell 
growth, proliferation and apoptosis. Often, the loss of tumour suppressors synergizes with the 
activation of oncogenes and this contributes to the neoplastic phenotype (Fearon and 
Vogelstein, 1990). Tumour suppressor genes are those genes where a loss of function results 
in the promotion of malignancy. The loss of both alleles of the gene, typically a deletion in 
one allele and a mutation or transcriptional silencing of the other allele, is required to unmask 
the malignant phenotype, in keeping with the long standing Knudson’s “two-hit” hypothesis.  
 
Accumulating evidence from this study and from existing literature indicates that Spry 





negative regulator of the Ras/ERK signalling pathway. Sprys have been shown to be lost in 
breast, liver and prostate cancers and have been shown to have a role in the inhibition of cell 
proliferation, migration, anchorage-independent growth and in vivo tumour formation. Further 
studies are needed to clarify whether Spry has a tumour suppressor role. These would involve 
in vitro knock down of Spry as well as in vivo analysis of Spry knock out mice. Knock down 
of the Spry gene could be carried out with siRNA techniques, while subsequent cellular 
motility and proliferation assays could be carried out to evaluate whether these functions are 
enhanced in these cells. However, if knock down techniques are not able to reduce the Spry 
gene expression to a sufficiently low level for a phenotype to be seen, mouse embryonic 
fibroblasts (MEFs) isolated from Spry knock out mice would be useful in analyzing the 
implications of the loss of Spry. MEFs of Spry2 knock out mice could be compared with 
wild-type cells to ascertain whether they are more prone to transformation with oncogenes. 
Similarly, Spry2 knock out mice could be tested for their susceptibility to chemically-induced 
carcinogenesis. Also, with the availability of many genetically engineered mouse models of 
human cancer involving the over-expression of oncogenes or loss of tumour suppressors, it is 
possible to evaluate whether the loss of Spry in such cancer models would synergize and 
accelerate the development of tumours.  
 
Based on the ability of Sprys to inhibit tumourigenesis, patients with a loss of expression of 
Sprys in cancers may have a poorer prognosis. In tumours with oncogenic lesions that 
contribute to an over-active Ras-ERK signalling pathway, the loss of function of Sprys in 
these cancers may permit the hyperactivity of this pathway to proceed unchecked. Further 
studies would be needed to determine whether patients who show a loss of expression of 
Sprys in cancers have a poorer prognosis. If so, Spry genes may potentially be used as 
molecular markers to predict a subset of cancer patients that may respond to therapeutic 






In order to fully understand the implications of down-regulation of Sprys in cancer, the 
mechanism of action of each Spry isoform in the inhibition of signalling from various RTKs 
needs to be fully elucidated. The spectrum of genetic changes that accumulate in human 
tumours is variable, even for tumours arising from the same organ type (Hahn and Weinberg, 
2002). Hence, the signal transduction pathways that are deregulated in each type of tumour 
need to be thoroughly investigated. That perspective, combined with the understanding of the 
mechanism of action of Spry, would enable us to predict the particular cancer type or subtype 
in which Spry could assist in dampening the tumourigenic process. One would expect that 
Spry2 could possibly have a role in cancers that are mediated by the hyper-activation of RTK 
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